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Abstract 
Most human deaths from ischaemic heart disease are caused by ventricular 
tachyarrhythmias (VT). Evidence of a possible role of ATP-sensitive K+ channels (KATp) 
in arrhythmogenesis is conflicting. The present study aims to resolve some of the 
controversy, by assessing effects of KATp modulating drugs on regional changes in 
suction electrode-recorded action potentials, in the rat isolated perfused heart. In a control 
group of 15 hearts, 10 minutes of left ventricular (LV) ischaemia caused transient, but 
significant (p < 0.05) lengthening of LV action potential duration at 80% repolarisation 
(LV APD80) from 34.1 ± 3.0 to 62.1 ± 4.3 ms (mean ± SEM). Post-ischaemic reperfusion 
shortened LV APD80 transiently but significantly, from 28.4 ± 1.8 to 18.6 ± 1.9 ms. In a 
similar group, reperfusion caused VT to occur in 90% of hearts. The KATp blocker 
glibenclamide, at both 1 and 10 pM had no significant effect upon VT incidence, but 
lengthened LV APD80 significantly after 9 minutes of ischaemia, suggesting that KATp 
channels were open at this time. The KATP opener Ro 31-6930 (Ro), was a potent 
vasodilator at 50 nM and greater, an effect that was compensated for by adjusting 
perfusion pressure. Prior to ischaemia Ro at 0.5 µM had no significant effect on LV 
APD80, but Ro at 5 µM caused marked and significant LV APD80-shortening, by 62%. 
During ischaemia, Ro at 5 . tM caused VT in 89% of hearts, an effect associated with 
significant ischaemic shortening of LV APD80. Ro at 0.5 µM caused less severe, non- 
arrhythmogenic, but significant LV APD80-shortening during ischaemia, an effect 
associated with a mild, but significant reduction in the incidence and duration of VT 
during reperfusion. Glibenclamide at 1 pM abolished the effects of Ro on both VT and 
APD. This suggests that KATp activation may be either pro- or anti-arrhythmic, depending 
both upon the degree of APD-shortening that it causes and whether the arrhythmias 
occurred during ischaemia or reperfusion. It may not be possible to exploit the anti- 
arrhythmic effects of KATp openers clinically, due to a risk of promoting reentrant 
arrhythmias through APD-shortening. 
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Chapter 1 
Clinical relevance of this study 
I Introduction 
The majority of human deaths which occur as a result of coronary heart disease are 
caused by a sudden disturbance of ventricular rhythm, ventricular arrhythmia. The 
commonest cause of the most severe cardiac arrhythmia, ventricular fibrillation (VF) is 
acute myocardial regional ischaemia (1). The disruption in myocardial electrical activity 
which characterises VF may be regarded as a consequence of the ionic disturbance within 
the muscle which accompanies an interruption of its blood supply (2). The adenosine 
triphosphate (ATP)-sensitive potassium channel (KATP) is a potassium ion (K+)-selective 
ion channel which is thought to be involved in the ionic and electrical changes associated 
with myocardial ischaemia (3). Since its discovery in 1983 by Noma (4), the KATpchannel 
has been the target of many pharmacological investigations which have attempted to 
understand the role it might play in the genesis or prevention of cardiac arrhythmias: for 
recent reviews, see (3i). Much of the evidence for this role is conflicting, however: for 
example, see Black & Lucchesi (6) and D'Alonzo & Grover (7). The present study aims to 
help to clarify some of this controversy. 
Physiological role of KATP channels 
The KATP channel was first identified in guinea-pig ventricular myocytes (4) and was 
characterised by the modulation of its K+ conducting properties by intracellular ATP 
(ATP);. This intracellular ligand maintained the channel in a closed state unless its 
concentration dropped sufficiently, causing the channel to open, or activate. For reasons 
discussed later, modulation of the conductance of the plasmalemma to K+ has profound 
electrical consequences for an excitable cell. The physiological role of the KATP channel 
may be to link the metabolic state of a cell with its electrical activity (8). Involvement of 
the KATP channel has been demonstrated in a variety of physiological processes. For 
example, it is involved in the regulation of vascular smooth muscle tone (9), such as that 
of the coronary vasculature (10). Pancreatic ß-cell KATP channels are involved in the 
regulation of insulin secretion (11). Skeletal muscle KATP channels may play a role during 
muscle fatigue (12) and KATP channels of the peripheral and central nervous systems may 
be involved in the regulation of neurotransmitter release (13). The physiological role for 
the cardiac KATp channel is less clear, however. 
Cardiac KATP channels: a pathophysiological role? 
KATp activation is known to be involved in K+ efflux and shortening of action potential 
duration (APD) (14,15), both of which occur shortly after the onset of myocardial 
ischaemia (3). These events may favour the induction of ventricular arrhythmias through 
reentrant mechanisms, during ischaemia (16) and also during reperfusion (17) of previously 
ischaemic myocardium. KATp activation might also inhibit ventricular arrhythmias which 
are caused by oscillations in membrane potential, called afterdepolarisations (18,19), which 
may be particularly prevalent during reperfusion (17). KATp activation also may be 
involved in some types of cardiac protection (20). For example, the formation of an 
infarcted zone, or the reduction in mechanical function during post-ischaemic reperfusion, 
under certain circumstances can be reduced (21,22). This is assumed by some workers to be 
a consequence of APD-shortening, since this may reduce the rise in the calcium ion 
(Ca2+) concentration [Ca2+] in the intracellular space ([Ca2+]i) during systole, limiting the 
deleterious effects of Ca2+ overload, and conserving contractile ATP t23l. Finally, under 
some circumstances, KATp channels seem to play a part in ischaemic preconditioning, the 
protective effect produced by short periods of ischaemic stress resulting in a resistance to 
a subsequent prolonged ischaemic insult (24). This might have clinical pathophysiological 
relevance to the intermittent ischaemia caused by coronary spasm, and might be 
exploitable therapeutically (25,26). KATp activation-mediated cardioprotection, either 
directly or through preconditioning, also is likely to be anti-arrhythmic (n). 
KATp modulation and the arrhythmia controversy 
As indicated above, pathophysiological or pharmacological activation of KATP channels 
might be involved in the promotion or the prevention of ventricular arrhythmias. For this 
reason, pharmacological blockade of KATP channels might also be expected to be either 
pro- or anti-arrhythmic. Many investigations into the effect of pharmacological 
modulation of KATP channels on arrhythmogenesis have been conducted, using a wide 
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variety of animal species and model. These have indeed demonstrated both pro- and anti- 
arrhythmic effects of both KATp openers and of KATp blockers. For example, in canine 
studies, the KATP opener pinacidil (27) was pro-arrhythmic (28), whilst another KATP 
opener, cromakalim (29) was anti-arrhythmic (30). The KATP blocker, glibenclamide (31) 
was anti-arrhythmic in the rat (32), but pro-arrhythmic in the dog (33). It may be speculated 
that the difference in the outcome of such studies might have arisen from model- 
dependent differences in the overriding consequence of KATP modulation, be it of a pro- 
or anti-arrhythmic nature. This will be discussed in detail in the context of my own 
experiments and those of other workers, in the following chapters. 
It should be noted here that controversy surrounds aspects of the KATP channel other than 
its role in arrhythmogenesis. Intracellular nucleotides have been shown, amongst a host of 
other intracellular ligands, to modulate KATP channel activity (34). For this reason, the 
term "nucleotide diphosphate-sensitive K+ channel" has recently been suggested as more 
appropriate than "KATp" (35). Since (ATP)i is the primary modulator of KATp channels in 
most tissues, including myocardium (35), the abbreviation "KATp " is considered 
appropriate here. KATP channels should not be confused with "ATP-activated K+ 
channels" (36). It is noteworthy that the very existence of the KATP channel has been called 
into question by Edwards & Weston (37). However, recent gene mapping and cloning 
studies (38,39) add support to the widely held view (40) that the KATP channel is a distinct 
entity. 
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Chapter 2 
Experimental models for the study of cardiac arrhythmias 
Introduction 
There is clinical evidence, from patients who developed VF outside the hospital and who 
were successfully resuscitated, that transient ischaemia without infarction can cause 
severe ventricular arrhythmias (41,42). There are also reports of patients with transient 
coronary artery spasm, in whom VF occurred within minutes of electrocardiographic 
signs of myocardial ischaemia (ST segment elevation) (43) and also in which ventricular 
arrhythmias were found to occur after ST segment changes had returned to normal (44). 
This indicates that acute myocardial reperfusion, as well as ischaemia, may induce lethal 
arrhythmias. However, the clinical study of arrhythmias which occur under such 
conditions, particularly regarding the underlying mechanisms, is limited for a number of 
reasons. For example, when arrhythmias occur after acute myocardial ischaemia, it is 
usually under conditions where the primary concern is to maintain the patient's life. Also, 
the number of tools available to investigate arrhythmogenic mechanisms are limited (45). 
In order to overcome these limitations, and to safely investigate the potential effect of a 
drug to prevent arrhythmias, which is the ultimate clinical goal, the use of animal models 
of cardiac arrhythmias play an invaluable role. These studies allow the use of additional 
experimental procedures and techniques, and have provided information which cannot be 
obtained from clinical studies (45). 
Choice of animal species 
The species most often used for the experimental study of arrhythmias following acute 
myocardial ischaemia is the dog (45), but pigs, cats, rabbits, ferrets, guinea-pigs, rats and 
hamsters have also been studied. Some of the electrical and anatomical properties of 
hearts from each of these are known to differ, from each other, and from those of the 
human. For example, the guinea-pig and hamster have a more extensive coronary 
collateral circulation than the other species mentioned (46,47), which may reduce the extent 
of an ischaemic region following occlusion of a coronary artery. The size of the ischaemic 
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zone is known to influence the severity of arrhythmias: the larger the area, the more 
frequent the arrhythmias (48). An example of a species-dependent cardiac electrical 
property is the unusually short APD seen in the rat. It might be anticipated that this would 
alter the ease of induction of reentry in comparison with other species, but there is no 
clear evidence for this (49). In terms of similarity to the human heart, each species has its 
own perceived advantages and disadvantages. Since the clinical relevance of these is 
frequently unclear, studies of a wide variety of animals is pertinent (49), and comparisons 
of their results necessary to form an overall view of the clinical scenario (45). 
The use of the rat in an experimental model 
The rat is small and therefore easy to handle, readily available and cheap (49). 
Additionally, from a scientific perspective, the rat has anatomical and electrical 
characteristics which make it an extremely useful experimental model. There is a lack of 
uniform coronary collaterals (46,47), such that a high left main coronary artery (LMA) 
occlusion consistently renders approximately half of the heart ischaemic (50,51). This type 
of regional ischaemia is thought to be particularly arrhythmogenic, since the area of 
"border zone" tissue which surrounds the ischaemic zone, and which promotes a high 
degree of heterogeneity of electrical activity, is relatively large (52). This may account for 
the ease with which severe ventricular arrhythmias can be induced in the rat. These occur 
within about 10 minutes of left ventricular (LV) regional ischaemia, both in vivo (51,53) 
and in vitro (54). Reperfusion-induced arrhythmias are particularly prevalent, usually 
occurring within a few seconds of reperfusion, again in vivo (55) and in vitro (54). 
In vitro or in vivo? 
In'vitro studies of the intact heart have several advantages over those carried out in vivo 
(45). In the absence of extra-cardiac factors, both neural and circulatory, interpretation of 
experimental measurement is less complicated. Also, constituents of the perfusion liquid 
may be adjusted, for example, to modify the effect of coronary occlusion on the incidence 
of arrhythmias. There is increased access to the heart, easing electrophysiological 
measurement and other manipulations. 
5 
The Langendorff-perfused rat heart as the model for the present study 
This model, in which the coronary arteries of the isolated heart are perfused retrogradely 
via the aorta (56), is simple and widely used. A modified version of the Langendorff 
apparatus, which forms the experimental basis of the present study, is shown in Figure la 
(page 9). The heights above the heart of the liquids from reservoirs 1 and 2 were normally 
set at 1 m, but could be independently adjusted in order to vary the perfusion pressure. A 
peristaltic pump transferred liquid from reservoir 1 to the overflow device, which kept the 
height of the liquid's surface constant. A two way valve allowed rapid switching between 
two perfusion liquids. A thermostated water heater and heat exchangers raised the 
perfusion liquid temperature in the glass aortic cannula to 37 ± 1°C. The heated jacket 
kept the air surrounding the heart warm. The aortic cannula was shaped to allow 
simultaneous perfusion and suspension of the heart, via the aorta. The "occlusion bracket" 
was designed and constructed to aid occlusion of the LMA and to maintain easy access to 
the LV wall for surface electrical recording. This device is illustrated in Figure lb. The 
rubber o-ring could be manoeuvred towards, and held rigidly against the epicardial wall 
immediately over the LMA. 
Experimental procedure common to all electrical recording studies 
Perfusion liquid 
A physiological salt solution (PSS) of the following ionic composition (mM): NaCl 
(136.9), glucose-(I 1.1), MgC12 (1.0), NaH2PO4 (0.3), NaHCO3 (11.9), CaC12 (0.9), KCl 
(variable) was made up in distilled water and placed in reservoir 1. This solution is based 
on one used by Tyrode (57), but modified following preliminary experiments to optimise 
the electrical stability of hearts. Only the concentration of KC1 [KC1] varied, and this will 
be highlighted for relevant experiments. The PSS was bubbled with a mixture of 95% 02 
and 5% C02, resulting in a pH of between 7.3 and 7.5. Using positive pressure from the 
peristaltic pump, it was then filtered using 8 tm and 5 µm filters (Isopore SC and SM, 
Millipore) and elevated to the overflow device (Figure la). The PSS was heated as 
described and air bubbles were removed by a bubble-trap situated above the two way 
valve. 
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Animals 
Male Sprague Dawley rats were bred and housed on site and fed ad libitum on a pellet 
and water diet. Those used weighed between 350 and 650 g. Details of animal husbandry 
are given in Chapter 7. 
Surgery 
Rats were killed by a sharp blow to the head. The ribs overlying the heart were removed 
and the pericardial sac was opened, exposing the heart. A braided silk suture of size 6/0, 
with round bodied curved needle attached (Type W593 Mersilk, Ethicon) was passed 
beneath the LMA at the level of the left atrial appendage, close to the left edge of the 
pulmonary conus, as described by Selye et al (58) Any tissue concealing the aorta was 
removed and an incision was made into the aorta 2-3 mm above where it emerged from 
the left ventricle. The aorta was cannulated and the heart rapidly removed, typically 
within 30 seconds of cutting the aorta. 
Experimental preparation 
The heart was connected to the Langendorff apparatus as shown in Figure lb. At the same 
time, any bubbles or blood clots were expelled from the aortic cannula using a PSS-filled 
syringe. Hearts were allowed to stabilise for 15 minutes. During this time, the occlusion 
bracket was manoeuvred into place. The free ends of the coronary snare were passed 
through the lumen of the o-ring, over the pulley wheel and attached to the weight (190 g). 
The weight was supported by a plate to keep the suture slack. At this point, electrodes 
were applied to the heart, for recording either the cardiac electrogram (CEG) or epicardial 
action potentials (APs). This will be detailed in appropriate experiments. The heated 
jacket was then raised to surround the heart and the insulating cover was assembled. 
Experimental protocol 
Following the 15 minute stabilisation period, electrical activity and coronary flow rate 
were recorded from hearts during 10 minutes of normal perfusion, followed by 10 
minutes of LV regional ischaemia and 10 minutes of post-ischaemic reperfusion. The 
severity of reperfusion arrhythmias in the rat is characteristically dependent on the 
duration of the preceding ischaemic insult, and is maximal after 5-10 minutes of 
ischaemia (59,60). If coronary occlusion is maintained for more than 10 minutes, 
irreversible myocardial damage may occur (61). Regional ischaemia was induced by 
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tightening the ligature around the LMA, simply by gently releasing the weight. An 
example of the changes in coronary flow rate caused by this procedure is shown in Figure 
2a. Use of the occlusion bracket allowed rapid and continuous ligation of the LMA, 
accurate timing of onset of ischaemia and reperfusion, and caused minimal mechanical 
interference with recording electrodes. Following reperfusion, the zone of non-perfused 
muscle was delineated by injecting 1 ml of dye (1240 Patent Blue V: 4 g/1) into the heart 
via the side arm cannula (Figure lb). The LMA was then reoccluded for 10 minutes, 
allowing complete washout of dye from normally-perfused muscle, but its retention 
within the ischaemic area. This zone was illustrated and typically varied little from that of 
Figure 2b. 
Exclusion criteria 
Those hearts not in normal sinus rhythm (NSR) at the end of the stabilisation period, or in 
which there was no drop in coronary flow rate during ischaemia, or in which a discreet 
zone of stained muscle similar to that shown in Figure 2b was not visible, were 
immediately excluded from further analysis. 
Statistics 
Values are expressed as mean ± SEM (standard error of the mean). Statistical tests used 
are detailed in the text for appropriate experiments. P<0.05 was considered to be 
significant. 
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Chapter 3 
Influence of KATP modulation on arrhythmogenesis 
Electrical and haemodynamic effects of a KATP opener, Ro 31-6930 (Ro) at a low 
concentration 
Introduction 
Part of the controversy surrounding the effect of KATP modulation on arrhythmogenesis 
centres on whether drugs which open KATP channels mediate their effects on the 
myocardium directly, or due to cardiac haemodynamic changes (for example, see 
D'Alonzo et al (62)). Therefore, an experiment was designed to address this issue, using 
the Langendorff-perfused rat heart model. There were two aims. Firstly, to investigate the 
effect of Ro at 50 nM and at 0.5 tM on coronary flow rate. Secondly, to investigate the 
effect of Ro at these same concentrations on the incidence and duration of arrhythmias 
occurring during regional ischaemia and reperfusion, and hopefully in the absence of any 
drug effect on coronary flow rate. Ro is one of a class of K+ channel openers, the 
substituted benzopyrans (63). Evidence that this drug opens K+ channels has been 
provided by Paciorek et al (M). Ro is related structurally to cromakalim (63), for which 
KATp-opening properties have been demonstrated (29). There is strong evidence that Ro is 
also a specific KATP opener, provided by studies of smooth muscle (64.65,66,67,68), cardiac 
muscle (MacKenzie I. Personal communication & 69) and brain tissue (70). In several of these studies, 
Ro was compared directly with cromakalim (64,65,66,67,68,70) and found to be 
approximately 5-10 times more potent than cromakalim. Ro is a potent vasorelaxant. In 
the rat portal vein, Ro at concentrations between 10 nM and 0.3 µM inhibited contractions 
caused by 20 mM KCl (M). 
Method 
Perfusion liquid 
A PSS containing KCl at 4 mM was prepared as described on page 6. Preliminary 
experiments with this solution had yielded a high incidence of reperfusion arrhythmias, 
with few hearts failing to gain NSR during stabilisation. Ro was kindly supplied by 
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Roche Research Centre and a stock solution of this was made up in distilled water. Prior 
to cannulation of hearts, aliquots of the Ro stock solution were added directly to the PSS, 
to give final concentrations of 50 nM or 0.5 µM. Coronary flow rate was measured by 
timed measurement of coronary effluent volume. 
Electrical recording 
Two stainless steel wire electrodes were inserted into the heart using retractable 
hypodermic syringe needles, as described by Kaplinsky et al (71). One was inserted 
through the apex and the other through the right atrium. These electrodes were attached to 
insulated copper wires, which were supported by thin steel wires. These in turn were bent 
into position, so that traction on the muscle was minimal, and the electrodes did not touch 
other parts of the apparatus, minimising electrical noise. The entire apparatus was earthed 
from the main supporting retort stand to a mains earth terminal. This reduced electrical 
interference to a minimum. Using these transmural leads, the CEG was observed using a 
scroll type storage oscilloscope (Cardiostore SEM 431, SE Labs) and recorded using a 
heated stylus recorder (Lectromed MX216). 
Arrhythmia classification and quantification 
Ventricular tachyarrhythmias were assessed from the CEG using the oscilloscope and 
were classified using the guidelines of the Lambeth Conventions (72). Therefore, a 
ventricular premature beat (VPB) was classed as a premature QRS complex (premature in 
relation to the previous sinus beat). Ventricular tachycardia was a run of 4 or more 
consecutive VPBs. VF was a signal in which individual QRS complexes could no longer 
be distinguished from one another, and for which a rate could no longer be measured. 
Using the present model, VF, as defined above, was observed only rarely, and briefly. 
This is because the most chaotic signal seen in an experiment usually exhibited a 
superimposition of some form of regular ventricular electrical activity. An example of this 
"irregular ventricular tachycardia" or "hybrid VF' is shown in Figure 3 (page 35). On the 
rare occasion that VF could be distinguished from ventricular tachycardia, 
interconversion between the two was often rapid. For these reasons, it was considered 
appropriate to group ventricular tachycardia, VF and intermediates of the two, as one 
class of arrhythmia, ventricular tachyarrhythmia. This is referred to in this and the 
following experiments as VT. The incidence and the duration of VT were quantified each 
minute using the chart recorder. 
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Statistics - 
All values are expressed as mean ± SEM. The incidences of arrhythmias were compared 
using a x2 test (with Yate's Correction) (73). The duration of arrhythmias and the coronary 
flow rates were compared using a Mann Whitney test (74). This non-parametric test was 
chosen since the application of the variance ratio test revealed that the distribution of data 
was unsuitable for parametric analysis. 
Results 
Coronary flow rate 
In a control group of 10 hearts perfused with a PSS at a head of pressure (HOP) of 1 m, 
the flow rate in the 10 minutes prior to ischaemia was 13.0 ± 0.3 ml/min. LMA occlusion 
rapidly caused a significant reduction during the ischaemic phase, to 8.3 ± 0.5 m]/min (a 
reduction of 36%). Reperfusion caused a rapid return to approximately pre-ischaemic 
values [Figure 2a (page 11) & Figure 4]. In a second group of hearts (n=10), Ro at 50 nM 
significantly increased the pre-ischaemic flow rate, by 34%, to 17.4 ± 0.5 ml/min. In a 
third group, hearts (n=10) were perfused with Ro at 50 nM, at a HOP of 0.7 m. In a fourth 
group, hearts (n=12) were perfused with Ro at 0.5 µM, also at a HOP of 0.7 m. In these 
last two groups, mean pre-ischaemic flow rates did not differ significantly from the 
control group, and were 11.3 ± 0.5 and 12.3 ± 0.6 ml/min, respectively. 
Arrhythmias 
In the control group, 1 of 11 hearts did not gain NSR during the stabilisation period. In 
the remaining 10 hearts, the maximum incidence of arrhythmias occurred during the first 
minute of reperfusion (Figures 5& 6), with 5 hearts entering VT, which persisted for 19.9 
± 7.6 s. Hearts perfused with Ro at either 50 nM or 0.5 µM attained a similar level of pre- 
ischaemic stability to the controls. Ro at 50 nM had no significant effect on the incidence 
or the duration of VT at any time compared to the controls. Ro at 0.5 µM caused a 
significant reduction in the incidence, but not the duration of VT during reperfusion 
(Figures 5& 6). The total duration of VT which occurred in control hearts in the 10 
minute reperfusion phase was 193 ± 79 s. This was not significantly altered by Ro at 
either 50 nM or 0.5 µM (Figure 7). 
Discussion 
Ro at 50 nM significantly dilated the coronary vessels, but had no effect on the incidence 
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or the duration of arrhythmias caused by coronary artery occlusion and reperfusion. Ro at 
a 10 times higher concentration did not increase the degree of vasodilation caused by Ro 
at 50 nM, and caused a significant, if mild reduction in the incidence of VT during 
reperfusion. The effect of Ro at 0.5 µM on arrhythmias therefore, is likely to have been 
independent of its effects on coronary flow. The potent vasodilatory action of Ro was also 
found by Paciorek et al 1641, in which half maximal inhibition of contraction of rat portal 
vein occurred at a concentration of 38 nM. In the present study, there may have been a 
differential sensitivity of coronary vessels and cardiac muscle to Ro. This was found to be 
the case in a study comparing the sensitivity of guinea-pig isolated portal vein and 
papillary muscle to cromakalim (75), where cromakalim caused half maximal shortening 
of cardiac APD at 30 pM, but half maximal inhibition of spontaneous mechanical activity 
in the portal vein at 21 nM. Other studies also indicate that cardiac KATp channels are 
activated by higher concentrations of KATp openers than smooth muscle KATp channels 
(76). In the present experiment, the severity of reperfusion arrhythmias in the control 
group was low compared to that of other studies using a similar model. For example, Bril 
et al (32), Lubbe et al (M), Adams et al (77) and Ibuki et al (78) all found that reperfusion 
following LV regional ischaemia caused at least an 80% incidence of reperfusion 
ventricular tachycardia. In two of these (32,78), ischaemia lasted for 10 minutes. However, 
the ionic composition of their perfusion liquids differed to the present study, especially 
with regard to [KC1] (78) and the concentration of CaC12 ([CaC12]) (32). In order to attempt 
to "amplify" the mild anti-arrhythmic effect observed with Ro at 0.5 µM, it was decided 
to try to increase the incidence of reperfusion-induced arrhythmias in the control group. 
Effect of lowering [KCI] in the PSS, on reperfusion arrhythmias in the control group 
Introduction 
In earlier experiments, in order to optimise electrical stability of hearts, [KC1] had been 
increased from 2.7 mM to 5.4 mM. In the last experiment, with a [KC1] of 4 mM, in 
which the incidence of reperfusion VT was 50%, the initial electrical stability (IES: the 
percentage of hearts in NSR at the end of the 15 minute stabilisation period) was high, at 
91%. In the study by Ibuki et al (78), in which a [KC1] of 3.2 mM was used, the incidence 
of reperfusion ventricular tachycardia was 100%. Lubbe et al (54) found that lowering 
[KC1] from 5.9 mM (which is physiological for the rat (54)) to 4.5 mM, increased the 
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incidence of reperfusion VF from 75% to 100%. It was hoped that lowering [KC1] in the 
present model below 4 mM might increase the incidence of reperfusion VT in the control, 
whilst maintaining IES. 
Method 
There were 5 experimental groups, where [KC1] varied between 1.5 and 3.5 mM. The 
PSS was otherwise of the same composition as that described on page 6. Groups were 
assessed for IES, incidence of ischaemia-induced VT and the incidence of reperfusion- 
induced VT. The incidence of reperfusion VT was only assessed in those hearts which 
were in NSR immediately before reperfusion. The incidences of IES and of arrhythmias 
were compared using a X2 test, with Yate's Correction. 
Results 
When viewed in conjunction with the control group from the previous experiment, a trend 
emerged [see Table 1 (page 33)], which suggested that high [KC1] was associated with 
high IES and a low incidence of reperfusion VT. Conversely, low [KC1] caused 
unacceptably low IES. There was no consistent effect of varying [KC1] on the incidence 
of ischaemia-induced VT. These results must be interpreted with caution for two reasons. 
Firstly, reperfusion arrhythmias may have been subject to "self-selection". Only a small 
proportion of hearts in some groups satisfied the IES criteria and so many were excluded 
from further use. The excluded hearts might have been more susceptible to reperfusion 
arrhythmias than the hearts actually included in reperfusion experiments. Secondly, there 
were only 3 hearts in two of the groups. However, at a [KC1] of 3.5 mM, the following 
observations were made: 
1) The incidence of IES was acceptably high, at 88% (n=17). 
2) The incidence of ischaemic VT was low (20%, n=15) and not significantly different 
from the control group at [KC1] of 4 mM (0%, n=10). 
3) The incidence of reperfusion VT was high (93%, n=14) and significantly higher than in 
the control with a [KC1] of 4 mM (50%, n=10). 
Discussion 
Decreased [KC1] has been found to reduce electrical stability during both stabilisation and 
reperfusion. In previous studies, Lubbe et al (54) observed a concentration-dependent 
increase in the incidence of reperfusion ventricular tachycardia, from 8% to 100%, when 
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[KC1] was lowered from 12 mM to 3 mM. Curtis & Hearse (79) found that the incidence 
of sustained reperfusion VF (which they defined as VF which lasted until the end of a 10 
minute reperfusion period) was higher at a [KC1] of 2 mM than at 4,6 or 8 mM, although 
hearts in VF at the end of the period of ischaemia were excluded from the reperfusion 
group. Excluded hearts were replaced by others, but the self-selection involved may still 
complicate interpretation of their results, as described above. In both of these studies 
(54.79), the incidence of ischaemia-induced arrhythmias'also increased when [KC1] was 
lowered. This was not observed in the present study. The discrepancy may be explained 
partly by differences in the duration of ischaemia between the studies. Curtis & Hearse 
(79) attributed the association between a low incidence of ischaemic VF and a high [KCI] 
to depolarisation of non-ischaemic tissue by high [KCI], thereby reducing regional 
heterogeneity in the concentration of K+ ([K+]) in the extracellular space ([K+]o) during 
ischaemia. 
The association between high [KC1] and low incidence of reperfusion arrhythmias is not 
easily explained. A candidate mechanism for the development of reperfusion 
tachyarrhythmias is the rapid but uneven washout of accumulated extracellular K+ (K+)o 
during reperfusion (52). The spatial heterogeneity of [K+]o this would cause should 
facilitate reentry (16,80). K+ is known to accumulate in the extracellular space of ischaemic 
myocardium of the rat after as little as 15 seconds of ischaemia and may reach 12 mM 
after 10 minutes (80). K+ accumulation is caused in part, by K+ efflux from ischaemic 
cardiomyocytes (80). A high [KC1] PSS would be expected to decrease the driving force 
for K+ efflux. Yan et al (81) indeed found that hypoxic perfusion of rabbit isolated 
papillary muscles with a solution containing 10.3 mM K+ inhibited the cellular K+ loss 
observed during hypoxic perfusion with a solution containing 4.1 mM K. It could be 
argued that reduction in K+ loss by a high [KC1] might inhibit the formation of a reentrant 
substrate caused by K+ washout, and that the converse would apply. However, it should 
be stressed that there is presently no proof that reentry is involved in reperfusion 
arrhythmias in the rat, let alone that K+ washout might precipitate it. A number of 
potential causes of reperfusion arrhythmogenesis have been proposed (2,17), some of 
which will be discussed in more detail. 
Whatever the cause of the high incidence of reperfusion arrhythmias using 3.5 mM KCl 
in the present experiment, the mild anti-arrhythmic effect of Ro in the last experiment 
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suggests that it might be amplified using a PSS [KC1] of 3.5 mM. 
The electrical effect of Ro, using a [KCI] of 3.5 mM in the PSS 
Introduction 
There were two aims. Firstly, to try to amplify the mild anti-arrhythmic effect of Ro at 0.5 
µM, by increasing the incidence and duration of VT in the control group. Secondly, to 
investigate the effect of Ro at 5 µM. 
Method 
A PSS was prepared as described on page 6, with a [KC1] of 3.5 mM. Aliquots of the Ro 
stock solution were added directly to this, to give final concentrations of 0.5 µM or 5 µM. 
In Ro-treated groups, the perfusion HOP was lowered to 0.85 m, instead of 0.7 m, in an 
attempt to normalise coronary flow rates during the first few minutes of reperfusion. Most 
arrhythmias would be expected at this time. Arrhythmias and coronary flow rates were 
recorded prior to, during and following 10 minutes of LV regional ischaemia, as 
described before. In addition, rat body weight was recorded in each experiment and the 
heart surface temperature was measured at the end of reperfusion, using a thermistor 
temperature probe (Wayne Kerr). The incidences of arrhythmias were compared using a 
X2 test, with Yate's Correction. Other variables were compared using a Mann-Whitney 
test (see page 14 for statistical justification). 
Results 
Initial electrical stability 
In a control group of 12 hearts, IES was 92%. Ro at both 0.5 and 5 µM caused a marked 
and significant loss of IES (Figure 8). In most cases, this destabilising action of Ro 
occurred within seconds of connecting hearts to the Langendorff apparatus. There was no 
significant difference in IES between the two drug-treated groups. Of 7 hearts perfused 
with Ro at 5 µM, however, only 2 gained NSR. This concentration was, therefore, 
significantly pro-arrhythmic and further analyses could not be made due to the small 
sample size. 
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Coronary flow rate 
In the control group (n=10 hearts), in which the perfusion HOP was 1 m, flow rate during 
the first 5 minutes of reperfusion was 15.5 ± 0.7 ml/min. In the group treated with Ro at 
0.5 µM (n=6 hearts), flow rate was not significantly different from control during this 
time (16.4 ± 1.7 ml/min), or at any other time in the experiment. 
Arrhythmias 
In the control group, 9 of 10 hearts entered VT during reperfusion. In both this and the 
group treated with Ro at 0.5 µM, the peak incidence of VT was observed in the first 
minute of reperfusion, as in earlier experiments. Ro at 0.5 µM significantly reduced the 
incidence (Figure 9) and the duration (Figure 10) of VT during the first two minutes of 
reperfusion, and markedly and significantly reduced the total duration of VT during 
reperfusion (Figure 11). 
Other variables 
There was no significant difference between the control group and the group treated with 
Ro at 0.5 µM in terms of rat weight (534 ±9 versus 512 ± 28 g), or heart surface 
temperature (36.9 ± 0.1 versus 37.0 ± 0.1°C), respectively. 
Summary 
The main finding was a significant electrical destabilising effect of Ro at both 0.5 and 5 
µM. In this and previous experiments, hearts were particularly unstable for the first 
minute of perfusion. A low [KC1] aggravated this effect. There may have been an 
amplification of the anti-arrhythmic effect of Ro at 0.5 µM using a [KC1] of 3.5 mM, 
compared to that observed with a [KC1] of 4 mM, particularly with regard to the reduction 
in the duration of VT. However, the initial destabilising effect of the KATP opener meant 
that only exceptionally stable hearts may have been retained for experiments with Ro. 
19 
Investigation of the effects of Ro, the KATp blocker glibenclamide, and their 
combination, using a refined perfusion method 
Aims 
1) To eliminate self-selection with a PSS composition giving a high degree of IES, but 
maintaining a high level of reperfusion arrhythmias. 
2) To refine the perfusion method to stabilise hearts immediately after excision. 
3) To investigate the effects of a KATP blocker, glibenclamide. 
4) To combine the KATP opener and blocker to investigate their interactions. 
Introduction 
Glibenclamide is a sulphonylurea hypoglycaemic agent used for the treatment of non- 
insulin-dependent diabetes mellitus (82). In 1985, Sturgess et al (83), using a patch clamp 
technique on plasma membranes excised from a rat insulin-producing cell line, observed a 
K+-selective channel with a conductance of 56 pS. This channel was closed by 1 mM 
ATP applied to the inside, but not to the outside of the cell membrane. Exposure of an 
outside-out patch of membrane to glibenclamide (10 µM) halved the number of open 
single KATP channels. A similar action of glibenclamide has been demonstrated in cardiac 
ventricular myocytes from the guinea-pig (84) and rat (31). This suggests that 
glibenclamide may be used to block KATP channels in the present experiments. 
Method 
Rat isolated hearts were subjected to 10 minutes of regional ischaemia and 10 minutes of 
post-ischaemic reperfusion, and assessed for VT according to the above method, with the 
following modifications and additions. 
1) [KC1] was raised to 5 mM. It was hoped that this would offset the initial destabilising 
effect of Ro at 5 µM, so that Ro at this concentration could be investigated during 
ischaemia and reperfusion. 
2) Hearts which were in VT immediately before reperfusion were not excluded from 
arrhythmia analysis during reperfusion. 
3) Drug preparation. Glibenclamide (Sigma Chemical Co) was dissolved in dimethyl 
sulphoxide (DMSO), and stored at 4°C. After warming to room temperature, an aliquot of 
this solution was added to the PSS, to give finally 10 tM glibenclamide with 0.02% 
DMSO. Ro was dissolved directly in PSS. PSS pH remained within the normal range of 
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7.3-7.5. 
4) Hearts were perfused from reservoir 2 [Figures la (page 9) & lb] with either drug-free 
PSS, or with glibenclamide solution, for 10 minutes following connection of the heart to 
the Langendorff apparatus. The HOP was set to normalise coronary flow rate during 
stabilisation. By turning the two way valve, reservoir 1 was then used to perfuse hearts 
with either PSS alone or with glibenclamide, or with added Ro, for the remaining 5 
minutes of the stabilisation period. This allowed all hearts to stabilise before starting 
perfusion with Ro. 
5) Heart rate was measured at 2 minute intervals from the heated stylus recordings. 
6) Following staining of the ischaemic zone, the stained and non-stained ventricular 
muscle was separated, lightly blotted to 'absorb surface liquid, and weighed. 
7) The use of an arrhythmia score (AS) was investigated. At minute intervals, AS was 
calculated as [duration of VT(s) + (No. VPBs/4)]. It was hoped that this formula would 
provide a fair representation, in terms of electrical disruption of the heart, of the severity 
of a VPB, compared to an episode of VT. 
Hearts were assigned sequentially to the following groups. 
1) PSS control (HOP =1 m, n=10) 
2) Ro at 0.5 tM (HOP = 0.85 m, n=10) 
3)Roat5 µM(HOP =0.85m, n=9) 
4) Glibenclamide at 10 pM (HOP =1 m, n=11) 
5) Glibenclamide at 10 pM (HOP = 1.15 m, n=9) 
6) Ro at 0.5 tM + glibenclamide at 10 tM (HOP =1 m, n=10) 
7) Ro at 5 tM + glibenclamide at 10 tM (HOP =1m, n=10) 
Results 
Of 82 rat hearts used, 14 were excluded from the analysis, 8 of which did not show a 
decrease in coronary flow rate during ischaemia, but actually showed an increase. 
Presumably this was due to aortic valvular incompetence from closing the LMA snare. 
Five hearts failed the IES criteria and 1 heart did not show a discreet area of ischaemic 
muscle following staining because the LMA was found to have been outside the loop of 
the silk snare. 1 
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Coronary flow rate 
There was no significant difference from control in flow rates measured in the first 5 
minutes of reperfusion in any of the drug-treated groups, with the exception of Ro at 5 
µM (Figure 12). Glibenclamide reduced the pre-ischaemic flow rate by 39%, from 11.7 t 
0.5 to 8.4 ± 0.4 ml/min/g total ventricular weight when perfused at the same HOP as the 
control. The pre-ischaemic flow rate of hearts perfused with glibenclamide at 10 µM was 
not equalised to that of the control by raising the HOP to 1.15 m. 
Heart rate 
In the control group, the initial heart rate was 255 ±8 beats/minute. In groups of hearts 
perfused with Ro at 0.5 µM, Ro at 5 µM, and glibenclamide at 10 µM, initial heart rates 
were 240 ± 19,221 ± 15 and 226 ± 14 beats/minute, respectively. At no time prior to, or 
during ischaemia did heart rate in these groups differ from control (Figure 13). 
Arrhythmias 
IES was high (94%) for the combined groups and there was no significant difference in 
IES between them. Hence, there was little opportunity for self-selection to operate. Ro 
was, not pro-arrhythmic prior to ischaemia, following stabilisation of hearts in drug-free 
PSS. In the control group, 90% of hearts entered VT during reperfusion. The incidence 
and the duration of reperfusion VT were not significantly different from those of earlier 
control groups using a [KC1] of either 3.5 or 4 mM. Glibenclamide at 10. tM had no 
significant effect on either the incidence or the duration of arrhythmias during ischaemia 
or reperfusion (Figures 14,16 & 18). Ro at 0.5 µM significantly reduced the incidence of 
VT during the first 3 minutes of reperfusion (Figure 14). Glibenclamide at 10 µM did not 
alter this effect (Figure 14). Ro at 5 µM significantly increased the incidence of VT. 
during ischaemia (Figure 15). Glibenclamide at 10 µM completely prevented this effect 
(Figure 15). Ro at 0.5 µM had a significant VT-shortening effect during the first minute 
of reperfusion (Figure 16). Glibenclamide at 10 µM did not modify this effect (Figure 
16): the combination of these drugs caused significant reduction in the duration of VT 
during the first 5 minutes of reperfusion (Figure 16). Ro at 5 µM significantly increased 
the duration of, VT during ischaemia (Figure 17). Glibenclamide at 10 µM completely 
offset the effect of 5 µM Ro during both ischaemia and reperfusion (Figure 17). In the 
control group, the time to onset of reperfusion VT was 18.2 ±. 7.6 s (n=9). In the groups 
treated with Ro at 0.5 µM, glibenclamide at 10 µM, and the combinations of Ro at 0.5 
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µM with glibenclamide at 10 µM, and Ro at 5 pM with glibenclamide at 10 µM, the time 
to onset of reperfusion VT was not significantly different from the control group, at 5.0 ± 
5.0 (n=2), 35.4 ± 26.9 (n=9), 80.5 ± 46.7 (n=6) and 16.7 ± 4.9 s (n=8), respectively. In the 
group treated with Ro at 5 µM, the only heart that did not display VT immediately prior 
to reperfusion, did not develop VT during reperfusion. The other hearts remained in VT 
during reperfusion. The effects of Ro, glibenclamide and their combination, on the total 
duration of VT observed throughout each experimental phase are summarised in Figure 
18. The apparent reduction in the total duration of reperfusion VT by glibenclamide at 10 
pM did not reach statistical significance. The total duration of reperfusion VT in the 
group of hearts perfused with the combination of Ro at 0.5 µM and glibenclamide at 10 
µM, was not significantly lower than that of hearts perfused with Ro at 0.5 µM alone 
(Figure 18). 
Arrhythmia score 
A comparison between the duration of VT and the AS was made in groups of hearts 
perfused with both PSS and with added glibenclamide (Figure 19). There was no 
significant difference between these two parameters in either group, and there was no 
significant difference in the AS between either group, at any time during the experiment. 
This illustrates the lack of superiority of AS over VT, for analysing arrhythmias in this 
situation. 
A comparison of all the other measured parameters is shown in Table 2. 
Discussion 
Ro exhibited both pro- and anti-arrhythmic activity. The type of effect seen was different 
during ischaemia and reperfusion. It also depended on the concentration of the drug used. 
Glibenclamide caused constriction of coronary vessels and had no effect on arrhythmias 
during ischaemia or reperfusion. Neither Ro nor glibenclamide had a significant effect on 
heart rate prior to or during ischaemia. Self-selection no longer impeded the interpretation 
of results. The high IES here, even in the presence of Ro, may have been due to changes 
in the composition of the PSS. There were no significant differences between any of the 
groups in the proportion of non-perfused muscle during LMA occlusion. The incidence of 
reperfusion arrhythmias in the control group was unexpectedly high, especially in view of 
earlier observations using a varying [KC1]. The reason for this is presently unclear. No 
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previous report was found on the effect of Ro on arrhythmias. There are several reports, 
however, in which drugs with similar properties to Ro have been used, in a wide variety 
of animal models (28,30,85,86,87,88). These studies point to both pro- and anti-arrhythmic 
effects from KATP openers which are likely highly dependent on the model used. The 
cardiac effects of glibenclamide have also been well documented (32,89,90,91) but a variety 
of experimental models have yielded conflicting results. Bril et al (32) used a similar 
model to the present one with a [KC1] of 4.4 mM, and 5,10 or 15 minutes of LMA 
occlusion and 10 minutes of reperfusion. They investigated effects on arrhythmias, of 
glibenclamide at 1 and 10 µM. In a control group, following 10 minutes of LMA 
occlusion, the incidence of reperfusion ventricular tachycardia and VF was 80% and 70%, 
respectively. Glibenclamide at 10 tM had no significant effect on either the incidence or 
the duration of these arrhythmias, irrespective of whether the drug was administered 
before, during or after reperfusion, and irrespective of the duration of LMA occlusion. 
The only significant effect of glibenclamide on arrhythmias which Bril and co-workers 
found, was a shortening of reperfusion VF when glibenclamide was administered at 1 
µM, prior to ischaemia. They also observed a significant reduction in coronary flow rate 
of approximately 29% by glibenclamide at both 1 and 10 µM, without a change in heart 
rate. 
The unexpected finding of the present work was that glibenclamide did not reverse the 
effects of Ro at 0.5 tM during reperfusion, and this needs to be explained. In this drug 
combination-treated group of hearts, the surface temperature at the end of reperfusion was 
significantly lower than in the control group. Perfusion of guinea-pig isolated hearts with 
a hypoxic and hypothermic (33°C) PSS, has been shown to reduce the incidence of 
ventricular arrhythmias during reoxygenation (92). The 0.6°C temperature drop seen in the 
present study however, is unlikely to have had a large effect on arrhythmias. More likely 
is that the effect on reperfusion arrhythmias was due to the drug combination, and this is 
corroborated by recent studies of Rees & Curtis (93,94). In the first of these (93), rat isolated 
hearts were perfused with a PSS and subjected to 30 minutes of LV regional ischaemia. 
All hearts entered ventricular tachycardia during ischaemia and 88% entered sustained VF 
(which they defined as VF lasting more than 2 minutes). Glibenclamide at 10 tM had no 
effect on the incidence of VF, but significantly reduced the incidence of sustained VF to 
14%. Hearts were also perfused with RP 49356, for which a KATp-opening action has 
been demonstrated in guinea-pig ventricular myocytes (95). This drug at 10 µM had no 
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effect on the incidence of VF or sustained VF during ischaemia. However, the 
combination of RP 49356 and glibenclamide, each at 10 µM, significantly reduced the 
incidence of VF to 25%. In the second study, Rees & Curtis (94) used a dual coronary- 
perfused rat heart model to investigate the effects of this same combination of drugs. The 
drug combination was again antifibrillatory, irrespective of whether it was introduced to 
the ischaemic left ventricle, the uninvolved right ventricle, or both ventricles. They 
concluded that the anti-arrhythmic mechanism of the drug combination remains an 
enigma. It should be noted that in the above reports (93,94), the anti-arrhythmic effects of 
glibenclamide and of the drug combination both occurred during ischaemia, not 
reperfusion. The electrophysiological mechanisms of arrhythmogenesis during ischaemia 
may be different from those of reperfusion (16). In addition, the method of arrhythmia 
quantitation used by Rees & Curtis differed to that of the present study. This highlights 
the difficulty in making direct comparisons between apparently similar studies. 
In the present study, the use of an AS was investigated. AS's are an arbitrary numerical 
grading of arrhythmias in terms of their perceived severity (49). It has been suggested that 
these might permit statistical analysis by parametric techniques (49). This assumes that the 
score is Guassian distributed (73), highlighting a limitation of their use, which was 
indicated in the Lambeth Conventions (72). The AS in the present study was not Guassian 
distributed and so a non-parametric test, the Mann-Whitney test (74) was used to compare 
the AS with the duration of VT. The result illustrates the value of using VT for analysing 
reperfusion arrhythmias in this situation. 
It is generally accepted that glibenclamide is the most specific KATP blocker available. 
There are reports, however, of effects of this drug additional to KATP blockade, such as 
chloride ion (Cl-) channel blockade and stimulation of glycolysis (80). These will be 
discussed in detail in Chapter 6. The antagonism by glibenclamide, of pro-arrhythmic 
effects of Ro that were seen during ischaemia, suggests that KATP channels were activated 
by Ro. This supports the view that Kph-opening may be pro-arrhythmic, at least during 
ischaemia. However, in view of the peculiar findings with the combination of Ro at 0.5 
. tM and glibenclamide at 10 µM, and of the potential influence of glibenclamide, 
particularly at 10 µM, on factors other than KATp blockade, it was decided to explore 
further the effect of KATP activation on arrhythmias during ischaemia and reperfusion, by 
using glibenclamide at 1 µM. 
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Effect of varying perfusion pressure on arrhythmias, in the absence of drugs 
Introduction 
In the above experiments, attempts were made, usually successfully, to keep coronary 
flow constant. This was done to establish the direct effect of drugs on arrhythmias, 
undisturbed by drug-induced changes in coronary flow. In the last experiment, coronary 
flow rates were normalised during early reperfusion, because most arrhythmias were 
expected to occur at that time. However, an unexpectedly low coronary flow rate was 
observed during reperfusion in the group treated with Ro at 5 µM. Ibuki et al (78) have 
demonstrated in a similar model to the present, that restricted reflow following 10 
minutes of regional ischaemia is accompanied by a delay in the time to onset of 
reperfusion-induced VF, but has no effect on the incidence of reperfusion-induced 
ventricular tachycardia or VF. Moreover, the pre-ischaemic flow rate may have been 
more influential on reperfusion arrhythmias than flow during reperfusion. Kojima et al 
(96) demonstrated that a variation in perfusion pressure in rat isolated hearts altered 
[Ca2+]i, myocardial contraction and 02 utilisation. These are effects which might 
conceivably influence reperfusion arrhythmias (97). Since pre-ischaemic flow rates varied 
significantly between some of the groups in the last experiment, this present investigation 
aimed to establish the effect on reperfusion arrhythmias, of the more extreme variations in 
coronary flow rate that were observed in response to drugs. 
Method 
Hearts were randomly allocated to two groups, both perfused without drugs, but at 
perfusion HOPs of 0.67 m ("low flow" group, n=10) and 1.33 m ("high flow" group, 
n=10). Any arrhythmias and the accompanying coronary flow rates were monitored and 
compared with those of the control group from the last experiment. 
Results 
Coronary flow rate 
In the low flow group, the HOP was 33% lower than that of the control, and flow rate 
prior to ischaemia was 42% lower than in the control, at 7.6 ± 0.6 ml/min/g total 
ventricular weight (Figure 20). A flow rate lower than this was not seen prior to 
ischaemia in any of the earlier experiments. During the first 5 minutes of reperfusion, the 
flow rate in the low flow group was 29% lower than in the control, at 7.9 ± 0.5 ml/min/g 
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total ventricular weight, a value similar to the lowest flow rate observed during this time 
in the previous experiments. In the high flow group, the HOP was 33% higher than in the 
control. Flow rates prior to ischaemia and in the first 5 minutes of reperfusion were, 
respectively, 29 and 58% higher than in the control (Figure 20), reaching respective 
values higher than those observed in any of the earlier experiments. The flow rates in the 
control and the low flow groups were similar during ischaemia. 
Arrhythmias 
There were no significant differences in the incidences or the durations of VT between 
any of the groups (Figures 21-23). 
Miscellaneous parameters 
The surface temperature of hearts in the low flow and high flow groups was 37.2 ± 0.1 
and 37.7 ± 0.1°C), respectively. These values were statistically significantly different 
from each other, but not from the control value. The proportion of non-perfused muscle 
measured during LMA occlusion in the low flow and high flow groups was 45.4 ± 2.9 
and 51.5 ± 1.5%, respectively. These values were not significantly different from each 
other, or from the control values. 
Discussion 
Alteration of the perfusion HOP between 0.67 and 1.33 m had a negligible effect on the 
incidence and duration of arrhythmias in the present experiments, suggesting that the 
drug-induced effects on arrhythmias seen above were not secondary to differences in 
coronary flow rates. Comparisons may be drawn between the present experiments and 
those performed by Ibuki et al (78) and Kojima et al (96). In the first of these studies, as in 
the present, ventricular arrhythmias were monitored in Langendorff-perfused rat isolated 
hearts, which were subjected to 10 minutes of regional ischaemia and 10 minutes of 
reperfusion. The authors used a dual coronary perfusion method, described by Curtis (98), 
with a HOP of 1 m. The pre-ischaemic flow rates did not vary between different groups of 
hearts, but the rates of flow during reperfusion were reduced to varying degrees of the 
pre-ischaemic value in different groups. Only by reducing the rate of reflow to 10 and 
20% of the pre-ischaemic value for the first 5 minutes of reperfusion did the authors 
observe a significant effect on arrhythmias, namely a delay in the onset of VF. It is 
noteworthy that a "hyperaemic" response during reperfusion, analogous to that of the 
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present study []Figure 2a (page 11)] was observed (78). By using constant flow conditions 
during reperfusion, this response was abolished, with no reduction in the severity of 
reperfusion arrhythmias. This suggests that any drug-induced alteration of hyperaemic 
effects in the present study did not influence arrhythmias. Unlike the study of Ibuki et al, 
the pre-ischaemic flow rate did vary between groups in the present study. Kojima et al (96) 
investigated the effect of varying perfusion pressure on myocardial mechanical function, 
[Ca2+]i and 02 consumption in the absence of ischaemia, using a similar model to the 
present. They allowed hearts to stabilise for 10 minutes at 1.4,1.1,0.8 and 0.5 m HOP. A 
linear decrease was found in coronary flow rate, LV developed pressure (LVDP), 02 
consumption and both systolic and diastolic [Ca2+]i with decreases in the perfusion HOP, 
suggesting that hearts were regulating the consumption of 02 in response to a decrease in 
coronary flow rate. If this was the case, then it might be expected to prevent the 
myocardial intracellular concentration of ATP ([ATP]; ) dropping sufficiently to open 
KATP channels under conditions of reduced coronary flow. It was decided to continue 
HOP adjustments that were selected for previous experiments, in future experiments. 
Effect of glibenclamide at 1 µM on arrhythmias 
Introduction 
In a study by Grover et al (30) on isolated globally ischaemic and reperfused rat hearts, 
glibenclamide at 1 µM antagonised the profibrillatory effect of the KATP opener 
cromakalim. If glibenclamide blocks KATP channels with a higher specificity at 1 µM 
than at 10 µM, as suggested above, it was felt that it might be useful to assess 
glibenclamide's action at 1 µM in this model, with a view to repeating the experiments 
which used it in combination with Ro. 
Method 
A control group of 10 hearts was perfused with PSS at a perfusion HOP of 1 m. Due to an 
unexpectedly low incidence of reperfusion VT (40%), this experiment was repeated 3 
months later. The repeat group is referred to as the "new control". A group of 10 hearts 
was also perfused with glibenclamide at 1 µM, at a HOP of 1.15 in. In addition, another 
group of 10 hearts was perfused with Ro at 0.5 µM, at a HOP of 1 m, to investigate the 
vasodilatory effect of Ro using a [KCI] of 5 mM. 
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Results 
Coronaryf low rate 
Prior to ischaemia, there was no significant difference between the new control group and 
the glibenclamide-treated hearts (perfused at a 15% higher HOP), at 10.6 ± 0.7 and 9.3 ± 
0.6 ml/min/g total ventricular weight, respectively. In hearts perfused with Ro at 0.5 µM 
(at the same HOP as the control), the pre-ischaemic flow rate was significantly increased, 
by 37%, to 14.5 ± 1.0 ml/min/g total ventricular weight. 
Arrhythmias 
Glibenclamide had no significant effect on the incidence or duration of VT compared to 
the contemporaneous new control. There was no significant difference in arrhythmias 
between the new control and the control detailed on page 21, which was performed 8 
months earlier, referred to here as "previous control" (Figures 24-26). A comparison 
between the previous control group and the 1 µM glibenclamide group revealed a 
seeming anti-arrhythmic effect of glibenclamide (Figures 24-26), but these two 
experiments were not performed contemporaneously. In the new control group, in the 
previous control group and in groups treated with glibenclamide at 1 and 10 µM, 
reperfusion VT onset times were similar, at 8.3 ± 1.1 (n=7), 18.2 ± 7.6 (n=9), 13.4 ± 2.6 
(n=7) and 35.4 ± 26.9 s (n=9), respectively. The anti-arrhythmic effect of Ro was 
confirmed, in spite of the higher pre-ischaemic flow rate compared to the new control, 
with a significant reduction in incidence of reperfusion VT, from 70% to 20%. 
Discussion 
The results suggest a lack of effect of KATP blockade on arrhythmogenesis in this model, 
and highlight the pitfalls of comparing non-contemporaneous groups. Adams et al (77) 
found that glibenclamide between 0.1 and 10 pM had no effect on ischaemia- or 
reperfusion-induced arrhythmias caused by 15 minutes of LMA occlusion in 
Langendorff-perfused rat hearts. A similar outcome was reported in vivo (77) Bril et al (32) 
observed a VF-shortening effect of 1 µM glibenclamide during reperfusion, in a similar 
model to the present. In that study, arrhythmias were classified according to the Lambeth 
conventions, and in contrast to the present study, VF was grouped separately from 
ventricular tachycardia. It is likely that arrhythmias were more severe in the experiments 
of Bril et al, compared to the present study, since [KC1] was lower, at 4.4 mM and 
[CaC12] was substantially higher, at 2.4 mM. The strain of rat they used, Wistar, might 
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also have accounted for the difference. There are several reports of anti-arrhythmic effects 
of glibenclamide in rat hearts (87,89.99,100,101). Kantor et al (89), Zhang et al (99) and Tosaki 
et al (101) used global low-flow ischaemia. Seigl et al (1®) did not specify the nature of the 
ischaemic insult used. In the above 5 studies, the anti-arrhythmic effect of glibenclamide 
was observed during ischaemia. Only Tosaki et al (101) observed an anti-arrhythmic effect 
during reperfusion. The apparent contradiction with the present study may be explained 
by the different model of ischaemia they used. Electrophysiological mechanisms of 
arrhythmogenesis during regional ischaemia and reperfusion may differ from those during 
global ischaemia and reperfusion, ie in the absence of the highly arrhythmogenic substrate 
of a border zone (52). 
Ro at 0.5 . tM dilated coronary vessels to a similar extent to that seen by Ro at 50 nM in a 
4 mM [KC1] PSS, supporting the view that vasodilation by Ro is maximal at 50 nM. The 
vasoconstrictor effect of glibenclamide appears to be less at 1 µM than at 10 µM, since a 
1.15 m HOP adequately normalised coronary flow rate using glibenclamide at 1 µM, but 
not at 10 µM (see Figure 12). This finding is corroborated by Lazdunski (102), who 
described a lower sensitivity to glibenclamide of vascular smooth muscle, compared to 
cardiac, endocrine and neural tissues, and a reversal of this order of sensitivity to KATP 
openers. 
Taking advantage of temporal variation in control arrhythmias: arrhythmogenic 
effects of Ro at 10 µM 
Introduction 
The control group described on page 21 was performed in June 1993. In the first control 
of the last experiment, performed in December 1993, the incidence of reperfusion VT was 
significantly lower than the June control (40% versus 90%). This suggested a seasonal 
variation in arrhythmogenesis, a phenomenon reported in rats by Abrahamsson & 
Almgren (103) and in dogs by Scherlag et al (104). To investigate fully any temporal 
changes in arrhythmias in the present model and to continue to avoid any false 
conclusions about drug effect on arrhythmias in future experiments, it was decided to 
perform a control experiment every 4 days, recording several parameters which might 
influence arrhythmogenesis. The outcome of this "arrhythmia running control" is detailed 
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in Chapter 7. An early observation was a drop in the incidence and duration of 
reperfusion VT in early July 1994, compared to that seen between April and May 1994. 
The aim of the present experiment is to exploit this "dip", by investigating electrical 
effects of a high concentration of Ro under these conditions. 
Method 
Hearts (n=7) were perfused with Ro at 10 µM at a HOP of 0.85 m. Arrhythmias were 
recorded as described earlier, and compared with a contemporaneous group of 12 hearts 
from the running control. 
Results 
Arrhythmias 
Ro at 10 tM was pro-arrhythmic prior to ischaemia, an effect which reached significance 
only a few minutes after introduction of the drug. All hearts were in VT by the end of 
ischaemia (Figures 27 & 28). The effect of Ro at 10 tM on the total duration of ischaemic 
VT is compared with that of earlier experiments using Ro at 0.5 and 5 µM (Figure 29). In 
the present control group, both the incidence and total duration of reperfusion VT were 
significantly lower than the control described on page 21, at 17% and 12.7 ± 9.9 s, 
respectively. Ro at 10 µM significantly increased these values to 100% and 600 s, 
respectively. 
Discussion 
Reperfusion arrhythmias undergo temporal variation in this model. Ro at 10µM is 
significantly pro-arrhythmic prior to, during and following ischaemia, when the severity 
of control arrhythmias is extremely low. Ro exhibits a concentration-dependent pro- 
arrhythmic effect during ischaemia. Pro-arrhythmic effects of KATP openers have been 
reported by others in rat isolated perfused hearts during ischaemia (87,88,100), but not 
during normal perfusion. In guinea-pig isolated perfused hearts, pinacidil at 30 tM 
caused spontaneous arrhythmias in the absence of ischaemia (tos). Di Diego & 
Antzelevitch (106) reported pro-arrhythmic effects of pinacidil (1-5 µM) in canine 
epicardial tissue. This was associated with significant and heterogeneous APD- 
shortening, leading to arrhythmias that were characteristic of reentry in 60% of 
preparations. Ro at 10 µM may have been arrhythmogenic in the present model by 
causing spatially heterogeneous APD-shortening, leading to reentry. This claim must be 
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supported by measuring effects of Ro on APD. 
Summary of Chapter 3 
Electrical and haemodynamic effects of a KATP opener Ro, a KATP blocker glibenclamide 
and combinations of these have been assessed prior to, during and following 10 minutes 
of LV regional ischaemia. Ro was a potent vasodilator and glibenclamide was a weaker 
vasoconstrictor. Such vascular effects were largely compensated for by altering the 
perfusion HOP, and in the absence of drugs, altering the HOP had no effect on 
arrhythmias. Therefore, electrical effects of Ro and glibenclamide probably were direct 
myocardial effects, and not secondary to vascular effects. The PSS constituents and 
perfusion protocol were optimised to cause a high incidence of reperfusion arrhythmias 
without causing self-selection of data through a prior drug-induced electrical instability. 
Ro had no effect on arrhythmias at 50 nM, was mildly anti-arrhythmic at 0.5 µM and 
exerted a concentration-dependent pro-arrhythmic effect during ischaemia, which reached 
significance at 5 and 10 µM. Glibenclamide at both 1 and 10 µM had no significant effect 
on arrhythmias. Ro and glibenclamide did not alter heart rate. There was a transient fall in 
the incidence and duration of arrhythmias in a control group, which then was exploited to 
demonstrate a highly pro-arrhythmic effect of a high concentration of Ro (10 µM), even 
in the absence of ischaemia. The ischaemic pro-arrhythmic effect of Ro at 5 µM may 
have been caused by KATP activation, since it was prevented by glibenclamide at 10 µM. 
However, the combination of Ro at 0.5 pM and glibenclamide at 10 µM curiously exerted 
an anti-arrhythmic effect. Glibenclamide at 10 µM may have exerted effects additional to 
KATp blockade, so it was decided that drug combination experiments would be repeated 
using glibenclamide at a lower concentration. 
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Table 1 
Effect of varying [KCI] on IES, incidence of ischaemia-induced VT and incidence of 
reperfusion-induced VT 
§= includes data from earlier experiments using identical conditions 
*= significant difference from group with [KC1] of 4 mM 
NV = no value recorded, due to zero incidence or discontinued group 
[KC1J (mM) IES Ischaemic-VT Reperfusion-VT 
4.0 91%(10/11) 0% (0/10) 50% (5110) 
3.5 § 88% (15/17) 20% (3/15) 93% (13/14) 
2.7 67% (4/6) 25% (1/4) 75% (3/4) 
2.4 60% (3/5) 33% (1/3) NV 
2.2 57% (4/7) 0% (0/4) 75% (3/4) 
1.5 0% (0/3) NV NV 
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Table 2 
Miscellaneous parameters 
glib = glibenclamide 
*= significant difference from the control group 
PSS control Ro at 0.5 µM Ro at 5µM HOP= 1m HOP = 0.85 m HOP =0 85 m n=10 hearts n =10 hearts 
. 
n=9 hearts 
mean SEM mean SEM mean SEM 
Rat weight (g) 516 8 512 7 523 9 
Stained ventricular weight (g) 0.67 0.03 0.70 0.06 0.78 0.07 
Total ventricular weight (g) 1.31 0.03 1.30 0.02 1.34 0.03 
Stained ventricular weight 
(% of total) 51.7 3 53.7 3.9 59.1 4.2 
Heart surface temperature (°C) 37.5 0.2 38.1 0.1 37.2 0.2 
Glib at 10 µM Ro at 0.5 tM + Ro at 5µM + 
HOP = 1.15 m glib at 10 µM glib at 10 µM n=9 hearts HOP =1m HOP =1m 
n=10 hearts n=10 hearts 
mean SEM mean SEM mean SEM 
Rat weight (g) 472 11 508 8 478 10 
Stained ventricular weight (g) 0.74 0.05 0.75 0.05 0.66 0.04 
Total ventricular weight (g) 1.25 0.04 1.36 0.03 1.28 0.03 
Stained ventricular weight 
(% of total) 59.6 4.2 55.2 3.3 52.1 3.3 
Heart surface temperature (°C) 37.7 0.1 36.9 0.0 37.6 0.1 
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Figure 3 
Typical CEG trace, showing reperfusion-induced ventricular tachyarrhythmias 
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Paper speed shown at top of each trace 
R= moment of reperfusion 
O= onset of ventricular tachycardia 
H= episode of "hybrid VF, with arrows showing 
regular ventricular beats 
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Pre-ischaemic electrical activity 
Onset of reperfusion-induced ventricular tachycardia 
Figure 4 
Coronary flow rate 
PSS = physiological salt solution, HOP = perfusion head of pressure 
Ro = Ro 31-6930, LMA =left main coronary artery 
Values are means, error bars = SEM 
Solid symbols denote significant differences from the control group 
at same time points 
--0- PSS control (HOP =1m, n=10 hearts) 
-p- Ro at 50 nM (HOP =1 m, n=10 hearts) 
-ý Ro at 50 nM (HOP = 0.7 m, n=10 hearts) 
ýA Ro at 0.5 µM (HOP = 0.7 m, n=12 hearts) 
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Figure 5 
Incidence of VT 
Values are means 
Solid symbols denote significant differences from the control group 
at same time points 
-0-- PSS control (HOP =1 m, n=10 hearts) 
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Figure 6 
Duration of VT 
Values are means, error bars omitted for clarity 
There were no significant differences between the control and 
drug-treated groups at same time points 
--0- PSS control (HOP =1m, n=10 hearts) 
V Ro at 50 nM (HOP = 0.7 m, n=10 hearts) 
&' Ro at 0.5 µM (HOP = 0.7 m, n=12 hearts) 
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Figure 7 
Total duration of VT, during reperfusion 
Values are means, error bars = SEM 
There were no significant differences in the duration of VT 
between groups 
Q PSS control (HOP =1m, n=10 hearts) 
® Ro at 50 nM (HOP = 0.7 m, n=10 hearts) 
Z Ro at 0.5 RM (HOP = 0.7 m, n=12 hearts) 
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Figure 8 
Incidence of initial electrical stability 
Values are means 
Asterisks denote significant differences from the control group 
Q PSS control (HOP =1m, n=12 hearts) 
EZ Ro at 0.5 µM (HOP = 0.85 m, n=12 hearts) 
12 Ro at 5 tM (HOP = 0.85 m, n=7 hearts)) 
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Figure 9 
Incidence of VT 
Values are means, 
Solid symbols denote significant differences from the control group 
at same time points 
-0- PSS control (HOP =1 m, n=10 hearts) 
V Ro at 0.5 µM (HOP = 0.85 m, n=6 hearts) 
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Figure 10 
Duration of VT 
Values are means, error bars omitted for clarity 
Solid symbols denote significant differences from control group 
at same time points 
-a- PSS control (HOP =1m, n=10 hearts) 
-V- Ro at 0.5 . tM (HOP = 0.85 m, n=6 hearts) 
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Figure 11 
Total duration of VT, during reperfusion 
Values are means, error bars = SEM 
Asterisk denotes a significant difference from the control group 
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Figure 12 
Coronary flow rate 
Values are means, error bars omitted for clarity 
Solid symbols denote significant differences from the control group 
at same time points 
-0- PSS control (HOP =1m, n=10 hearts) 
v Ro at 0.5 tM (HOP = 0.85 m, n=10 hearts) 
Ro at 5 µM (HOP = 0.85 in, n=9 hearts) 
ý- Glibenclamide at 10µM (HOP =1.15 m, n=9 hearts) 
I Ro at 0.5 µM + glibenclamide at 10 µM (HOP =1 m, n=10 hearts) 
-0- Ro at 5 µM + glibenclamide at 10 tM (HOP =1m, n=10 hearts) 
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Figure 13 
Heart rate 
Values are means, error bars omitted for clarity 
There were no significant differences between the control and 
drug-treated groups 'at same time points 
-a- PSS control (HOP =1m, n=10 hearts) 
ý- Ro at 0.5 µM (HOP = 0.85 m, n=10 hearts) 
-ý- Ro at 5 µM (HOP = 0.85 m, n=9 hearts) 
D Glibenclamide at 10µM (HOP =1.15 m, n=9 hearts) 
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Figure 14 
Incidence of VT 
Values are means 
Solid symbols denotes significant differences from the control group 
at same time points 
fi = overlapping points are both significantly different from the control 
-a- PSS control (HOP =1m, n=10 hearts) 
ý- Ro at 0.5 . tM (HOP = 0.85 m, n=10 hearts) 
ý- Glibenclamide at 10µM (HOP = 1.15 m, n=9 hearts) 
EB Ro at 0.5 µM + glibenclamide at 10 µM (HOP =1 m, n=10 hearts) 
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Figure 15 
Incidence of VT 
Values are means 
Solid symbols denote significant differences from the control group 
at same time points 
-p- PSS control (HOP =1m, n=10 hearts) 
- Ro at 5 tM (HOP = 0.85 m, n=9 hearts) 
-0- Glibenclamide at 10 tM (HOP = 1.15 m, n=9 hearts) 
---0- Ro at 5 µM + glibenclamide at 10 tM (HOP =1m, n=10 hearts) 
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Figure 16 
Duration of VT 
Values are means, error bars omitted for clarity 
Solid symbols denote significant differences from the control group 
at same time points 
-Q- PSS control (HOP =1 m, n=10 hearts) 
V Ro at 0.5 µM (HOP = 0.85 m, n=10 hearts) 
.D Glibenclamide at 10µM (HOP= 1.15 m, n=9 hearts) 
E Ro at 0.5 gM + glibenclamide at 10 µM (HOP =1m, n=10 hearts) 
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Figure 17 
Duration of VT 
Values are means, error bars omitted for clarity 
Solid symbols denote significant differences from the control group 
at same time points 
--a- PSS control (HOP =1m, n=10 hearts) 
A Ro at 5 µM (HOP = 0.85 m, n=9 hearts) 
-ý' Glibenclamide at 10 µM (HOP = 1.15 m, n=9 hearts) 
Ro at 5 µM + glibenclamide at 10 µM (HOP =1m, n=10 hearts) 
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Figure 18 
Total duration of VT, during reperfusion 
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Asterisks denote significant differences from the control group 
§ denotes "invisible column" 
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Figure. 19 
Comparison of the parameters VT and AS 
Values are means, error bars omitted for clarity 
There were no significant differences between VT and AS in control 
and drug-treated groups, or between the AS of control and drug-treated 
groups, at same time points 
--a- VT (PSS control, HOP =1m, n=10 hearts) 
$- AS (PSS control, HOP =1m, n=10 hearts) 
--E]- VT (glibenclamide at 10µM, HOP = 1.15 m, n=9 hearts) 
ED - AS (glibenclamide at 10 µM, HOP = 1.15 m, n=9 hearts) 
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Figure 20 
Coronary flow rate 
Values are means, error bars omitted for clarity 
Solid symbols denote significant differences from the control group 
at same time points 
-V- PSS 'low flow' (HOP = 0.67 m, n=10 hearts) 
--a- PSS control (HOP =1m, n=10 hearts) 
-A PSS 'high flow' (HOP = 1.33 m, n=10 hearts) 
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Figure 21 
Incidence of VT 
Values are means 
There were no significant differences between groups 
at same time points 
ý- PSS 'low flow' (HOP = 0.67 m, n=10 hearts) 
-0- PSS control (HOP =1m, n=10 hearts) 
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Figure 22 
Duration of VT 
Values are means, error bars omitted for clarity 
There were no significant differences between groups 
at same time points 
---- PSS 'low flow' (HOP = 0.67 m, n=10 hearts) 
--a- PSS control (HOP =1m, n=10 hearts) 
-j--- PSS 'high flow' (HOP = 1.33 m, n=10 hearts) 
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Figure 23 
Total duration of VT, during reperfusion 
Values are means, error bars = SEM 
There were no significant differences between groups 
EJ PSS 'low flow' (HOP = 0.67 m, n=10 hearts) 
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Figure 24 
Incidence of VT 
Values are means - There were no significant differences between contemporaneous control 
and drug-treated groups at same time points 
Asterisks denote significant differences between glibenclamide at 1 µM 
group and previous control group at same time points 
E3 New control (n=10 hearts) 
ES Glibenclamide at 1 µM (n=10 hearts) 
Q. Previous control (n=10 hearts) 
RS Glibenclamide at 10 µM (n=9 hearts) 
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Figure 25 
Duration of VT 
Values are means, error bars omitted for clarity 
There were no significant differences between contemporaneous control 
and drug-treated groups at same time points 
Asterisks denote significant differences between glibenclamide at 1 µM 
group and previous control group at same time points 
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Figure 26 
Total duration of VT, during reperfusion 
Values are means, error bars = SEM 
Asterisk denotes a significant difference between groups 
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Figure 27 
Incidence of VT 
Values are means 
Solid symbols denote significant differences from the control group 
at same time points 
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Figure 28 
" Duration of VT, 
Values are means, error bars omitted for clarity 
Solid symbols denote significant differences from the control group 
at same time points 
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Figure 29 
Total duration of ischaemia-induced VT 
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Chapter 4 
Action potential recording in the intact heart 
Rationale for recording APD in this model 
There have been numerous investigations into effects of KATP modulation on AP 
characteristics, using standard microelectrode recordings from cardiac isolated myocytes 
and muscle strips. However, there have been relatively few studies of such effects in 
intact hearts using any method of AP recording. No reports were found of studies of 
effects of KATp modulators on APs in intact rat hearts during ischaemia and reperfusion. 
This is probably due to the technical difficulty of recording stable APs from a relatively 
small, beating heart. Valuable pathophysiologically relevant information regarding 
potential electrophysiological mechanisms of arrhythmogenesis, and the involvement of 
KATp modulation in these, could be gained by measuring regional changes in APD during 
ischaemia and reperfusion in the present model. 
KATp activation, whether induced by ischaemia or by drugs, would be expected to shorten 
APD. In cardiac myocytes there is a difference (known as the electrochemical gradient) 
between the resting membrane potential (EM) (typically -80 mV in the rat (113)) and the 
electrochemical diffusion potential for K+ (EK), which is about 10 mV more negative 
(114). A substantial component of EM is due to the relatively high conductance of the 
plasmalemma to K+. An increase in this conductance would allow K+ to diffuse out of the 
cell, down its electrochemical gradient, which tends to move EM towards EK (see 
Northover (115)). This K+ efflux therefore constitutes a hyperpolarising or repolarising 
current. Since the conductance of KATp channels is both voltage- and time-independent 
(4,116), current flowing through the KATp channels, (IKATp), would be expected to 
contribute to net outward current flow during repolarisation, and thus accelerate 
repolarisation and shorten APD. 
In 1988, both Sanguinetti et al (29) and Escande et al (117) demonstrated APD-shortening 
by cromakalim in isolated cardiac myocytes. Similar KATP opener-induced effects have 
since been demonstrated (118,119,120.120. In the present model, a glibenclamide-sensitive 
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APD-shortening effect of Ro during normal perfusion alone, would suggest involvement 
of the KATp channel in the above effects of Ro on arrhythmias. Additional information on 
APD changes during ischaemia and reperfusion, however, would be invaluable. 
It is generally accepted that arrhythmias occur through abnormalities in either AP 
initiation or propagation, or a combination of these. The majority of ischaemic 
arrhythmias are thought to be due to an abnormality of propagation, namely reentry (16). 
As will be discussed later, myocardial APD-shortening, particularly of a spatially 
heterogeneous nature, may provide an ideal substrate for reentry. KATP activation has 
been implicated in the APD-shortening which occurs during ischaemia (102). This raises 
some obvious questions. Does APD shorten during ischaemia in the rat, and if so, is it 
glibenclamide-sensitive? Could Ro at 5 tM shorten APD sufficiently during ischaemia to 
cause arrhythmias through reentry? Non-reentrant arrhythmogenic mechanisms, such as 
triggered activity due to afterdepolarisations have been implicated as the primary stimuli, 
if not maintainers of reperfusion arrhythmias (122). So, do afterdepolarisations occur in 
this model? If so, could the anti-arrhythmic effect of Ro at 0.5 pM seen above be due to 
KATP activation-induced opposition of these? This might help to explain the lack of effect 
of glibenclamide on reperfusion arrhythmias. Although recording of afterdepolarisations 
must be interpreted with caution due to possible mechanical artifacts, Yuan et al (123) 
suggest that valid afterdepolarisations have been recorded from monophasic APs (MAPs) 
in several species, including human. Answering the questions posed above by recording 
APs in the present model, however, provides a considerable challenge. 
Choice of APD recording method 
The most accurate representation of the cardiac transmembrane AP (TAP) is obtained 
through intracellular recordings, usually with glass microelectrodes. This permits 
measurement of EM, maximum upstroke velocity (Vm,,,, ) AP amplitude (APA) and APD. 
The impalement of a single myocyte in an intact beating heart over a reasonable length of 
time is difficult to achieve; and reports of such studies are few. Inoue et al (124), using a 
Langendorffperfused rat ventricular preparation have achieved some success, although 
they admit to difficulty in separating true resting potentials from "bend, tip, or damage 
potentials". Floating microelectrodes, in which the distal tip of a glass microelectrode is 
allowed to move freely with the contracting epicardial wall, have been used in dogs 
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(125,126), and, more recently, in rats (127). This technique, like standard microelectrode 
recording, suffers from the difficulty of maintaining electrical contact with the inside of 
single moving cells. Perchenet & Kreher (127) noted that "multiple impalements were 
required to provide continuous electrophysiological data during ischaemia and 
reperfusion". Several investigators have recorded the QT or QRS interval from the CEG 
in rat hearts (19,128,129,130,131,132,133), providing an indirect measure of APD. This method 
can provide no accurate information on regional changes in APD, however. Local 
epicardial electrograms have been recorded, for example, in dogs (125) using 5 mm 
diameter disc electrodes. These provide more information than the CEG, but still only an 
indirect measurement of APD. A compromise between CEG and TAP recording is MAP 
recording. MAPs are extracellularly-recorded waveforms, that can reproduce the 
repolarisation time-course of TAPs (123-134). These provide more precise information on 
local repolarisation and activation than the CEG, since they derive from a limited area not 
more than 5 mm in diameter (134). The MAP is a measure of an injury current flowing 
between a region of depolarised and hence inactivated cells beneath an electrode, and 
electrically active cells surrounding this region (134). As such, MAPs cannot be used to 
measure EM or Vm, and APA is considered to be too variable to be measured reliably 
(123). However, the time-course of MAP repolarisation has been shown to faithfully mimic 
that of the TAP recorded from closely adjacent sites (see Figure 2 of Ino et al (135)) and 
can be used to measure regional variation of APD. The depolarising stimulus used to 
cause the injury current is often contact pressure and the contact catheter electrode is 
commonly used in clinical and experimental studies (123,136). Alternatively, negative 
pressure may be used, with the suction electrode. 
The suction electrode 
Since its development in 1936 (137), the suction electrode has been used to record APs 
from the hearts of several species (138,139,140,141,142,143), including human (144), but in rats 
only by Rees & Curtis (94,145). In these studies (94,145), in which APD was measured 
during ischaemia, but not during reperfusion, there are no details of electrophysiological 
methodology, or at what level of repolarisation APD was measured. Suction electrodes 
should allow continuous recording of MAPs, without the need for spring-loaded devices 
used with some pressure contact electrodes (136), since the applied vacuum will hold the 
electrode in place. 
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The "brush suction electrode" 
Several prototype suction electrodes were tested. Eventually, by modification of a design 
used by Autenrieth et al (140), an electrode specifically designed for use in the rat was 
constructed. I shall refer to this as the brush suction electrode. Details of the electrode 
construction and validation are given in the Appendix (page Al). A technique was 
developed to record APs simultaneously from left and right ventricular (RV) epicardial 
walls, prior to, during and following regional ischaemia. A summary of findings from 
this, which are relevant to the study of the role of KATp modulation in arrhythmogenesis, 
ie mainly APD changes in a control group and in the presence of drugs used in the 
validation, is given below. 
Regional APD changes during ischaemia and reperfusion, in a PSS control group 
Introduction 
The aim was to record APD simultaneously in LV and RV muscle walls using suction 
electrodes, prior to, during and following 10 minutes of LV regional ischaemia. This was 
with a view to investigating effects of KATP modulation on APD changes under such 
conditions, in an attempt to elucidate potential mechanisms of effects of KATP modulation 
on arrhythmogenesis. 
Method 
Electrical recording 
Brush suction electrodes were used to record APs in a group of hearts perfused under 
similar conditions to the control group detailed on page 21. The methodology is described 
in detail in the suction electrode validation study (see Appendix). Briefly, hearts were 
perfused with PSS, prior to, 'during and following 10 minutes of LV regional ischaemia. 
APD at 50% and 80% repolarisation (APD50 and APD80, respectively) was recorded from 
both ventricles simultaneously, at 1 minute intervals except during the first 2.5 minutes of 
reperfusion, when recordings were taken every 10 seconds. The interval between the RV 
and the LV peaks, relative to the RV peak (referred to as LV lag), was recorded at the 
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same time points as APD. In APs with a "notched" appearance, the interval between the 
AP spike and the AP dome (referred to as S-D interval), was recorded every 5 minutes. 
Experiments were performed as part of a running control, the "APD running control", on 
the same day as hearts that were included in the arrhythmia running control. This 
permitted: a) investigation of any temporal changes in APD, contemporaneous with those 
of arrhythmias, and b) contemporaneous comparison of APD in control and drug groups. 
When possible, comparisons also were made with data from the Appendix. 
Data analysis 
Data from the first 15 hearts of the APD running control group (referred to here as "PSS 
control") were grouped and various comparisons were made, using a Mann Whitney test. 
This non-parametric statistical test was chosen since APD data was not normally 
distributed. This test will also be used for APD data analyses in the following chapters. At 
each time point, comparisons were made between LV APDso and APD80, between LV 
and RV APD50 and between LV and RV APD80. Temporal changes in LV and RV APD50 
and APD80 were analysed. During ischaemia, data from each time point were compared 
with minute 10 of normal perfusion. During reperfusion, data from each time point were 
compared with minute 10 of ischaemia. In the present study, as in the suction electrode 
validation study, the coronary ligature was tightened and loosened 2-3 seconds after 
taking recordings at minute 10 of normal perfusion and minute 10 of ischaemia, 
respectively. In the validation study, ischaemic APD-lengthening was always seen within 
3 minutes [see Figures H (page A 19), I, M, 0& T] and reperfusion APD-shortening was 
always seen within 90 seconds (see Figures J, N, P& U). 
In the present study, the longest and shortest APD values seen respectively in the first 3 
minutes of ischaemia and the first 90 seconds of reperfusion, were noted and referred to 
as the ischaemia-induced "APD peak" and the reperfusion-induced "APD nadir". 
Results 
Types of electrical activity observed 
Both "standard" and notched APs were seen [Figure 30 (page 77)] in both ventricles in all 
experimental phases. APs recorded from a heart during normal perfusion, ischaemia and 
reperfusion are shown in Figure 31. The AP changes were typical of those observed in 
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other hearts of the group. During reperfusion, several hearts exhibited chaotic electrical 
activity indicative of arrhythmias (CEA) in both ventricles (Figure 32A). Other hearts 
remained in NSR during reperfusion. Typical AP changes recorded from the left ventricle 
in such a heart are shown in Figures 32Bi & ii. In many hearts, intermittent electrical 
activity indicative of transient episodes of arrhythmias occurred during reperfusion 
(Figure 32C). An attempt to measure APD was only made in such cases, from APs which 
appeared at NSR. In one heart, in the first few seconds of reperfusion, APs with 
substantially extended late repolarisation phases were observed and referred to as "long- 
footed" APs (Examples of such APs are shown in Figure 32D). APD was recorded from 
these since they did not appear at an accelerated rate. APD80 often exceeded 100 ms in 
these long-footed APs, although APD50 often remained unchanged. These "long feet", 
which may represent afterdepolarisations, were not seen in any heart prior to reperfusion. 
APD recordings 
Mean APD (± SEM) was recorded at each time point, when 4 or more APs could be 
measured. In a group of 15 hearts, this was always possible prior to and during ischaemia. 
During reperfusion, this was possible at most time points: APD80 was recorded in at least 
6 APs in each ventricle during reperfusion. 
LVAPD 
A comparison between changes in LV APD50 and LV APD80 is shown in Figures 33 & 
34. APD8o was significantly longer than APD50 at all time points. LMA occlusion caused 
a rapid, significant and transient lengthening of LV APD50 and LV APD80 [Figure 33 & 
Table 3 (page 76)]. The APD peak was recorded at 1 minute of ischaemia. By minute 5 of 
ischaemia, APD had returned to approximately pre-ischaemic values. LMA occlusion did 
not cause significant shortening of LV APD in this group of hearts (Figure 33 & Table 3). 
Reperfusion caused a rapid, significant and transient shortening of LV APD50 and LV 
APD80, compared to values at ischaemia minute 10 (Figure 34 & Table 3). The nadir of 
both APD50- and APDso-shortening was recorded at 30 seconds of reperfusion. This may 
have been preceded by a relatively small increase in LV APD80, but values were not 
significantly longer than at minute 10 of ischaemia. After approximately 2 minutes of 
reperfusion, APD had returned to approximately pre-ischaemic values. 
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RVAPD 
APD50 and APD80 were significantly shorter in the right ventricle, than the left, at most 
time points during normal perfusion (Figures 35 & 37). LMA occlusion caused similar 
APD-lengthening in the right ventricle, to that seen in the left ventricle, although peak RV 
APD values were not significantly longer than those recorded at minute 10 of normal 
perfusion, in this group of hearts (Figures 35,37 & Table 3). By ischaemia minute 10, RV 
APD had returned to approximate pre-ischaemic values. During reperfusion, RV APD 
changes followed no obvious trend (Figures 36 & 38). RV APD80 may have lengthened 
after 20 seconds of reperfusion. Such an increase might have been caused by long-footed 
APs, mentioned above. These APs were rare and so the standard error of mean RV APD 
values was relatively large at this time: RV APD80 at 20 seconds of reperfusion was 29.7 
±8 ms (n=11 APs), compared to 21.5 ± 2.4 ms (n=12 APs) at ischaemia minute 10. RV 
APD values were not significantly different from those recorded at ischaemia minute 10, 
at any time point in the first 3 minutes of reperfusion (Figures 36 & 38). 
Comparison of LV and RV APD changes 
A trend emerged in which normal interventricular disparity of APD disappeared after 
ischaemic APD-lengthening, and returned after reperfusion APD-shortening (Figures 35- 
38). However, at 30 seconds of reperfusion, LV APD50 was shorter than RV APD50. 
Comparisons with previous control groups 
The present control group was compared to those of the validation study (see Appendix). 
These validation control groups are referred to as "group A" [see Figure H (page A19)] 
and "group B" [see Figure T (page A31)]. In all three groups, significant LV APD- 
lengthening occurred during ischaemia (compare Tables 3& 4). In group B, in which RV 
APD changes were also measured, the RV ischaemic APD peak was significantly longer 
than the value at normal perfusion minute 10 (Table 4). In group A, the LV APD value at 
10 minutes of ischaemia was significantly shorter than that at 10 minutes of normal 
perfusion. This was not the case for group B and the present control group. In those 
groups in which APD was recorded every 10 seconds during reperfusion, a significant 
reperfusion-induced LV APD80-shortening was observed (Table 4). In group B and the 
present control group, a similar time-course of changes in interventricular APD difference 
was observed [compare Figures 37 &T (page A31)]. 
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LV lag 
LMA occlusion caused a rapid, significant and substantial increase in LV lag. 
Reperfusion caused an equally abrupt return to pre-ischaemic values (Figure 39). This 
may indicate a slowing of conduction in ischaemic myocardium. 
S -D interval 
Prior to ischaemia, this was 6.7 ± 0.4 and 5.1 ± 0.5 ms (n=24 & 22 APs) in left and right 
ventricles, respectively. During ischaemia, S-D increased significantly in the left 
ventricle, to 15.3 ± 2.2 ms (n=6 APs). There was a small but significant increase in RV S- 
D at this time, to 8.2 ± 1.2 ms (n=14 APs). After 10 minutes of reperfusion, LV and RV 
S-D had returned to pre-ischaemic values, at 6.2 ± 0.5 and 5.2 ± 0.6 ms (n=10 & 16 APs), 
respectively. The S-D interval changes appeared to follow those of APD. 
Discussion 
It is generally accepted that myocardial ischaemia causes a shortening of APD. The 
present study suggests that in Langendorff-perfused rat hearts, the opposite is true, at least 
during the first 3 or 4 minutes of ischaemia. This is in agreement with the recent work of 
Perchenet & Kreher (127). Reperfusion-induced APD changes will be discussed after 
further experimental corroboration. 
Notched Aft 
The AP notch does not appear to be mechanically induced, since its incidence and its 
amplitude is not affected in a predictable manner by pharmacologically altering 
myocardial contractility [see Appendix, Figures Q (page A28) & S]. Although the AP 
notch may become more visible during ischaemia due to a widening of the S-D interval, it 
is not peculiar to ischaemia, either regional or global (see Appendix, page A10). 
Furthermore, it is not caused by mechanical interference between two rigid and opposing 
suction electrodes (see Appendix, page A4), and neither does this set-up alter APD 
compared to the situation with only one suction electrode [see Appendix, Figures I (page 
A20) & J]. That the notch might be real, is supported by similar observations from glass 
microelectrode recordings in ventricular myocytes of the rabbit (107), the cat (108) and in 
ventricular myocytes and muscles of the dog (109). In the dog and rabbit studies, notched 
APs were found in epicardium, but not endocardium. In the rabbit study, Fedida et al 
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concluded that the regional difference in AP type was due to a variation in transient 
outward K+ channel density between the two tissue types. Notched APs have not been 
recorded from ventricles of the guinea-pig, a species thought to be devoid of cardiac 
transient outward channels (146), unlike dogs, cats, rabbits and rats. Notched APs with an 
almost identical configuration to those of Figure 30 have been recorded from human 
ventricular myocardium, by MAP recording (see Figure 3 of Zipes (147)). Franz (134) has 
described artifacts in the MAP upstroke caused by the superimposition of relatively 
remote ventricular electrical activity. In the present study, such artifacts were seen 
occasionally, when using the "Roche suction electrode" and rarely with the brush suction 
electrodes. This may be because the Roche electrode had a relatively large outer pole [see 
Appendix, Figure D (page A 15)]. Yuan et al (123) suggested that a "spiked AP" may be 
caused by "the remnant of the intrinsic deflection and usually has little effect on MAP 
measurements". Franz (iM) notes that a close inter-electrode distance helps to cancel 
remote potentials. TAPs recorded from rat isolated ventricular myocytes (113.124), and 
from rat isolated muscle preparations (148.149) are not notched, suggesting that the notched 
APs from MAP recordings in rat, include an electrical artifact component. 
Mechanoelectric feedback" 
Although there is likely to be no mechanical interference with the present AP recordings, 
true electrophysiological changes resulting from myocardial contraction and relaxation 
may influence the recordings. This mechanoelectric feedback (150), or "contraction- 
excitation coupling" (151) can lead to changes in APD (152). Lab and co-workers (153,154) 
have demonstrated that mechanical or pharmacological reduction in myocardial load 
prolongs APD and vice-versa. This phenomenon might be expected to have more 
influence on MAPs than TAPs. The increase in both LVDP and APD by ouabain at 25 
µM, and the decrease in LVDP and APD by verapamil at 0.5 µM, do not suggest an 
influence of mechanoelectric feedback in the present study. 
Drug-induced APD changes 
In the present and the suction electrode validation studies, LV APD was longer than RV 
APD. Watanabe et al (113) have reported similar findings in rat isolated myocytes and 
muscle strips using standard microelectrodes and the APD values reported agree with 
those of our study. Schouten et al (155) reported similar observations and recorded a larger 
LV myocyte volume compared to the right. In the validation study, inotropic drugs 
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changed pre-ischaemic APD80 in both ventricles (Figure 40) in a manner which could be 
predicted from other studies using different AP recording techniques. For example, 
Kimura et al (156) demonstrated an APD50-shortening effect of verapamil in a feline LV 
preparation. Clark et al (112), using whole cell voltage clamped rat ventricular myocytes, 
demonstrated a 4-aminopyridine (4-AP)-induced lengthening of APD50. Ouabain is 
thought to increase an inward Ca2+ current generated by exchange of sodium ions (Na+) 
and Ca2+ via the Na+/Ca2+ exchanger, through the inhibition of the Na+-K+ pump (157). 
Since the prolonged repolarisation phase of APs seen in the rat is thought to be due to a 
flow of this Ca2+ current (158), ouabain would be expected to prolong APD80. The drug- 
induced changes in APD observed in the validation study, coupled with an absence of 
drug-induced mechanical interference with AP recordings, provides confidence in the 
validity of APD changes caused by ischaemia and reperfusion. 
Ischaemia-induced changes in APD 
At the beginning of this discussion, an apparent contradiction was raised. A shortening in 
APD during ischaemia has been demonstrated in several species and experimental 
models. It is due to an increase in a time-independent K+ conductance (159,160)" The ability 
of the metabolic inhibitors cyanide and 2-deoxyglucose (DOG) to stimulate this increase 
in K+ conductance, and of glibenclamide to decrease it (161,162), suggest the involvement 
of KATp activation in ischaemic APD-shortening. The following evidence suggests that 
ischaemic APD changes are both species- and model-dependent. 
John et at (163) provided clinical evidence of ischaemic APD-shortening in a study on 28 
patients with ischaemic heart disease. They recorded endocardial MAPs from normal and 
ischaemic areas during atrial pacing, and observed a significantly shorter APDga in 
ischaemic, compared to non-ischaemic regions. A similar shortening of APD has been 
recorded in the dog in vivo (125), and in vitro (126) following coronary artery occlusion. In 
both studies, APD-shortening was observed within 2 minutes of ischaemia. Furukawa et 
at (162) and Kimura et at (iM) found similar effects in the cat within 10 minutes of either 
metabolic inhibition by cyanide, or ischaemia, respectively. In the rabbit, Ruiz-Petrich et 
at t165l observed a 70% decrease in LV APD25 after 10 minutes of hypoxic perfusion of 
intact hearts, while Weiss et at (166), using isolated inter-ventricular septa, observed APD- 
shortening after 5 minutes of global ischaemia. In separate studies on guinea-pig isolated 
hearts, both using floating microelectrodes, global ischaemia (167) and low-flow ischaemia 
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(168), both caused a steady shortening of APD during 30 minutes of ischaemia. In 
Langendorff-perfused rat hearts, Inoue et al (124) and Vovk & Meerson (1w) reported' 
shortening of APD after 15 minutes of regional and global ischaemia, respectively. 
Perchenet & Kreher (127) reported a marked shortening of APD within approximately 3 
minutes of perfusing rat hearts with a hypoxic PSS. In rat isolated perfused tissues, 
simulated ischaemia also caused APD-shortening (170.171). It is noteworthy that both 
hypoxic perfusion and simulated ischaemia do not reproduce the haemodynamic effects 
of true ischaemia, and in the study by Perchenet & Kreher, APD did not shorten during 25 
minutes of global ischaemia (see below). 
In many of the above reports of ischaemic APD-shortening, the first APD recording was 
made after 2 or more minutes of ischaemia. However, by measuring APD prior to this, 
several researchers have observed an initial ischaemic APD-lengthening. Dilly & Lab 
(172) recorded MAPS from the pig heart using suction electrodes. They reported an 
increase in APD20,30,40,50,60,70,8o and 9o after 1 minute of ischaemia (see Figure 3a of 
Dilly & Lab (172)). In a separate porcine study, Downar et al (173) reported similar results. 
Penny & Sheridan (174) and MacKenzie and colleagues (P ona1 communication) have reported 
an initial APD-prolongation following'ischaemia in guinea-pig hearts. Penny & Sheridan 
recorded APs intracellularly from isolated hearts, by making multiple impalements during 
global low-flow and no-flow ischaemia. APD lengthened during the first two minutes of 
ischaemia and subsequently shortened, reaching pre-occlusion values after 10 minutes. 
MacKenzie observed a similar course of events using a suction electrode. In sheep 
Purkinje fibres, Carmeliet (175) has reported an APD-lengthening after 5 minutes, 
followed by APD-shortening after 20 minutes of application of 2,4-dinitrophenol (DNP) 
at 0.2 mM. More recently, Perchenet & Kreher (127) reported that in Langendorff-perfused 
rat hearts, global low flow ischaemia caused rapid and transient lengthening of the 
duration of LV epicardial TAPs. In this study, changes in the AP repolarisation time 
course during the first 10 minutes of ischaemia were similar to the present study, and 
during the next 15 minutes APD did not shorten below pre-ischaemic values, but 
lengthened again, particularly at 90% repolarisation. 
The timing of both the first APD measurement following ischaemia and the total duration 
of the ischaemic episode, are critical to the reported outcome of investigations into 
ischaemic APD changes. For example, in the rat study by Inoue et al (124) the first 
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ischaemic APD value was reported after 6 minutes of ischaemia. Presumably, this interval 
was required in order to gain enough APD data, since APs were recorded at successively 
deeper layers of cells, starting from the epicardium. Using this technique, then, their first 
APD recording would not accurately reflect APD changes occurring during the first two 
minutes of ischaemia. Suction electrode-recording of APs from the rat has been reported 
by Rees & Curtis (94). In this study, the point of repolarisation at which APD was 
measured was not specified. However, it is likely to be higher than 80%, since the pre- 
ischaemic APD value was 78 ±5 ms. The first reported ischaemic APD value, at minute 
5, may have been longer, at 101 ± 10 ms. At minute 10 of ischaemia, APD was 92 ±8 ms. 
Also in the rat, the QT interval, which is indicative of APD (176) and the QRS interval, 
have been recorded both in vitro (128) and in vivo (131). In both of these studies, LMA 
occlusion caused a lengthening of the recorded interval after 1 minute of ischaemia. 
Cause of ischaemic APD-lengthening 
This is unknown. Dilly & Lab (172) speculated on several possible causes: temperature 
drop in non-perfused myocardium, fall in intracellular pH, endogenous catecholamine 
release and mechanical changes. Perchenet & Kreher (127) suggested that in the rat, rapid 
accumulation of (K+)° might cause APD-lengthening by suppression of an "early outward 
current" during ischaemia. In the present study, there was no significant drop in LV 
epicardial temperature during ischaemia [see Appendix, Figure W (page A34)]. Dilly & 
Lab (172) reported a fall in this temperature during ischaemia, of 0.5°C. In a study by 
Hollander & Webb (177), APD (point of repolarisation not specified) was 27.4 ms at 37°C, 
in a rat atrial preparation. By cooling this to 30°C, APD lengthened to 58.5 ms. If the 
relationship between temperature and APD in this study is assumed to be linear, then a 
drop in temperature of 0.5°C would lengthen APD by 8%. If this can be applied to the 
present study, and to that of Dilly & Lab (172), then a 0.5°C temperature drop would have 
a relatively small influence on the ischaemic APD-lengthening seen in both studies. 
Mechanoelectric feedback may cause APD-lengthening during ischaemia, due to reduced 
ventricular stretch resulting from deflation of coronary vessels. This is consistent with the 
reported lack of APD-lengthening during hypoxic perfusion at unaltered flow rate (127). 
Platou et al (178) recorded APD in the dog, using a tripodal suction electrode. As in the 
present study, they found no correlation between APD and APA, and noted that during 
"mild ischaemia", in the border zone, there was a homogeneous prolongation of APD. In 
the present study, the initial APD-lengthening following LMA occlusion, may have been 
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caused by either a "wave" of border zone-like conditions traversing the muscle beneath 
the LV suction electrode, or by a period of border zone-like conditions persisting beneath 
the LV suction electrode for the first few minutes of ischaemia. Whatever the cause of 
APD-lengthening in the present study, however, this phenomenon is likely to be related to 
the change in amplitude of the AP dome [see Appendix, Figure L (page A23)]. This, in 
turn, is likely to be related to the influx of Cat+, since verapamil at 0.5 pM reduced the 
AP dome amplitude [see Appendix, Figure R (page A29)]. 
APD changes concurrent in left and right ventricles 
The increase in APD80 in the right ventricle following LMA occlusion is substantial [see 
Appendix, Figure T (page A31), & Figure 37]. Coronary flow rate in the right ventricle is 
high during ischaemia, so an APD similar to the pre-ischaemic value might be expected at 
this time. In all hearts included in the APD analysis, staining of the non-perfused zone 
during ischaemia showed that the RV suction electrode was placed centrally in the 
perfused zone, well clear of stained muscle. Reverse-staining of the RV region 
(performed in 5 hearts in this group, during ischaemia), confirmed RV suction electrode 
placement in stained (perfused) muscle, with LV suction electrode placement in non- 
stained (non-perfused) muscle. The RV APD-lengthening would appear to be an 
electrophysiological phenomenon, which has not been specifically reported in other 
studies. Coronel (52) describes a "lateral gradient" of [K+]o surrounding an ischaemic zone 
in the porcine heart. This gradient was primarily determined by extracellular flow of K+, 
via "assisted diffusion" from ischaemic to normal tissue. Although in the present model, 
the RV suction electrode is situated away from the stained zone, an effect on RV APD of 
substances diffusing from the ischaemic to the non-ischaemic zone cannot be excluded. 
However, the high coronary flow rate observed in the present study during ischaemia 
suggests that (K+)o (or any other extracellularly diffusing substances, such as 
catecholamines, released from the ischaemic zone (172)) would be washed out of the 
extracellular space, before influencing myocardium "sensed" by the RV suction electrode. 
A more likely cause of LV ischaemia-induced RV APD-lengthening is electrotonic 
current flow (179.180) between ischaemic and non-ischaemic myocardium. 
The lack of synchronisation of LV and RV APs which has been observed (see Figures 
32C, 32D & 39), suggests that electrotonic currents which might flow between the 
patches of cells sensed by the two suction electrodes do not influence APs recorded from 
opposing electrodes, but that the RV APD-lengthening is caused directly by electrotonic 
74 
currents flowing as a result of ischaemia. The thickness of muscle wall between the two 
suction electrodes is relatively small using the rat heart, and as Franz indicates (134), 
although suction electrode-recorded APs reflect electrical activity from a small area: not 
less than the electrode size, and probably not more than 5 mm in diameter, it is unknown 
to what depth of cells a suction electrode detects electrical currents. It is noteworthy that 
Inoue et al (124), using a Langendorff-perfused rat heart model of LV regional ischaemia, 
observed changes in intracellularly recorded APD, APA and Vm"', which were concurrent 
in LV (presumably ischaemic) and RV (presumably normally perfused) myocytes. These 
authors concluded that due to an artifact of their technique for staining non-perfused 
muscle, AP data from myocytes in the non-perfused region may have been contaminated 
with that of myocytes in the ischaemic region. Data from the present model, and possibly 
from that used by Inoue et al, suggest that in intact hearts as small as those of the rat, 
electrical changes which occur in the left ventricle, directly influence electrical activity in 
the right ventricle: This may have occurred only during ischaemia, although the present 
study indicates that such an effect occurred during reperfusion also. Watanabe et al (113) 
measured APD75 in isolated LV and RV endocardial myocytes. LV APD75 was 78% 
longer than RV APD75. In the present study, LV APD50 and LV APD80 were 32 and 45% 
longer than the respective RV APD values. This suggests that LV electrical activity may 
influence RV electrical activity -during normal perfusion of intact hearts, although not to 
the extent of abolishing significant LV and RV APD differences. Such an electrical 
coupling between ventricles might have implications in arrhythmogenesis and of course 
may occur in larger hearts. 
Summary of Chapter 4 
In a model which is widely used for studying ventricular arrhythmias, a method has been 
developed of reliably recording regional APD changes during ischaemia and reperfusion. 
APD recordings were not hampered by mechanical interference. APs may have been 
influenced by electric currents flowing beneath and caused by the recording electrodes, in 
addition to those giving rise to APs. LV regional ischaemia caused transient LV and RV 
APD-lengthening. Reperfusion caused a transient LV APD-shortening, and in one heart, 
the possible appearance of early afterdepolarisations (EADs). Any, or all of these AP 
changes might be associated with reperfusion-induced ventricular arrhythmias. 
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Table 3 
APD (ms) [mean ± SEM (n APs)] at various time points, from PSS control group 
Ischaemia-induced APD peak: recorded in first 3 minutes of ischaemia 
Reperfusion-induced APD nadir: recorded in first' 
. 
90 seconds of reperfusion 
0's denote significant differences from normal perfusiön minute 10 
is denote significant differences from ischaemia minute 10 
Normal Ischaemia- Ischaemia Reperfusion- 
perfusion induced peak minute 10 induced nadir 
minute 10 
LV APD50 15.5 ± 1.5 (11) 30.5 ± 4.1 (15) 13.4 ± 1.5 (13) 6.0 ± 0.9 (6) 
LV APD80 34.1 ± 3.0 (15) 62.1 ±4.3 (15) 28.4 ± 1.8 (13) 18.6 ± 1.9 (9) 
RVAPDSO 11.7±0.9(11) 17.5 ± 2.9 (12) 9.7 ± 1.6 (8) 10.0 ± 2.2 (8) 
RV APD80 23.5 ± 1.3 (15) 37.0 ± 5.8 (13) 21.5 ± 2.4 (12) 23.3 ± 3.0 (10) 
Table 4 
APD (ms) [mean ± SEM (n APs)] at various time points, from two control groups 
from the validation study 
Ischaemia-induced APD peak: recorded in first 3 minutes of ischaemia 
Reperfusion-induced APD nadir: recorded in first 90 seconds of reperfusion 
Group A [see figure H (page A 19)], group B [see figure T (page A3 1)] 
0's denote significant differences from normal perfusion minute 10 
is denote significant differences from ischaemia minute 10 
§= APD recorded at 1 minute intervals only 
Normal Ischaemia- Ischaemia Reperfusion- 
perfusion induced peak minute 10 induced nadir 
minute 10 
Group A 
LV APD8o 40.8 t 3.3 (15) 62.9 ± 3.5 (18) - 26.3 ± 3.2 (9) 
§ 
20.4 t 2.0 (9) 
Group B 
LVAPD8o 30.2±2.0(16) 
- 
52.1±3.1 (15) 26.9±3.2(11) 
t 
15.1±3.1 (11) 
Group B 
RV APDgo 20.5 ± 1.2 (14) 37.1 ± 3.6 (13) 24.0 t 3.2 (10) 
T 
17.6 t 1.4 (10) 
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Figure 30 
Examples of high quality AP recordings 
Distance between vertical dotted lines indicates APD80 
i: Representation of a notched AP (C-B is positive) 
Notch amplitude was defined as C-B 
ii: Example of a notched AP 
Recorded from the left ventricle of a control heart, after 5 minutes of regional 
ischaemia 
iii: Example of a standard AP 
Recorded from the same region as (ii), after 1 minute of reperfusion 
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Figure 31 
Simultaneous recordings of LV and RV AN prior to, during and following 
10 minutes of LV regional ischaemia .. 
Scale: horizontal 10 cm =Is, vertical 15 mm = 10 mV. Values are minutes, seconds. 
APs at minutes 10 and 20 were recorded 2 seconds before tightening and loosening 
coronary ligature, respectively. 
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Figure 32A 
Simultaneous LV and RV recordings of reperfusion-induced 
chaotic electrical activity 
Scale: horizontal 10 cm =1 second, vertical 15 mm = 10 mV 
Values are seconds following reperfusion, -*= continuation of recording 
i: Example of typical degeneration of AP configuration 
ii: Example of abrupt onset of chaotic activity 
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Figure 32B i 
Example of severe LV APD-shortening, during reperfusion 
Scale: horizontal 10 cm =1 second, vertical 30 min = 10 mV. 
Values = seconds following reperfusion 
-º = continuation of recording, '= coronary ligature loosened, *= premature beat 
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Figure 32B ii 
Continuation of figure 32B i 
-1 
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Figure 32C 
Example of transient episodes of electrical activity indicative of 
triggered arrhythmia, following reperfusion 
Scale: horizontal 10 cm =1 second, vertical 15 mm = 10 mV 
Recording starts 15 seconds after reperfusion. -º= continuation of recording 
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Figure 32 D 
i) Simultaneous recording of CEG, LV and RV APs during normal perfusion 
Scale: horizontal 10 cm =1 second, vertical 15 mm = 10 mV, *= premature beat 
ii) Example of ischaemic LV lag 
AN recorded 10 minutes after LV regional ischaemia, at 10 cm/second 
Horizontal scale stretched: 1 mm = 3.5 ms, vertical 15 mm = 10 mV. 
LV lag=12.3ms 
iii) Example of simultaneous recordings of LV and RV long-footed APs 
AN recorded at 20 seconds of reperfusion 
Scale: horizontal 10 cm =1 second, vertical 30 mm = 10 mV 
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Figure 33 
LV APD at 50% and 80% repolarisation 
Values are means, error bars omitted for clarity, n=15 hearts 
Solid symbols denote significant differences between groups 
at same time points 
Asterisks denote significant differences from minute 10, within groups, 
during ischaemia 
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Figure 34 
LV APD at 50% and 80% repolarisation, 
during reperfusion 
Values are means, error bars omitted for clarity, n=15 hearts 
Solid symbols denote significant differences between groups 
at same time points 
Asterisks denote significant differences from minute 20, within groups 
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Figure 35 
LV and RV APD 
Values are means, error bars omitted for clarity, n=15 hearts 
Solid symbols denote significant differences between groups 
at same time points 
Asterisks denote significant differences from minute 10, within groups, 
during ischaemia 
-0 - Left ventricle (n=5-15 APs) 
---a- Right ventricle (n=6-15 APs) 
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Figure 36 
LV and RV APD, during reperfusion 
.. 
Values are means, error bars omitted for clarity, n=15 hearts 
Solid symbols denote significant differences between groups 
at same time points 
Asterisks denote significant differences from minute 20, within groups 
EDLeft ventricle (n=5-13 APs) 
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Figure 37 
LV and RV APD 
Values are means, error bars omitted for clarity, n=15 hearts 
Solid symbols denote significant differences between groups 
at same time points 
Asterisks denote significant differences from minute 10, within groups, 
during ischaemia 
--ED- Left ventricle (n=6-15 APs) 
--a- Right ventricle (n=6-15 APs) 
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Figure 38 
LV and RV APD, during reperfusion 
Values are means, error bars omitted for clarity, n=15 hearts 
Solid symbols denote significant differences between groups 
at same time points 
Asterisks denote significant differences from minute 20, within groups 
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Figure 39 
LV lag 
Measured as the interval (relative to the RV AP peak) 
between RV AP peak and LV AP peak 
Values are means, error bars omitted for clarity, n=15 hearts, 7-15 APs 
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Figure 40 
Effect of various inotropic drugs on LV and RV APD 
Values are means, error bars = SEM, n=12-17 hearts, 7-17 APs 
Asterisks denote significant differences between control and 
drug-treated groups in either the left ventricle (L) 
or the right ventricle (R) 
Crosses denote significant differences between ventricles 
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Chapter 5 
Modulation by Ro and glibenclamide, of ischaemia- and 
reperfusion-induced electrical changes 
Effects of Ro on electrical activity 
Introduction 
The aim was to investigate effects of Ro on APs, at concentrations which exerted both 
pro- and anti-arrhythmic effects in the experiments above, ie at 5 and 0.5 µM, 
respectively. 
Method 
Electrical recording 
This was as described on pages A2 & A3 of the Appendix. LV and RV APD50, APD80 
and LV lag were recorded every minute prior to, during and following 10 minutes of LV 
regional ischaemia, except during the first 2.5 minutes of reperfusion, when recordings 
were taken every 10 seconds. A group of hearts was perfused with Ro at 5 tM and the 
results were compared with a contemporaneous control group, namely the group 
described in Chapter 4 (see page 66), referred to here as control group 1. Another group 
of hearts was perfused with Ro at 0.5 µM. Results from this group were compared with 
their own contemporaneous control group, namely hearts 10-24 of the APD running 
control (see Chapter 7), referred to here as control group 2. 
Data analysis 
At each time point, comparisons were made between LV and RV APD in the relevant 
control groups, between LV APD of control and drug-treated groups, and between LV 
and RV APD in drug-treated groups, using a Mann Whitney test. Temporal changes in 
APD within each ventricle were analysed during both ischaemia and reperfusion in all 
groups, according to the method detailed on page 66. Both the ischaemic APD peak and 
the reperfusion APD nadir were noted. The distribution of control APD data was analysed 
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prior to ischaemia and during the first 90 seconds of reperfusion. 
Results 
Comparison of control groups l and 2 
Similar APD changes were seen in both of these controls, ie LV APD50 and APD80 
lengthened significantly during ischaemia, LV APD80 shortened significantly during 
reperfusion, but RV APD did not shorten during reperfusion [see Table 5 (page 114) and 
compare Figures 41-44 (page 118) with Figures 35-38 (page 86)]. Interventricular 
differences in APD80 were similar in both groups. This difference was lost at minute 5 of 
ischaemia but restored after 2-4 minutes of reperfusion [compare Figures 43 & 44 with 
Figures 37 & 38 (page 88)]. There were, however, small differences between these two 
groups. In group 2, the peak ischaemic RV APD80 value was significantly longer than the 
value at minute 10 of normal perfusion and in group 2, LV APD80 had shortened 
significantly below the pre-ischaemic value, by minute 10 of ischaemia. 
Effect of Ro on APD during normal perfusion 
Ro at 0.5 µM had no significant effect on mean LV APD50, LV APD8o, RV APD50 or RV 
APD80 values, but Ro at 5 tM significantly shortened these, by 50,62,47 and 49%, 
respectively (Figure 45 & Table 5). 
Effect of Ro on subsequent electrical changes, compared to contemporaneous control 
groups 
Ro at 0.5 µM significantly attenuated ischaemic APD-lengthening, significantly 
shortened LV APD80 at all time points during ischaemia, but had no significant effect on 
APD during reperfusion (Figures 46-49 & Table 5). Ro at 5 gM abolished ischaemic 
APD-lengthening (Figures 50,51 & Table 5) and significantly shortened LV APD at all 
recorded time points during ischaemia. In hearts perfused with Ro at 5 µM, at minute 4 of 
ischaemia LV APD50 and LV APD80 were 4.0 ± 0.4 and 6.7 ± 0.5 ms, respectively: 
shorter than any LV or RV APD values recorded above (compare these values with, for 
example, the control reperfusion-induced APD nadirs of Figures 50 & 51). After 4 
minutes of ischaemia, there was insufficient LV data to record APD, due to the following 
electrical disturbances. At minute 1 of ischaemia 4 of 15 hearts (27%) exhibited CEA in 
left and right ventricles simultaneously. At minute 2 of ischaemia, a further 3 hearts 
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showed similar electrical activity, so 7 of 15 hearts (47%) appeared to be in arrhythmia at 
that time. At minute 4 of ischaemia, one of these hearts developed LV electrical silence 
(see Figure 52), while an additional heart developed simultaneous LV and RV CEA, so 8 
of 15 hearts (53%) showed RV CEA. RV CEA was subsequently recorded in these hearts 
only, during ischaemia, and at each ischaemic time point. At ischaemia minute 5, LV 
electrical silence was recorded in an additional heart. This previously showed LV and RV 
CEA. At ischaemia minutes 6,8 and 9, separate hearts developed LV electrical silence. 
All of these had exhibited normal RV APs at previous time points. No RV electrical 
silence was observed during ischaemia. No heart developed LV CEA following electrical 
silence. Therefore, at minute 10 of ischaemia, of 15 hearts, 6 (40%) showed simultaneous 
LV and RV CEA, an additional 2 (13%) showed LV electrical silence with RV CEA and 
an additional 3 (20%) showed LV electrical silence with normal RV APs. The remaining 
4 hearts (27%) showed normal APs in both ventricles. 
Effect of Ro on simultaneous LV and RV APD changes 
Significant interventricular differences in APD were observed prior to ischaemia, in 
groups of hearts perfused with Ro at both 0.5 and 5 p. M (Figures 53,55,57 & 58). In 
hearts treated with Ro at 0.5 µM, interventricular difference in APD80 was lost at minute 
2 of ischaemia and subsequently reversed, with LV APD80 reaching a significantly 
shorter value than RV APD80 at minute 4 of ischaemia (Figure 55). In hearts perfused 
with Ro at 5 µM, a similar effect on interventricular difference in APD80 was observed 
during ischaemia (Figure 58), compared to that of Ro at 0.5 µM. During reperfusion, in 
hearts perfused with Ro at 0.5 µM, interventricular differences in APD reached 
significance only at 10 seconds of reperfusion (Figures 54 & 56). 
Effect of ischaemia and reperfusion on APD in drug-treated hearts 
Group of hearts treated with Ro at 0.5µM 
In this group, in contrast to the control groups, ischaemia did not cause significant LV or 
RV APD-lengthening (Figure 55 & Table 5). LV APD50 was significantly shorter at 
minute'5 of ischaemia than at minute 10 of normal perfusion, and LV APD80 was 
significantly shorter at all time points between 4 and 10 minutes of ischaemia, than at 
minute 10 of normal perfusion (Figures 53 & 55). There was no significant ischaemic- 
shortening of APD50 or APD80 in the right ventricle of these hearts (Figures 53 & 55). 
Reperfusion did not cause further significant shortening of LV APD80, below the value 
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recorded at minute 10 of ischaemia (Figure 56), in contrast to the control group (Table 5). 
In the right ventricle, but not the left, APD80 was significantly longer at 20 seconds of 
reperfusion, than at minute 10 of ischaemia (Figure 56). This is unlikely to have been 
anomalous, since a similar trend was seen for RV APD50 in hearts treated with Ro at 0.5 
µM (Figure 54) and for RV APD80 in hearts treated with Ro at 5 µM (Figure 58). This 
lengthening of RV APD80 was caused by long-footed APs. These occurred rarely (see 
below) and at times when relatively few APD data were available. For these reasons, the 
standard error of mean APD values was relatively high at these times. For example, RV 
APD80 at 20 seconds of reperfusion was 48.5 ± 13.4 ms (n=8 APs), compared to a value 
of 19.5 ± 3.0 ms (n=8 APs) at minute 10 of ischaemia. 
Group of hearts treated with Ro at 5 pM 
In this group, there was no LV APD-lengthening during ischaemia, and negligible RV 
APD-lengthening during this time. At minute 3 of ischaemia, LV APD50 was 
significantly shorter than at minute 10 of normal perfusion. At minutes 3 and 4 of 
ischaemia, LV APD80 was significantly shorter than the pre-ischaemic value (Figures 57 
& 58). No significant APD-shortening was seen in the right ventricle at any time point 
during ischaemia. During reperfusion, in spite of LV electrical disruption, sufficient RV 
APD data was available at this time, which revealed no significant reperfusion-induced 
changes in APD50 or APD80 values (Figures 57 & 58). However, there was a trend 
towards RV APD80-lengthening in the first minute of reperfusion, which was caused by 
long-footed APs. The standard error of mean APD values was high when these APs 
occurred. For example, RV APD80 at 20 seconds of reperfusion was 44.4 ± 18.8 ms (n=4 
APs), compared to a value of 10.3 ± 1.1 ms (n=6 APs) at minute 10 of ischaemia. This 
resulted in the lack of significant APD-lengthening at that time. 
Long-footed APs 
Examples of such APs are shown in Figure 32D, iii (page 83). These were observed in 
both control and drug-treated groups of hearts, within the first 90 seconds of reperfusion. 
Since APD80 values in these long-footed APs frequently exceeded 100 ms and since they 
occurred with a low incidence, at time points yielding relatively few APD data, a 
quantitative assessment of drug effects on these APs could not be made reliably, by 
comparing APD data at fixed time points. A frequency distribution analysis of APD 
values was performed during normal perfusion and during reperfusion. The combined LV 
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APD80 data from control group 2 during normal perfusion is shown in Figure 59. This 
was approximately Guassian distributed. LV APD80 values from minute 10 only were not 
normally distributed (Figure 59), illustrating the necessity for non-parametric statistical 
comparisons to be made with other groups at that time point. The combined LV APD data 
from this group during the first 90 seconds of reperfusion is shown in Figure 60. There 
were high frequencies of short APD50 and APD80 values. There were 4 instances of 
APD80 values which exceeded 80 ms, each without associated extended APD50 values. 
These represented long-footed APs. In order to compare these quantitatively between 
groups, it was decided to define long-footed APs from this point, as those in which 
APD80 Z 80 ms. Details of all LV and RV long-footed APs observed in both control and 
drug-treated groups are given in Table 6. Extended APD80 values appeared to be 
associated with normal, or even shortened APD50 values. An extended LV APD50 was 
associated with an extended RV APD80 in all but one AP, recorded from a heart treated 
with Ro at 0.5 µM. The corollary applied, in all but two hearts, both treated with Ro at 5 
µM. There were no significant differences between any of the groups in the number of 
hearts exhibiting long-footed APs (p < 0.05, X2 with Yate's Correction). 
LV lag 
This rapidly lengthened in both control and drug-treated groups, following LMA 
occlusion (Figure 61). In both control groups, this may have preceded a partial return to 
pre-ischaemic values after approximately 5 minutes. Peak values were observed at 
ischaemia minute 10. Reperfusion caused a rapid return to pre-ischaemic values, 
following a possible RV lag after approximately 1 minute of reperfusion. Ro at both 0.5 
and 5 µM had a negligible effect on these changes. There was a trend towards a 
lengthening of LV lag by Ro at 0.5 µM, although this rarely reached significance. 
Discussion 
These results point towards electrophysiological mechanisms which might account for the 
pro- and anti-arrhythmic effects of Ro that were reported in Chapter 3, but the role of 
KATp modulation can only be speculated upon in the absence of experiments with the 
combination of Ro and a KATP blocker. 
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Control APD changes 
In the third successive control group, LV regional ischaemia caused substantial, 
significant but transient APD-lengthening, followed by a return to approximately pre- 
ischaemic values. Equally, post-ischaemic reperfusion caused substantial and significant 
LV APD-shortening within 90 seconds of reperfusion. Reperfusion-induced APD- 
shortening in previously ischaemic myocardium, has been reported in intact hearts from 
several species. As in reports of early ischaemic APD-lengthening (see Chapter 4, page 
72), the recording of APD at close intervals was essential for detecting such events. 
Culling et al (181), using floating microelectrode recording in the guinea-pig heart, 
reported a shortening of APD after 1 minute of reperfusion. Montrucchio et al (182) 
reported a similar event in the rabbit. Coronel (52) recorded epicardial electrograms and 
TAPs from the left ventricle of pig hearts during reperfusion, following 10 minutes of LV 
regional ischaemia. This worker observed an approximate 100% shortening (85 ms) of 
APD90 from the value at ischaemia minute 10, after 45 seconds of reperfusion. More 
recently, Perchenet & Kreher (127) found that in rat isolated hearts, APD90 of LV TAPs 
was 45% shorter after 1 minute of reperfusion (the first measurement taken during 
reperfusion), than at ischaemia minute 25. Penny & Sheridan (174) recorded TAPs from 
guinea-pig hearts during reperfusion, following low-flow and no-flow ischaemia. In this 
study, reperfusion rapidly shortened APD in groups of hearts subjected to low-flow 
ischaemia, after 30 minutes, but not after 5 or 60 minutes of ischaemia. The incidences of 
reperfusion arrhythmias recorded after these ischaemic intervals were 90,0 and 40%, 
respectively. These authors suggested that APD-shortening caused reperfusion 
arrhythmias. 
Electrophysiological effects of Ro: correlation of AP changes with previously observed 
arrhythmias 
APD 
Ro at 5 tM substantially shortened APD, abolished ischaemic APD-lengthening and 
caused ventricular disruption characteristic of arrhythmias during ischaemia. APD- 
shortening by Ro has been observed during normal perfusion in rat isolated hearts and in 
human ventricular muscle. In rat, MacKenzie (Personal communication) found a 53% shortening 
of APD50 (from 19.3 ms) by Ro at 2 µM. The control value and the degree of Ro-induced 
APD-shortening agree with the present study, in which Ro at 5 tM was used. This 
suggests that a maximal Ro-induced APD-shortening occurred at 5 tM in the present 
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study. In human ventricular muscle, Ro at 2 pM shortened APD50 and APD80 values, 
each by 85%. Bott et al (69) have reported shortening of APD50 by Ro at 3 µM, in 
electrically stimulated RV papillary muscles of the guinea-pig. In the present study, the 
incidence of hearts exhibiting electrical disruption at various time points during ischaemia 
(either CEA, electrical silence, or both) correlated with the incidence of hearts in VT at 
similar time points in the demonstration in Chapter 3, of pro-arrhythmia by Ro at 5 µM 
(see page 22). Ro at 0.5 µM had no effect on APD during normal perfusion, but 
significantly shortened LV APD80 during ischaemia. During reperfusion, Ro at 0.5 µM 
prevented significant reperfusion- shortening of APD80, at a time when a significant anti- 
arrhythmic effect was seen in Chapter 3 (see page 22). 
Long-footed APs 
These APs, which may represent APs with EADs, were seen only during reperfusion, and 
with a low incidence, in both control and Ro-treated groups of hearts. Zipes (147) has 
reported similar long feet in human RV MAPs. These were interpreted as EADs (see 
Figure 3 of Zipes (147)). In the majority of such APs in the present study, the occurrence 
of the extended phase during late repolarisation (ie at 80%, as opposed to 50% 
repolarisation), supports the view that these long feet may be EADs, since a Ca2+ current 
flowing through the Na+/Ca2+ exchanger is thought to predominate at this time (158). The 
frequent occurrence of long feet simultaneously in LV and RV APs does not support this 
view, however, since EADs would not be expected to occur simultaneously at distant 
ventricular sites, and as suggested on page 74, electrotonic current flow between such 
sites is likely to be negligible. If long-footed APs represent EADs, then an effect of Ro, 
consistent with its ability to shorten APD, might be to prevent these from occurring. 
Analysis of the available data revealed no such effect of Ro, at either 0.5 or 5 µM. 
Interventricular heterogeneity of APD 
It was initially thought that RV APs might maintain characteristics seen during normal 
perfusion, during LV regional ischaemia and reperfusion. The effect of KATP modulation 
on any spatial disparity in APD which might have preceded ventricular arrhythmias, 
could then have been investigated. However, during the suction electrode validation 
study, it became clear that changes in RV APD were at least partially reflected by 
changes in LV APD, particularly during ischaemia. In a control group of that study, and 
in those of the present, an effect of ischaemia and reperfusion on the normal 
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interventricular difference in APD emerged: it was lost after 4 minutes of ischaemia, and 
was not regained until after 2-4 minutes of reperfusion. Paradoxically, these intervals 
have been associated with high incidences of arrhythmias. For example, Li & Northover 
(183) demonstrated the onset of ventricular arrhythmias after 5-10 minutes of LMA 
occlusion in the rat heart, in vivo. The highest incidence of VT reported in control groups 
in Chapter 3 occurred within the first 3 minutes of reperfusion. It was, therefore, 
considered prudent to analyse any effects of KATp modulators, specifically on this loss of 
normal interventricular APD difference. Ro at 5 tM not only caused a loss of this 
difference during ischaemia: it reversed it. Although this might be arrhythmogenic in 
itself, this is unlikely, since Ro at 0.5 tM had a similar effect, without causing ischaemic 
arrhythmias. Therefore, the measurement of effects of Ro (and possibly other drugs) on 
interventricular disparity in APD, as an indicator of the potential to cause or prevent 
arrhythmias, does not appear to be useful in this model. 
LV lag 
The changes in LV lag which were seen during ischaemia and reperfusion reflect changes 
in LV myocardial conduction velocity. Levine et al (184) suggested that the MAP upstroke 
provides a means of characterising local myocardial conduction velocity. MAP recordings 
cannot provide an accurate measure of Vm, due to the averaging of the sequential 
depolarisation of perhaps hundreds of myocytes, beneath a contact, or suction electrode. 
However, MAP recording can detect slowing of myocardial conduction velocity, through 
lengthening of activation delay (123). Activation delay in the present model can be seen in 
Figure 32D, i (page 83). LV lag is likely to represent the combination of a slowing of 
both LV conduction velocity and of LV Vm.. Webb & Hollander (171) using 
microelectrodes recorded a slowing of conduction velocity in rat atrium after 10 minutes 
of simulated ischaemia. In the rat isolated heart, Mertz & Kaplan (131) measured the delay 
between activation of the sinoatrial node and the myocardium beneath a LV epicardial 
electrode. They reported a rapid increase after 1 minute of LMA occlusion, followed by a 
partial decrease after 3 minutes, followed by a further increase in the delay. These 
changes agree with those of LV lag, observed in the present study. It was assumed that 
prior to ischaemia, at least, Ro would affect conduction velocity equally in both 
ventricles. By measuring LV lag, therefore, an effect of Ro on conduction velocity during 
ischaemia would only be detected if this drug had a differential electrical effect on 
ischaemic and non-ischaemic myocardium. APD was affected in this way by Ro at 0.5 
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µM, but the present results suggest that conduction velocity was not, either by Ro at 0.5 
or 5 µM. 
Ro-induced modulation of LV APD, as the major potential influence on arrhythmias 
The strongest indication that the mild anti-arrhythmic effect of Ro at 0.5 p. M that was 
demonstrated in Chapter 3, might have arisen through modulation of LV APD, is the 
attenuation of APD-lengthening, and the subsequent APD-shortening that was seen 
during ischaemia in the present study. The degree of APD-shortening caused by Ro at 0.5 
µM was presumably insufficient to'cause arrhythmias through reentry, during ischaemia. 
As mentioned in Chapter 4 (page 74), such an effect on APD may be associated with 
attenuation of Ca2+ influx and is, therefore, consistent with the hypothesis that KATP 
activation is cardioprotective through such a mechanism. If so, then why does the APD 
not shorten to such an extent during ischaemia in the absence of Ro? In Chapter 3, the 
anti-arrhythmic effect of Ro at 0.5 µM was reported during reperfusion. It may be 
speculated that any cardioprotective effect of Ro during ischaemia is manifest as a 
prevention of APD-shortening during reperfusion. 
It is likely that in hearts perfused with Ro at 5 µM, the APD-shortening seen in both 
ventricles caused (or at least facilitated) arrhythmogenesis during ischaemia. It is 
significant that LV APD shortened to the lowest value yet seen in this model, prior to the 
onset of LV CEA or LV electrical silence. It is also significant that electrical silence was 
recorded only in the left ventricle, during ischaemia, and that LV CEA was not recorded 
after LV electrical silence in any heart. During regional ischaemia, border-zone-like 
conditions' may provide such spatial heterogeneity in myocardial excitability, refractory 
period and conduction velocity, as to cause unidirectional conduction block and initiate 
arrhythmias through reentry(16). The flow of an injury current between ischaemic and 
non-ischaemic myocardium may provide a trigger for reentry although, in the rat, this 
remains controversial (185). Such spatial heterogeneity of electrical activity may have 
caused the simultaneous LV and RV CEA recorded at 1 minute of ischaemia, in hearts 
perfused with Ro at 5 µM. The subsequent onset of ischaemic RV CEA was only 
recorded in conjunction with onset of LV CEA. In those hearts which developed electrical 
silence, this was presumably due to electrical inactivation of myocardium beneath the LV 
suction electrode, which may have arisen through local accumulation of (K+)o. In hearts 
in which LV electrical silence and RV CEA were recorded concurrently, it is conceivable 
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that the source of RV CEA might have been a reentering AP wavefront, circulating 
around a zone of muscle in the border-zone, close to inactivated myocardium situated in 
the centre of the non-perfused zone. Whether or not hearts exhibited LV electrical silence, 
such a reentrant loop might be sustained in myocardium perfused with Ro at 5 RM, due to 
a severely shortened APD. This is because the refractory period would be expected to 
shorten in addition to APD. This would decrease the minimum path length required for a 
successful reentrant loop, since this path length is related to the product of the refractory 
period and the conduction velocity (115). KATP openers have been shown to cause 
significant heterogeneity in APD, in addition to APD-shortening (106). In the three hearts 
perfused with Ro at 5 µM in which LV electrical silence was recorded concurrently with 
normal RV APs, either any border zone reentrant activity did not occur, or it might not 
have been detected by the RV suction electrode. The idea of border zone reentrant activity 
occurring concurrently with normal AP propagation in non-border zone areas, might help 
to explain a certain CEG phenomenon seen earlier using this model, namely, the apparent 
superimposition of a regular ventricular beat upon a background of otherwise chaotic 
electrical activity [for example, see Figure 3 (page 35)]. A similar signal was seen 
occasionally in the CEG recorded during ischaemia in the study of the pro-arrhythmic 
effects of Ro at 5 µM, reported in Chapter 3. 
Many of these suggestions are speculative at present, and reentry has not yet been 
unequivocally demonstrated in the rat, by full mapping of AP propagation. However, 
Mertz & Kaplan (131) recorded epicardial electrical activity using 10 pairs of wire 
electrodes in the rat isolated heart. These workers described ischaemia-induced 
fragmentation and delay in waveforms, suggestive of reentry, although they did not 
exclude the possibility of afterdepolarisation involvement in these. 
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Effects of glibenclamide on electrical activity 
Introduction 
The aim was to investigate the effects of glibenclamide at 1 and 10 µM, on APD 
characteristics seen in groups of hearts used to create the APD running control. This was 
with two purposes in mind. Firstly, to assess any contribution of KATP activation to 
ischaemia- or reperfusion-induced APD changes. Secondly, to select a suitable 
concentration of glibenclamide to use in combination with Ro, in later experiments. 
Method 
Electrical recording 
This was as described on pages A2 & A3 of the Appendix. LV and RV APD50, APD80 
and LV lag were recorded every minute prior to, during and following 10 minutes of LV 
regional ischaemia, except during the first 2.5 minutes of reperfusion, when recordings 
were taken every 10 seconds. One group of hearts was perfused with glibenclamide at 10 
µM. Results were compared with a contemporaneous control group, namely hearts 19-25 
plus hearts 30-37 of the APD running control, referred to here as control group 3. Another 
group of hearts was perfused with glibenclamide at 1 µM. Results from this group were 
compared with another contemporaneous control group, namely hearts 22-36 of the APD 
running control, referred to here as control group 4. It should be noted that there was 
considerable temporal overlap between the control groups. 
Data analysis 
Comparisons were made between groups at same time points and between time points 
within groups, as described on page 66. In addition, frequency distribution analyses were 
made of results from hearts treated with 10 µM glibenclamide and from hearts in the 
contemporaneous control group. 
Results 
Control APD changes 
In both control groups, LV APD50 and APD80 lengthened significantly during ischaemia, 
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LV APD80 shortened significantly during reperfusion, and RV APD did not shorten 
during reperfusion (Table 7). These changes are consistent with those of control groups 1 
and 2, from the last experiment (see Table 5). In both control groups 3 and 4, as in control 
group 2, ischaemic LV APD-lengthening was accompanied by significant RV APD8o- 
lengthening. In both control groups 3 and 4, as in control group 1, LV and RV APD were 
not shortened significantly below respective pre-ischaemic values, at minute 10 of 
ischaemia (compare Tables 5& 7). The time courses of APD changes seen in control 
groups 3 and 4 are shown in Figures 62-69. At 8 and 9 minutes of ischaemia, significant 
LV APD80-shortening was found in at least one of these time points (Figures 64 & 68), 
which was also the case for control group 2 (see Figure 43). In both control groups 3 and 
4, LV APD50 values were not recorded (n <4 APs) at several time points during 
reperfusion (Figures 63 & 67). This was due to exclusion of several APs from APD50 
measurement at these times [see "method 2" (Appendix, page A7)], rather than through 
interruption of APD recording by arrhythmias. LV and RV APD80 may have lengthened 
prior to the significant shortening seen during reperfusion, in both control groups (Figures 
65 & 69). This was caused by the occurrence of long-footed APs. In control group 3, for 
example, these APs appeared only during reperfusion, and APD80-prolongation was seen 
in the absence of substantial APD50-prolongation in all but 1 AP (Figures 70 & 71). 
However, in neither control group did any reperfusion-induced LV APD50- or APD80- 
lengthening reach significance prior to APD shortening, compared to the respective 
values at ischaemia minute 10. This lack of significance was due to a wide distribution of 
available APD data in the first minute of reperfusion: in control group 3, the standard 
error of mean LV APD80 values at 10,20,30,40 and 50 seconds of reperfusion was 12.3, 
13.9,22.6,10.8 and 6.8 units, respectively, compared to 4 SEM units at minute 10 of , 
ischaemia and 1.5 SEM units at minute 1 of reperfusion. In control group 4, these values 
were 12.3,14.8,25.4,12.8 and 7.7 during the first 50 seconds of reperfusion, 
respectively, compared to 4.2 and 1.5 SEM units at minutes 10 of ischaemia and 1 of 
reperfusion, respectively. A similar distribution of RV APD80 values was seen in both 
control groups at these time points. However, in control group 4, (but not control group 
3), RV APD80 values were significantly longer at 10,20 and 30 seconds of reperfusion, 
than the value at ischaemia minute 10, despite large standard error values at these time 
points. 
The APD running control group, from which data for control groups 1-4 were taken, ran 
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concurrently with the arrhythmia running control group, throughout the course of 
experiments to investigate effects of Ro and glibenclamide on APD. There appeared to be 
no significant differences in the incidences and durations of reperfusion VT recorded in 
the arrhythmia running control group, between intervals concurrent with those of control 
groups 1-4. This will be investigated further in Chapter 7. 
Effect of glibenclamide on APD during normal perfusion 
Glibenclamide at 1 µM significantly shortened LV APD50 and LV APDgO and there was a 
trend towards a similar effect in the right ventricle (Figure 72). There was a trend towards 
an APD-lengthening effect of glibenclamide at 10 µM in both ventricles. This reached 
significance only for RV APD50 (Figure 72 & Table 7). LV and RV APD50 and APD80 
values were similar in both control groups. 
Effect of glibenclamide on subsequent LV electrical changes, compared to 
contemporaneous control groups 
Glibenclamide at 1 µM (Figures 73-76) 
There was no significant drug-induced effect on LV APD50 or APD80 during ischaemia or 
reperfusion at any time point, apart from one: LV APD50 in drug-perfused hearts was 
significantly longer than in the controls at minute 3 of ischaemia. This exception (see 
Figure 73) is likely to have been anomalous, since the direction of the drug effect was not 
reflected at adjacent time points at APD50 or APD50 (see Figures 73 & 75). There was a 
trend towards shorter LV APD50 and APD80 values during ischaemia compared to 
controls, after minute 4 of ischaemia. Such an effect of glibenclamide was of a similar 
magnitude to that seen prior to ischaemia (Figures 73 & 75). During approximately the 
first minute of reperfusion, LV APD data from glibenclamide-treated hearts was scarce 
(Figures 74 & 76), possibly due to interruption of APD recording by arrhythmias. 
Glibenclamide at 10 µM (Figures 77-80) 
There was no significant drug-induced effect on APD50 or APD80 during ischaemia, 
except at minute 10. At this time point, both LV APD50 and LV APD80 values were 
significantly longer than the respective control values (Figures 77 & 79). These 
exceptions were unlikely to have been anomalous, since a similar trend was seen in the 
preceding 3 or 4 minutes, for both APD50 and APD80. The magnitude of drug-induced 
APD-lengthening at minute 10 of ischaemia, appeared to be greater than that observed 
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prior to ischaemia (Figures 77,79, & Table 7). During reperfusion, sufficient LV APD 
data was available to record any drug-induced changes relative to the controls. Drug- 
treated and control hearts exhibited remarkably similar reperfusion-induced changes in 
LV APD80 (Figure 80). 
Effects of glibenclamide at l and 10 µM on simultaneous LV and RVAPD changes 
These are shown in Figures 81-88. Interventricular differences in APD were observed 
prior to ischaemia, in hearts perfused with glibenclamide at both 1 and 10 . tM. In hearts 
treated with glibenclamide at 1 µM, this effect reached significance only in measurements 
of APD80 (compare Figures 81 & 83). However, in hearts perfused with glibenclamide at 
10 µM, this effect reached significance at both APD50 and APD80 (see Figures 85 & 87). 
During ischaemia, significant interventricular disparity in APD80 was lost after 
approximately 5 minutes, in hearts treated with glibenclamide at both 1 and 10 tM 
(Figures 83 & 87). However, in contrast to control groups 3 and 4 (see Figures 64 & 68), 
it was regained at minute 10 of ischaemia. This may have been due to selective 
prevention of the return of APD80 to pre-ischaemic values following ischaemic APD- 
lengthening, in the left ventricle. - During the first 2 minutes of reperfusion, changes in RV 
APD80 may have followed similar patterns to those of LV APD80 in both drug-treated 
groups of hearts, although such a relationship was not clear (Figures 84 & 88). 
Effect of ischaemia and reperfusion on APD in drug-treated hearts 
In both drug-treated groups of hearts, as in both control groups, LMA occlusion caused 
significant lengthening of LV APD50, LV APD8o, RV APD80, but not RV APD50. 'In both 
drug-treated groups of hearts, LV APD80 was significantly longer at minute 10 of 
ischaemia, than at minute 10 of normal perfusion (Table 7, Figures 83 & 87). This 
represented a prevention of the return of LV APD80 to pre-ischaemic values following 
ischaemic APD-lengthening, by glibenclamide, both at 1 and 10 µM. In both control and 
drug-treated groups of hearts, reperfusion caused a shortening of LV APD80 within the 
first 90 seconds (Table 7, Figures 84 & 88). In drug-treated hearts this was also associated 
with LV APD50-shortening (Figures 82 & 86). In hearts treated with glibenclamide at 1 
µM, this was additionally associated with RV APD80-shortening (Figure 84). In these 
hearts, but not in those treated with glibenclamide at 10 µM, RV APD values may have 
lengthened in the first 30 seconds of reperfusion (Figures 82 & 84). However, RV APD50 
and APD50 values were not significantly longer at any time point in the first 3 minutes of 
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reperfusion than the respective APD values at ischaemia minute 10. 
Long-footed APs 
These were observed in 2 hearts in control group 3,3 hearts in control group 4 and in 1 
heart in each of the glibenclamide-treated groups (Table 8). Long-footed APs were 
recorded within the first minute of reperfusion only, and in both ventricles. In most cases, 
long-footed APs were recorded simultaneously in each ventricle, and with little extension 
of APD50. Glibenclamide at both 1 and 10 µM had no significant effect on the incidences 
of long-footed APs, compared to the respective control groups. A frequency distribution 
analysis of APD was performed during normal perfusion and reperfusion, in hearts treated 
with glibenclamide at 10 p. M (Figures 89 & 90). The distribution of combined APD data 
during normal perfusion appeared to be more widely dispersed in glibenclamide-treated 
hearts, than in those of the contemporaneous control (compare Figure 70 with Figure 89). 
During the first 90 seconds of reperfusion, there was a trend towards a reduction in the 
number of long-footed APs, in association with an increase in APs with APD80 values in 
the range of 50-80 ms, by glibenclamide at 10 µM (compare Figure 71 with Figure 90). 
Such an effect of glibenclamide at 10 µM caused no substantial effect on mean APD 
values recorded during the first 2 minutes of reperfusion, compared to those of the } 
contemporaneous controls (see Figure 80). 
LV lag 
This followed a similar time course in both control and drug-treated groups of hearts 
(Figure 91). Glibenclamide at 1 tM significantly reduced LV lag at minutes 4 and 5 of 
ischaemia. The magnitude of this effect was small, and not reflected in hearts treated with 
glibenclamide at 10 µM: glibenclamide had little effect on LV lag. 
Discussion 
Interruption of perfusion of the LV myocardium can be expected to cause a fall in [ATP]; 
in this region (186). Since a drop in [ATP]j causes opening of KATP channels (4), the 
presence of the KATP blocker glibenclamide in ischaemic myocardium would be expected 
to abolish any KATP opening-induced APD changes that might occur as a result of 
ischaemia. 
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The main findings in the present experiments were a lack of effect of glibenclamide on, 
APD during the first 9 minutes of the ischaemic insult and during reperfusion, but a 
significant lengthening by glibenclamide at 10 tM of LV APD at minute 10 of ischaemia, 
compared to control groups. The effect of 10 µM glibenclamide at minute 10 of 
ischaemia represents a prevention of the return of LV APD to pre-ischaemic values 
following the initial ischaemic APD-lengthening. Hence, this could also be viewed as an 
attenuation of LV APD-shortening at minute 10 of ischaemia. Such an effect would be 
consistent with changes in APD80 seen in groups of hearts perfused with glibenclamide at 
either 1 or 10 µM. In both of these groups, in contrast to control groups 1-4, LV APD80 
values at minute 10 of ischaemia were significantly longer than was seen at minute 10 of 
normal perfusion or the RV APD80 values seen at minute 10 of ischaemia. The lack of 
effect of glibenclamide during the first 9 minutes of ischaemia may have been due to one 
or more of the following. 
1) Insufficient KATp opening to alter APD significantly during that time. 
2) A KATp opening-induced APD change occurring concurrently with a non-KATp 
opening-induced APD change. 
3) The concentrations of glibenclamide used were too low to block open KATp channels 
during that time. 
4) The effectiveness of glibenclamide to block KATp channels was reduced during 
metabolic stress, ie under conditions where metabolic demand exceeded energy supply, 
such as would be expected during ischaemia. 
These are referred to respectively as scenarios 1-4. The relevance of each to the present 
study will be discussed. 
Evidence for ischaemic activation of KATP channels 
There is considerable evidence from several models, including intact heart preparations, 
to suggest that sufficient KATP opening occurs during ischaemia to cause APD- 
shortening. That conclusion is based on partial or complete reversal of the APD- 
shortening by KAIp blockers. Nichols & Lederer, in their review on KATP channels in the 
cardiovascular system (23) suggest hat KATP activation in as little as 1% of the available 
conductance, would be sufficient to shorten APD by 50%. They speculated that in the rat 
ventricle, measurable APD-shortening might occur if [ATP]1 fell even slightly below 
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normal levels. Moritani et al (187) conducted a study in dogs in vivo, in which MAPS were 
recorded from ischaemic regions of hearts during 5 minute periods of coronary artery 
occlusion. These authors administered either glibenclamide or 5-hydroxydecanoate (5- 
HD) at various times and found a suppression of artery occlusion-induced shortening of 
APD50 and APD90 by both drugs. 5-HD is a non-sulphonylurea blocker of the KATP 
channel (188) and it did not exert additional effects on APD when administered following 
pre-treatment with glibenclamide. ' Smallwood et al (189) recorded MAPS from ischaemic 
zones of rabbit hearts in vivo. They reported an attenuation of ischaemic APD-shortening 
by glibenclamide. In rabbit hearts perfused in vitro, Ruiz-Petrich et al (190) recorded 
hypoxia-induced APD-shortening. After 45 minutes of hypoxia, glibenclamide at 30 µM 
caused significant prolongation of APD compared to the control (in the absence of , 
glibenclamide). In a similar model, Bellemin-Baurreau et al (191) reported a delay in the 
onset of ischaemia-induced shortening of the effective refractory period, by glibenclamide 
at both 0.1 and 1 µM. In guinea-pig isolated hearts, Tweedie et al (192) reported 
shortening of the refractory period following low-flow ischaemia, which was abolished 
by glibenclamide at 3 µM. In guinea-pig isolated papillary muscles, MacKenzie et al (193) 
reported shortening of APD90 following 20 minutes of hypOxic perfusion, or ischaemia 
and these effects were partially reversed (by approximately 85%) by glibenclamide at 10 
µM. Nakaya et al (194), using a similar model reported attenuation by glibenclamide at 10 
µM of both hypoxia- and DNP-induced APD-shortening. These authors reported similar 
findings in canine isolated myocardium, by glibenclamide at 20 µM. Beckheit et al (195) 
used plunge electrodes to record the duration of the intracardiac electrogram, in the I 
ischaemic zone of canine hearts in vivo. Glibenclamide caused significant lengthening of 
this parameter during 10 minutes of ischaemia. In rat isolated ventricular myocytes, 
glibenclamide has been demonstrated to block open KATP channels. Ripoll er al (31) 
activated I Tp in inside out membrane patches, by exposing the membrane inner surface 
to low, and to zero concentration of ATP [ATP]. Glibenclamide did not affect the single 
channel conductance, but reduced the open probability from either side of the membrane, 
at a concentration causing half-maximal reduction (IC50), of 6 µM. In a similar model, 
Findlay (196) observed total, but transient inhibition of DNP-activated IKATP, by 
glibenclamide at 1 µM. Complete inhibition was reported using whole cell recording, but 
not using excised membrane patches. 
In the above studies, the timing of reported effects of glibenclamide on APD following 
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ischaemia was critical [as was the case for reported APD changes which followed 
ischaemia in the absence of drugs (see Chapter 4)]. For example, Ruiz-Petrich et al (190) 
reported no effect of glibenclamide at 30 gM on hypoxic APD-shortening, before 
approximately 45 minutes. It is possible that in the models they used, KATP channels did 
not open in the first 45 minutes of hypoxia. In the study by MacKenzie et al (193), 
glibenclamide was administered after 20 minutes of hypoxia, when APD-shortening had 
reached a nadir. These authors noticed a delay of 15 minutes before an effect of 
glibenclamide reached significance. Presumably, in the present model, such a delay might 
have taken place during the stabilisation phase. In the studies by both Tweedie et al (192) 
and Smallwood et al (189), effects of glibenclamide on refractory period and APD, 
respectively, were recorded within 10 minutes of ischaemia. This suggested that KATP 
channels opened in this interval in both of these models. No reports of effects of 
glibenclamide on APD changes during ischaemia were found using intact rat hearts. 
Non KATP activation-induced APD changes 
In the studies by both MacKenzie et at (193) and Nakaya et at (194), glibenclamide at 10 
tM only partially reversed hypoxic APD-shortening. Smallwood et at (189) reported only 
attenuation of ischaemic APD-shortening by glibenclamide. Bellemin-Baurreau et at 0191) 
reported a delay in the onset of refractory period-shortening, but not attenuation, or 
prevention of shortening. In a study using a guinea-pig RV preparation, Cole et at (197) 
reported shortening of APD90 during 30 minutes of no-flow ischaemia. Glibenclamide at 
10 gM attenuated this, but a decline in APD90 of 24% was still recorded. If glibenclamide 
is assumed to have blocked KATP channels in these studies during ischaemia, hypoxia or 
metabolic blockade, then this suggests that the observed APD- or refractory period- 
shortening occurred through the flow of electric current additional to IK jTp. There are 
several possible candidates for this additional current. Tohse (198) demonstrated 
enhancement of the delayed rectifier K+ current resulting from increased [Ca2+]i. 
Kameyama et at (199) demonstrated activation of a K+ current induced by an increased 
concentration of intracellular Na+ ([Na+]; ). Increases in both [Na+]i and [Ca2+]i occur 
during ischaemia (200) and an increase in [Ca2+]1 during ischaemia has been demonstrated 
by Brooks et at (97) in a similar model to the present. Nakaya et at (194) suggested the 
possible involvement of a decrease in the slow inward Ca2+ current, in ischaemic APD- 
shortening. Such an ischaemic effect on this current may of course have occurred 
secondarily to KATP activation. 
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Concentration-dependent effects of glibenclamide on ischaemic APD changes 
In many of the reports cited above for ischaemic KATP activation (pages 107 & 108), 
glibenclamide was used at concentrations greater than 10 µM. MacKenzie et al (193) 
reported that 10 tM was the threshold concentration for a drug-induced effect on APD 
during ischaemia. Ruiz-Petrich et al (190) reported an effect of glibenclamide at 30 µM, 
but not at 3 µM. In addition, Venkatesh et al (201) reported inhibition of ischaemia- 
induced APD-shortening by glibenclamide, only at a very high concentration: 100 µM. 
These, and the study of Ripoll et al (31), suggest hat activated KATp channels might only 
be blocked by relatively high concentrations of glibenclamide during ischaemia. 
Reduction of effects of glibenclamide during metabolic stress 
This possibility has been suggested by Findlay (196), since the inhibition by glibenclamide 
at 1-100 tM of a DNP-activated K+ current in rat isolated ventricular myocytes, did not 
occur during a caffeine-induced contracture. It was concluded that glibenclamide did not 
block KATp channels during the final stages of metabolic stress. Glibenclamide is also 
thought to influence myocardial metabolism. This will be discussed in the next chapter. 
The influence of scenarios 1-4 above (page 107), on the effect of glibenclamide on 
ischaemic APD changes, may be linked. For example, it is conceivable that the effect of a 
low concentration of glibenclamide (1 µM), on the APD-shortening during metabolic 
stress, may falsely indicate a relatively small contribution of IKATP to such APD- 
shortening, due to the combined influence of scenarios 3 and 4. To complicate matters 
further, electrical effects of glibenclamide are likely to be highly model-dependent: 
Venkatesh et al concluded from their study (201) that "the [sulphonylurea's] ability to 
prevent cellular K+ loss and shortening of APD during ischaemia or hypoxia in the intact 
heart is modest compared to their efficacy at blocking KATP channels in excised 
membrane patches". Such model-dependence was also reported by Findlay (196). 
In the present model, glibenclamide at both 1 and 10 pM affected LV APD at minute 10 
of LV regional ischaemia, with the most pronounced effect occurring at 10 µM. This 
suggests that the influences of scenarios 3 and 4, above, might not be as relevant to the 
lack of effect of glibenclamide on APD during early ischaemia, compared to the, 
influences of scenarios 1 and 2. Both the absence of significant ischaemic APD- 
shortening in control groups, and the presence of significant shortening of LV APD by Ro 
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at 0.5 µM during ischaemia, but not prior to ischaemia (see page 93), suggests that the 
influence of scenario 1 may be the most relevant to the present study: ie that insufficient 
KATP channels opened to significantly alter LV APD during the first 9 minutes of 
ischaemia. This claim may be substantiated by data obtained through a combination of 
suitable concentrations of Ro and glibenclamide. 
LV lag 
Glibenclamide, both at 1 and 10 tM had a negligible effect on LV lag. Any effect of 
glibenclamide might have been seen only at minute 10 of ischaemia, since only at this 
time point did glibenclamide have a significant differential electrical effect in left and 
right ventricles. The absence of a drug-induced effect on LV lag is consistent with the 
lack of effect of glibenclamide on Vm.... which has been reported by Smallwood et al 
(189). 
Effect of glibenclamide on APD during normal perfusion 
Glibenclamide at 1 µM significantly shortened LV APD and a similar trend was observed 
in the right ventricle. Glibenclamide at 10 tM significantly lengthened RV APD50 and a 
similar trend was observed for LV APD50 and RV APD80. The consistency of control 
APD values at minute 10 of normal perfusion suggested that these were not anomalous 
effects, particularly by glibenclamide at 1 µM. Further analysis of pre-ischaemic APD 
data confirmed this: the combination of APD data from each time point during normal 
perfusion, in respective control and drug-treated groups resulted in the conversion of all 
"trends" mentioned above, to significant effects, leaving little doubt about these drug 
effects. A significant prolongation of combined LV APD80 data during normal perfusion, 
by glibenclamide at 10 µM, occurred even though the distribution of data was relatively 
wide in drug-treated hearts, compared to control hearts. The wide distribution of drug 
group data may reflect a heterogeneous electrical response of LV myocardium to 
glibenclamide, either over time, between hearts, between regions of hearts, or all of these. 
Glibenclamide at both 1 and 10 µM might have been predicted to have no effect on APD 
prior to ischaemiä, when KATP channels are assumed to be closed. Glibenclamide-induced 
APD-prolongation therefore suggested the blockade of KATP channels which might have 
been open in the control group, in this interval. Faivre & Findlay (202) perfused intact rat 
hearts with a solution of a similar composition to the PSS used in the present study, and 
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paced them electrically at between 1.5 and 3 Hz. These workers recorded ventricular 
epicardial APD50 using floating microelectrodes, and reported a concentration-dependent 
prolongation of APD by glibenclamide at 10-100 µM, of 7-33%, during normal perfusion. 
In that study, glibenclamide at 10 tM did not significantly prolong APD, which was 12.3 
± 0.5 ms in control, and 13.1 ± 0.6 ms in drug-treated hearts. However, glibenclamide at 
100 pM lengthened APD significantly, from 13.9 ± 0.5, to 25.8 ± 1.6 ms. They found 
tolbutamide caused a similar effect. In the same study, these authors confirmed 
sulphonylurea-induced KATP blockade using tolbutamide, in enzymatically dissociated rat 
isolated myocytes, using single channel recording of IKATp in excised membrane patches. 
They concluded that K+ flows through KATp channels in intact and working hearts during 
normal perfusion, and that the APD-prolongation they saw was caused by glibenclamide- 
induced inhibition of this current. They continued along this line of reasoning, pointing 
out that similar prolongation of APD by al-adrenergic agonists and protein kinase C- 
activating phorbol esters has been seen in rat ventricular myocytes, and that phorbol 
esters have been shown to block KATP channels. Glibenclamide-induced APD 
prolongation during "normal perfusion" has also been reported in vivo, in a canine study 
by Smallwood et al (189). The work of Faivre & Findlay (202) might help to explain the 
APD-prolongation seen by glibenclamide at 10 µM in the present experiments. A similar 
effect of glibenclamide on vascular KATp channels might also explain the vasoconstrictor 
effect of glibenclamide reported in the present study, and by other researchers (see pages 
29-30). 
The observed APD-shortening by glibenclamide at 1 tM in the present experiments is 
less easy to account for, however, and no similar report of such a sulphonylurea-induced 
electrical effect was found. This will be investigated in the next chapter. 
Effect of glibenclamide on reperfusion-induced APD characteristics 
Glibenclamide at both 1 and 10 pM did not affect reperfusion APD-shortening seen in the 
respective control groups, nor the occurrence of long-footed APs. An APD-prolongation 
by glibenclamide at 10 gM might have been expected to promote afterdepolarisations 
(33,90), but this was not evident. These observations are consistent with the idea 
(mentioned on page 97), that reperfusion-induced APD-shortening might cause 
reperfusion arrhythmias, since glibenclamide at both 1 and 10 µM had no significant 
effect on the incidence or the duration of reperfusion VT in groups of hearts perfused 
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under similar conditions to the present (see Chapter 3). 
Summary of Chapter 5 
Prior to ischaemia, Ro at 0.5 µM had no effect on APD, but Ro at 5 µM caused 
significant APD-shortening. Ro at both 0.5 and 5 tM caused significant shortening of LV 
APD during ischaemia. In hearts perfused with Ro at 5 µM, this was associated with 
CEA, whilst in hearts perfused with Ro at 0.5 µM, this shortening of APD during 
ischaemia was associated with prevention of subsequent reperfusion-induced further 
APD-shortening. Glibenclamide had no significant effect on the ischaemic APD changes 
that were seen in control groups during the first 9 minutes of ischaemia, but significantly 
prolonged APD at minute 10 of ischaemia. This suggests a lack of involvement of KATP 
channels in the ischaemic APD changes seen before minute 10, after which point 
sufficient KATp channels may have become activated in the controls to shorten APD. A 
flow of IKATp may occur prior to ischaemia in this model, since glibenclamide at 10 µM 
prolonged APD at that time. The APD-shortening observed with glibenclamide at 1 µM 
however, is not consistent with that view, and requires further investigation. 
Glibenclamide had no significant effect on APD characteristics during reperfusion. This 
suggests a lack of involvement of KATP channels in reperfusion-induced APD-shortening 
that was seen following 10 minutes of ischaemia. This may account also for a lack of 
effect of glibenclamide on the reperfusion-induced arrhythmogenesis that was reported in 
Chapter 3. Evidence for KATP channel involvement in the electrical changes described 
above would be provided by a demonstration of an antagonism between the effects of 
glibenclamide and Ro. Glibenclamide at either 1 or 10 µM might suitably be combined 
with Ro. This will be discussed in the next chapter. 
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Table 5 
APD (ms) [mean ± SEM (n APs)] at various time points, from both control and 
drug-treated groups 
Ischaemia-induced APD peak: recorded in first 3 minutes of ischaemia 
Reperfusion-induced APD nadir: recorded in first 90 seconds of reperfusion 
group 1= control group, contemporaneous with Ro at 5 PM group 
group 2= control group, contemporaneous with Ro at 0.5 µM group 
0's denote significant differences from normal perfusion minute 10 
is denote significant differences from ischaemia minute 10 
*'s denote significant differences from contemporaneous contr ol group 
NV = no value recorded 
Normal Ischaemia- Ischaemia Reperfusion- 
perfusion induced peak minute 10 induced nadir 
minute 10 
group 1 
LV APD50 15.5 ± 1.5 (11) 30.5 ± 4.1 (15) 13.4 ± 1.5 (13) 6.0 ± 0.9 (6) 
group 1 t 
LV APD8o 34.1 ± 3.0 (15) 62.1 ± 4.3 (15) 28.4 ± 1.8 (13) 18.6 f 1.9 (9) 
group 1 
RVAPD50 11.7 ± 0.9 (11) 17.5 ± 2.9 (12) 9.7 ± 1.6 (8) 10.0 f 2.2 (8) 
group 1 
RV APD80 23.5 ± 1.3 (15) 37.0±5.8 (13) 21.5 ± 2.4 (12) 23.3 3.0 (10) 
LALV 
APD50  7.8 ± 1.0 (9) 7.3±0.9(6) NV NV 
Lo 5µM 
LV APD80 12.8 ± 0.7 (10) 12.8 ± 1.1 (6) NV NV 
Ro 5µM 
RVAPDso 6.2 ± 1.0 (7) 7.7 ± 1.3 (4) 5.4±0.9 (6) 4.9 ± 0.6 (5) 
Ro51. LM 
RV APDgo 12.0±1.1(10) 13.6±1.5(8) 10.3±1.1(6). 10.6±1.7(5) 
group 2 
LV APD50 14.4± 1.3 (10) 38.1 ± 4.9 (13) 14.5 ± 1.7 (11) 10.3±4.1 (4) 
group 2 t 
LV APD80 36.5 ± 3.2 (13) 65.0±4.5 (14) 28.1 ± 2.3 (11) 19.4 ± 2.6 (8) 
group 2 
RVAPD50 10.7 ± 1.1 (10) 16.4± 3.8 (10) 11.9±2.3 (7) 9.1± 1.2 (8) 
group 2 
RV APD80 21.6 ± 1.7 (15) 39.1 ± 6.7 (11) 25.3 ± 2.8 (9) 25.2 ± 3.3 (9) 
Ro 0.5 µM 
LV APD50 12.4 ± 1.6 (12) 
* 
22.1 ± 2.9 (12) 9.5 ± 1.5 (7) 7.3 ± 1.5 (4) 
Ro 0.5µM 
LVAPD80 29.5 ± 3.4 (12) 40.7 ± 4.4 (12) 16.5 ± 1.3 (7) 15.9 ± 1.7 (8) 
Ro 0.5µM 
RVAPDSo 10.6±1.3 (9) 11.6 ± 1.5'(6) 10.5 ± 1.8 (5) 7.8 ± 0.9 (6) 
Ro0.5µM 
RV APD80 245±2.0(12) 29.7 ± 2.5 (12) 19.5 ± 3.0 (8) 20.6±2.8(10) 
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Table 6 
Details of all long-footed APs and corresponding data, recorded during the first 90 
seconds of reperfusion 
Long-footed APs are defined as those in which APD80'>_ 80 ms 
Heart number in control groups = that of APD running control (see Chapter 7) 
group 1= control group, contemporaneous with Ro at 5 . tM group 
group 2= control group, contemporaneous with Ro at 0.5 VM group 
NV = no value recorded 
Heart 
no. 
Seconds 
following 
re perfusion 
LV 
APD50 
(ms) 
LV 
APD80 
(ms) 
RV 
APD50 
(ms) 
RV 
APD80 
(ms) 
Group 1 
11 20 NV 91.2 18.7 108.7 
Ro 5 µM 8 30 5.0 82.5 7.5 10.6 
10 40 2.5 7.5 6.2 108.1 
10 50 3.7 7.5 7.5 102.5 
Group 2 
11 20 NV 91.2 18.7 108.7 
18 40 NV 147.5 NV NV 
22 20 4.4 98.1 23.7 72.5 
22 30 4.4 92.5 28.7 93.7 
22 40 8.7 78.5 16.2 91.2 
Ro 0.5 µM 3 10 6.9 92.5 1.9 19.4 
9 70 13.1 82.5 NV 63.1 
9 80 14.4 87.5 10.6 79.4 
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Table 7 
APD (ms) [mean ± SEM (n APs)] at various time points, from both control and 
drug-treated groups 
Ischaemia-induced APD peak: recorded in first 3 minutes of ischaemia 
Reperfusion-induced APD nadir: recorded in first 90 seconds of reperfusion 
group 3= control group, contemporaneous with glibenclamide at 10 µM group 
group 4= control group, contemporaneous with glibenclamide at 1 pM group 
glib = glibenclamide 
0's denote significant differences from normal perfusion minute 10 
is denote significant differences from ischaemia minute 10 
*'s denote significant differences from contemporaneous control group 
Normal Ischaemia- Ischaemia Reperfusion- 
perfusion induced peak minute 10 induced nadir 
minute 10 
group 3 
LV APD50 15.6 ± 0.9 (14) 42.2 ± 4.0 (13) 13.1 ± 2.0 (8) 7.7 ± 1.9 (5) 
group 3 t 
LV APD80 38.8 ± 2.5 (15) 68.6 ± 5.9 (12) 32.5_± 4.0 (8) 17.1 ± 1.5 (9) 
group 3 
RVAPD50 9.8 ± 1.0 (11) 10.6 ± 1.4 (13) 12.4 ± 3.1 (5) 7.5 ± 0.5 (9) 
group 3 
RV APD80 21.0±2.3 (14) 32.1 ± 3.3 (13) 23.8 ± 3.6 (7) 20.3 ± 2.2 (8) 
glib 10 µM 
LV A0 
g 19.0 ± 1.7 (9) 43.4± 5.4 (10) 
* 
22.1± 1.7 (6) 
t 
8.8 ± 1.9 (6) 
glib 10 µM 
LV APD80 38.8 ± 3.2 (14) 78.5 ± 3.8 (14) 53.0 ± 4.3 (6) 19.6 ± 4.2 (9) 
glib 10 µM 
RVAPDso 13.0 ± 1.6 (9) 16.5 ± 4.8 (6) 14.9 ± 3.4 (5) 10.4 ± 2.1 (7) 
glib 10 µM 
RV APD80 25.6 ± 3.5 (14) 
* 
44.0 ± 4.0 (13) 34.9 ± 5.9 (7) 22.7 ± 3.1 (10) 
group 4 0 
LV APD5o 15.5 ± 1.0 (13) 40.5 ± 4.9 (12) 14.6 ± 2.4 (8) 8.5 ± 1.8 (4) 
group 4 -ý 
LV APD80 38.1 ± 2.3 (13) 68.4± 6.3 (11) 31.5 ±4.2 (7) 18.4 ± 1.5 (7) 
group 4 
RVAPD50 10.3 ± 1.0 (10) 13.7 ± 2.1 (11) 13.1± 2.9 (5) 8.6 ± 1.0 (9) 
group 4 
RV APD80 21.6 ± 1.8 (12) 36.6 ± 3.4 (13) 24.3 ± 3.5 (7) 20.4 ± 1.9 (8) 
glib 1µM 
LV APD50 11.7 ± 1.3 (9) 35.4 ± 5.0 (11) 15.9 ± 2.0 (10) 5.9 t 2.0 (4) 
glib 1µM 
LVAPDgo 27.8 ± 2.4 (12) 75.5 ± 4.1 (15) 37.4 ± 3.7 (10) 14.7 f 2.5 (7) 
glib 1µM 
RVAPDso 9.6 ±'1.3 (6) 18.6 ± 5.3 (8) 14.5 ± 4.6 (5) 8.8 ± 1.8 (8) 
glib 1µM 
RV APD80 17.7 ± 2.6 (10) 36.5 ± 4.9 (11) 
0 
25.3 ± 2.3 (9) 
t 
15.7 ± 2.1 (10) 
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Table 8 
Details of all long-footed APs and corresponding data, recorded during the first 90 
seconds of reperfusion 
Long-footed APs are defined as those in which APD80 >_ 80 ms 
Heart number in control groups = that of APD running control (see Chapter 7) 
group 3= control group, contemporaneous with glibenclamide at 10 tM group 
group 4= control group, contemporaneous with glibenclamide at 1 tM group 
glib = glibenclamide 
NV = no value recorded 
Heart 
no. 
Seconds 
following 
re erfusion 
LV 
APD50 
(ms) 
LV 
APD80 
(ms) 
RV 
APD50 
(ms) 
RV 
APD80 
(ms) 
Group 3 
22 20 4.4 98.1 23.7 72.5 
22 30 4.4 92.5 28.7 93.7 
22 40 8.7 78.5 16.2 91.2 
30 30 93.1 145.6 14.4 39.4 
glib 10 µM 12 10 ND 84.4 ND 40.6 
Group 4 
22 20 4.4 98.1 23.7 72.5 
22 30 4.4 92.5 28.7 93.7 
22 40 8.7 78.5 16.2 91.2 
26 10 ND 85.6 71.2 193.7 
26 20 ND 20.0 27.5 135.0 
30 30 93.1 145.6 14.4 39.4 
glib 1µM 8 10 65 152.5 145.0 171.9 
8 20 ND 145.0 128.1 165.6 
8 30 ND 162.5 121.9 160.6 
8 50 ND ND ND 151.9 
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Figure 41 
LV and RV APD in control group 2 
Values are means, error bars omitted for clarity, n=15 hearts 
Solid symbols denote significant differences between groups 
at same time points 
Asterisks denote significant differences from minute 10, within groups, 
during ischaemia 
EDLeft ventricle (n=4-14 APs) 
--0- Right ventricle (n=6-13 APs) 
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Figure 42 
LV and RV APD in control group 2, during reperfusion 
Values are means, error bars omitted for clarity, n=15 hearts 
Solid symbols denote significant differences between groups 
at same time points 
Asterisks denote significant differences from minute 20, within groups 
® Left ventricle (n=4-11 APs) 
--a- Right ventricle (n=6-9 APs) 
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Figure 43 
LV and RV APD in control group 2 
Values are means, error bars omitted for clarity, n=15 hearts 
Solid symbols denote significant differences between groups 
at same time points 
Asterisks denote significant differences from minute 10, within groups, 
during ischaemia 
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Figure 44 
LV and RV APD in control group 2, during reperfusion 
Values are means, error bars omitted for clarity, n=15 hearts 
Solid symbols denote significant differences between groups 
at same time points 
Asterisks denote significant differences from minute 20, within groups 
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Figure 45 
Effect of Ro on LV and RV APD, during normal perfusion 
Values (taken from minute 10) are means, error bars = SEM 
Asterisks denote significant differences between drug and 
contemporaneous control groups 
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Figure 46 
Effect of Ro at 0.5 µM on LV APD 
Values are means, error bars omitted for clarity 
Solid symbols denote significant differences between groups 
at same time points 
Asterisks denote significant differences from minute 10, within groups, 
during ischaemia 
-p- Control group 2 (n=15 hearts, 4-14 APs) 
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Figure 47 
Effect of Ro at 0.5 µM on LV APD, during reperfusion 
Values are means, error bars omitted for clarity 
Solid symbols denote significant differences between groups 
at same time points 
Asterisks denote significant differences from minute 20, within groups 
-a- Control group 2 (n=15 hearts, 4-11 APs) 
-3 Ro at 0.5 µM (n=12 hearts, 4-10 APs) 
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Figure 48 
Effect of Ro at 0.5 µM on LV APD 
Values are means, error bars omitted for clarity 
Solid symbols denote significant differences between groups 
at same time points 
Asterisks denote significant differences from minute 10, within groups, 
during ischaemia 
--a- Control group 2 (n=15 hearts, 7-15 APs) 
-ý- Ro at 0.5 µM (n=12 hearts, 6-12 APs) 
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Figure 49 
Effect of Ro at 0.5 µM on LV APD, during reperfusion 
Values are means, ` error bars omitted for clarity 
Solid symbols denote significant differences between groups 
at same time points 
Asterisks denote significant differences from minute 20, within groups 
--0- Control group 2 (n=15 hearts, 7-11 APs) 
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Figure 50 
Effect of Ro at 5 µM on LV APD 
Values are means, error bars omitted for clarity 
Solid symbols denote significant differences between groups 
at same time points 
During ischaemia, asterisks denote significant differences from minute 
10, within groups 
During reperfusion, asterisks denote significant differences from minute 
20, within groups 
-0-- Control group 1 (n=15 hearts, 5-15 APs) 
ý- Ro at 5 µM (n=15 hearts, 4-13 APs) 
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Figure 51 
Effect of Ro at 5 µM on LV APD 
Values are means, error bars omitted for clarity 
Solid symbols denote significant differences between groups 
at same time points 
During ischaemia, asterisks denote significant differences from minute 
10, within groups 
During reperfusion, asterisks denote significant differences from minute 
20, within groups 
--a- Control group 1 (n=15 hearts, 6-15 APs) 
6 Ro at 5 µM (n=15 hearts, 4-13 APs) 
70 
60 
50 
40 
APD80 
(ms) 
30 
20 
10 
0 
Time (minutes) 
128 
05 10 15 20 25 30 
LMA occlusion 
Figure 52 
Examples of electrical activity'recorded during ischaemia, 
simultaneously from left and right ventricles of hearts 
perfused with Ro at 5 µM 
Scale: horizontal 10 cm =i second, vertical 15 mm = 10 mV 
i: Onset of LV electrical silence, in the absence of 
electrical activity indicative of arrhythmia 
Recording taken at minute 6 of ischaemia. At minute 7, the left 
ventricle was electrically silent, whilst RV AN remained unchanged 
ii: LV electrical silence, in conjunction with RV electrical 
activity characteristic of arrhythmia 
Recording taken at minute 7 of ischaemia. First recordings of RV 
arrhythmia and of LV electrical silence were at minutes 2 and 5 of 
schaemia, respectively. Similar LVand RV electrical activity was 
observed in all subsequent recordings during ischaemia 
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Figure 53 
Effect of Ro at 0.5 µM on LV and RV APD 
Values are means, error bars omitted for clarity, n=12 hearts 
Solid symbols denote significant differences between groups 
at same time points 
Asterisks denote significant differences from minute 10, within groups, 
during ischaemia 
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Figure 54 
Effect of Ro at 0.5 µM on LV and RV APD, 
during reperfusion 
Values are means, error bars omitted for clarity, n=12 hearts 
Solid symbols denote significant differences between groups 
at same time points 
Asterisks denote significant differences from minute 20, within groups 
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Figure 55 
Effect of Ro at 0.5 µM on LV and RV APD 
Values are means, error bars omitted for clarity, n=12 hearts 
Solid symbols denote significant differences between groups 
at same time points 
Asterisks denote significant differences from minute 10, within groups, 
during ischaemia 
-0 Left ventricle (n=6-12 APs) 
-p- Right ventricle (n=6-12 APs) 
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Figure 56 
Effect of Ro at 0.5 µM on LV and RV APD, 
during reperfusion 
Values are means, error bars omitted for clarity, n=12 hearts 
Solid symbols denote significant differences between groups 
at same time points 
Asterisks denote significant differences from minute 20, within groups 
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-Q-- Right ventricle (n=6-10 APs) 
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Figure 57 
Effect of Ro at 5 µM on LV and RV APD 
Values are means, error bars omitted for clarity, n=15 hearts 
Solid symbols denote significant differences between groups 
at same time points 
During ischaemia, asterisks denote significant differences from minute 
10, within groups 
During reperfusion, asterisks denote significant differences from minute 
20, within groups 
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Figure, 58 
Effect of Ro at 5 µM on LV . and RV APD 
Values are means, error bars omitted for clarity, n=15 hearts 
Solid symbols denote significant differences between groups 
at same time points 
During ischaemia, asterisks denote significant differences from minute 
10, within groups 
During reperfusion, asterisks denote significant differences from minute 
20, within groups 
-ý- Left ventricle (n=4-13 APs) 
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Figure 59 
Frequency 'distribution of LV APD data from control 
group 2, during normal perfusion 
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Figure 60 
Frequency distribution of combined LV APD data from 
control group 2, in the first 90 seconds of reperfusion 
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Figure 61 
Effect of Ro on LV lag 
Values are means, error bars omitted for clarity 
Solid symbols denote significant differences between groups 
at same time points 
-0- Control group 2 (n=15 hearts, 7-15 values) 
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Figure 62 
LV and RV APD in control group 3 
Values are means, error bars omitted for clarity, n=15 hearts 
Solid symbols denote significant differences between groups 
at same time points 
Asterisks denote significant differences from minute 10, within groups, 
during ischaemia 
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Figure 63 
LV and RV APD in control group 3, during reperfusion 
Values are means, error bars omitted for clarity, n=15 hearts 
Solid symbols denote significant differences between groups 
at same time points 
Asterisks denote significant differences from minute 20, within groups 
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Figure 64 
LV and RV APD in control group 3 
Values are means, error bars omitted for clarity, n=15 hearts 
Solid symbols denote significant differences between groups 
at same time points 
Asterisks denote significant differences from minute 10, within groups, 
during ischaemia 
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--a- Right ventricle (n=5-14 APs) 
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Figure 65 
LV and RV APD in control group 3, during reperfusion 
Values are means, error bars omitted for clarity, n=15 hearts 
Solid symbols denote significant differences between groups 
at same time points 
Asterisks denote significant differences from minute 20, within groups 
--ý- Left ventricle (n=6-10 APs) 
--a- Right ventricle (n=5-9 APs) 
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Figure 66 
LV and RV APD in control group 4 
Values are means, error bars omitted for clarity, n=15 hearts 
Solid symbols denote significant differences between groups 
at same time points 
Asterisks denote significant differences from minute 10, within groups, 
during ischaemia 
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Figure 67 
LV and RV APD in control group 4, during reperfusion 
Values are means, error bars omitted for clarity, n=15 hearts 
Solid symbols denote significant differences between groups 
at same time points 
Asterisks denote significant differences from minute 20, within groups 
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Figure 68 
LV and RV APD in control group 4 
Values are means, error bars omitted for clarity, n=15 hearts 
Solid symbols denote significant differences between groups 
at same time points 
Asterisks denote significant differences from minute 10, within groups, 
during ischaemia 
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Figure 69 
LV and RV APD in control group 4, during reperfusion 
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Figure 70 
Frequency distribution of LV APD data from 
control group 3, during normal perfusion 
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Figure 71 
Frequency distribution of combined LV APD data from 
control group 3, in the first 90 seconds 
of reperfusion 
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Figure 72 
Effect of glibenclamide on LV and RV APD, 
during normal perfusion 
Values (taken from minute 10) are means, error bars = SEM 
Asterisks denote significant differences between drug and 
contemporaneous control groups 
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Figure 73 
Effect of glibenclamide at 1 µM on LV APD 
Values are means, error bars omitted for clarity 
Solid symbols denote significant differences between groups 
at same time points 
Asterisks denote significant differences from minute 10, within groups, 
during ischaemia 
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Figure 74 
Effect of glibenclamide at 1 tM on LV APD, 
during reperfusion 
Values are means, error bars omitted for clarity 
Solid symbols denote significant differences between groups 
at same time points 
Asterisks denote significant differences from minute 20, within groups 
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Figure 75 
Effect of glibenclamide at 1 µM on LV APD 
Values are means, error bars omitted for clarity 
Solid symbols denote significant differences between groups 
at same time points 
Asterisks denote significant differences from minute 10, within groups, 
during ischaemia 
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Figure 76 
Effect of glibenclamide at 1 µM on LV APD, 
during reperfusion 
Values are means, error bars omitted for clarity 
Solid symbols denote significant differences between groups 
at same time points 
Asterisks denote significant differences from minute 20, within groups 
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Figure 77 
Effect of glibenclamide at 10 µM on LV APD 
Values are means, error bars omitted for clarity 
Solid symbols denote significant differences between groups 
at same time points 
Asterisks denote significant differences from minute 10, within groups, 
during ischaemia 
-C)-- Control group 3 (n=15 hearts, 4-14 APs) 
'- Glibenclamide at 10 µM (n=16 hearts, 4-12 APs) 
45 
40 
35 
30 
APD50 
25 
20 
15 
10 
5 
Time (minutes) 
154 
05 10 15 20 25 30 
LMA occlusion 
Figure 78 
Effect of glibenclamide at 10 µM on LV APD, 
during reperfusion 
Values are means, error bars omitted for clarity 
Solid symbols denote significant differences between groups 
at same time points 
Asterisks denote significant differences from minute 20, within groups 
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Figure -79 
Effect of glibenclamide at 10 µM on LV APD 
Values are means, error bars omitted for clarity 
Solid symbols denote significant differences between groups 
at same time points 
Asterisks denote significant differences from minute 10, within groups, 
during ischaemia 
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Figure 80 
Effect of glibenclamide at 10 µM on LV APD, 
during reperfusion 
Values are means, error bars omitted for clarity 
Solid symbols denote significant differences between groups 
at same time points 
Asterisks denote significant differences from minute 20, within groups 
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Figure 81 
Effect of glibenclamide at 1µM on LV and RV APD 
Values are means, error bars omitted for clarity, n=16 hearts 
Solid symbols denote significant differences between groups 
at same time points 
Asterisks denote significant differences from minute 10, within groups, 
during ischaemia 
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Figure 82 
Effect of glibenclamide at 1µM on LV and RV APD, 
during reperfusion 
Values are means, error bars omitted for clarity, n=16 hearts 
Solid symbols denote significant differences between groups 
at same time points 
Asterisks denote significant differences from minute 20, within groups 
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Figure 83 
Effect of glibenclamide at 1 µM on LV and RV APD 
Values are means, error bars omitted for clarity, n=16 hearts 
Solid symbols denote significant differences between groups 
at same time points 
Asterisks denote significant differences from minute 10, within groups, 
during ischaemia 
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Figure 84 
Effect of glibenclamide at 1 µM on LV and RV APD, 
during reperfusion 
Values are means, error bars omitted for clarity, n=16 hearts 
Solid symbols denote significant differences between groups 
at same time points 
Asterisks denote significant differences from minute 20, within groups 
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Figure 85 
Effect of glibenclamide at 10 µM on LV and RV APD 
Values are means, error bars omitted for clarity, n=16 hearts 
Solid symbols denote significant differences between groups 
at same time points 
Asterisks denote significant differences from minute 10, within groups, 
during ischaemia 
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Figure 86 
Effect of glibenclamide at 10 µM on LV and RV APD, 
during reperfusion 
Values are means, error bars omitted for clarity, n=16 hearts 
Solid symbols denote significant differences between groups 
at same time points 
Asterisks denote significant differences from minute 20, within groups 
At 21 minutes 50 seconds LV, but not RV APD was significantly 
shorter than at minute 20 
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Figure 87 
Effect of glibenclamide at 10 µM on LV and RV APD 
Values are means, error bars omitted for clarity, n=16 hearts 
Solid symbols denote significant differences between groups 
at same time points 
Asterisks denote significant differences from minute 10, within groups, 
during ischaemia 
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Figure 88 
Effect of glibenclamide at 10 µM on LV and RV APD, 
during reperfusion 
Values are means, error bars omitted for clarity, n=16 hearts 
Solid symbols denote significant differences between groups 
at same time points 
Asterisks denote significant differences from minute 20, within groups 
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Figure 89 
Frequency distribution of LV APD data from glibenclamide 
at 10 µM group, during normal perfusion 
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Figure 90 
Frequency distribution of combined LV APD data from 
glibenclamide at 10 µM group, in the first 90 seconds 
of reperfusion 
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Figure 91 
Effect of glibenclamide on LV lag 
Values are means, error bars omitted for clarity 
Solid symbols denote significant differences between drug 
and contemperaneous control groups at same time points 
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Chapter 6 
Electrical effects of combinations of Ro and glibenclamide 
This chapter is divided into 3 parts. The first part is a further investigation into the actions 
of glibenclamide, which includes a review of the reported effects of glibenclamide 
additional to KATP blockade. This study was carried out in order to select suitable 
concentrations of the KATP blocker for use in drug combination experiments. The second 
part is an investigation into effects of various combinations of Ro and glibenclamide on 
APD. The third part is a further investigation into the effects of various combinations of 
Ro and glibenclamide on arrhythmias. 
Further investigation into actions of glibenclamide 
Introduction 
In Chapter 3, glibenclämide by itself at both 1 and 10 µM had no effect on arrhythmias, 
but glibenclamide at 10 µM abolished the pro-arrhythmic effect of Ro at 5 µM, that was 
seen during ischaemia. In addition to implicating KATP activation in the electrical effect 
of Ro, this suggested KATP blockade by glibenclamide at 10 µM. However, the ability of 
glibenclamide at 10 µM to modulate KATP channels selectively was brought into question 
by the curious anti-arrhythmic effect of a combination of Ro at 0.5 µM and glibenclamide 
at 10 µM, which corroborates the work of Rees & Curtis (93) and is consistent with the 
view that glibenclamide at 10 µM influences processes additional tö KATP blockade. In 
Chapter 5, KATP blockade by glibenclamide at both 1 and 10 µM was suggested, owing to 
drug-induced effects on ischaemic APD changes, and because glibenclamide appeared to 
have a stronger effect at 10 µM than at 1 µM. It is conceivable that APD-shortening 
caused by glibenclamide at 1 µM during normal perfusion, might have been caused by 
effects additional to KATP blockade. Indeed, recent studies by Huang, Fagbemi & 
Northover (personal communication), carried out within this department, indicated that in the 
Langendorff-perfused rat heart, glibenclamide exerted a negative inotropic effect during 
normal perfusion, even in nanomolar concentration. Using a similar model, Wilson & 
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Woodward (203) have reported a negative inotropic effect of glibenclamide at 1 nM. Such 
an effect on myocardial contractility would not be expected if glibenclamide had 
influenced KATp channels alone. Several authors (cited on page 109) suggest that KATp 
blockade during ischaemia requires relatively high concentrations of glibenclamide. 
Clearly, any antagonism between the electrical effects of a KATp opener and 
glibenclamide involves some conflict between the potency and specificity of 
glibenclamide for KATp channels. This hinders interpretation of the role of KATp 
activation in these electrical events brought about by giving glibenclamide. 
The following experiments were designed to investigate this potential conflict, by 
measuring both electrical and mechanical effects of glibenclamide under various 
conditions. 
Methods 
Arrhythmia study 
A group of hearts was perfused with a combination of Ro at 10 µM and glibenclamide at 
1 µM. Incidence and duration of VT were measured from the CEG. Details of arrhythmia 
recording and drug perfusion are provided on pages 13 and 20, respectively. Briefly, the 
drug combination was started after 10 minutes of equilibration of the hearts to PSS 
containing glibenclamide at 1 µM, ie 15 minutes before LMA occlusion. Arrhythmias 
were recorded prior to, during and following 10 minutes of LV regional ischaemia. This 
experiment took advantage of a dip in the incidence and duration of reperfusion VT of the 
running control group. This allowed a comparison of data from the present group, not 
only with the contemporaneous control group, but also with a group of hearts perfused 
earlier with Ro at 10 µM, in the absence of glibenclamide (see page 30). 
AP study 
Groups of hearts were perfused with glibenclamide at 0.1 µM, using either PSS, or a 
solution of the composition that was used in the study described in the introduction, by 
Huang et al and based on a modification of Kreb's Solution (204). The latter was referred 
to as KS and contained (mM): NaC1(118.6), KCl (4.75), MgSO4 (1.18), CaC12 (2.0), 
NaHCO3 (25.0), glucose (11.7), KH2PO4 (1.18), pyruvate (2.0) and insulin at 5 units/I. 
The LV and RV APD50 and APD80 were recorded during normal perfusion, ie at 1 minute 
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intervals, for 10 minutes prior to LMA occlusion. Results from hearts perfused with 
glibenclamide in PSS, were compared with results from a contemporaneous control 
group, namely hearts 40-54 of the APD running control, referred to here as control group 
5. Results from hearts perfused in KS were compared also with results from the 
glibenclamide in PSS group. 
Mechanical function study 
Groups of hearts were treated with glibenclamide at 0.01,0.1,1 and 10 µM, respectively 
and with Ro at 0.5 and 5 µM, respectively. LVDP was recorded during normal perfusion, 
according to the method described in the Appendix (see page A7). Briefly, a latex balloon 
was inserted into the left ventricle during the stabilisation period and inflated with 
approximately 0.2 ml of water. LVDP was recorded using a pressure transducer, at 
minute 20 of normal perfusion, by which time the LVDP had increased to a plateau in all 
groups of hearts. All drugs were administered in PSS. Results from glibenclamide- and 
Ro-treated hearts were compared with results from contemporaneous control groups. 
Results 
Arrhythmia study 
During normal perfusion, the drug combination had no effect on the incidence or the 
duration of VT compared with contemporaneous controls [Figures 92 & 93 (page 202)]. 
During ischaemia, the drug combination had no effect on the duration of VT, but it 
caused a significantly higher incidence of VT at minute 10 of ischaemia than in the 
contemporaneous controls. During reperfusion, the drug combination caused a 
significantly higher incidence and duration of VT than in the contemporaneous controls at 
most time points (Figures 92 & 93). Both the control group contemporaneous with the 
present drug-treated group of hearts, and that used earlier in experiments with Ro at 10 
µM (see page 30) exhibited a similarly low incidence and duration of VT at all time 
points (Figures 92 & 93). The effect on arrhythmias of Ro at 10 µM seen earlier, was 
compared with a combination of Ro at 10 µM and glibenclamide at 1 µM. In the last 
minute of stabilisation and at all subsequent time points, the duration of VT was 
significantly longer in hearts treated with Ro at 10 µM, than in hearts treated with the 
combination of Ro at 10 µM and glibenclamide at 1 tM (Figure 93). At all time points 
except the last minute of stabilisation and minutes 1 and 5 of reperfusion, the incidence of 
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VT was significantly higher in hearts treated with Ro at 10 µM, than in hearts treated with 
the drug combination (Figure 92). 
AP study 
At minute 10 of normal perfusion, glibenclamide at 0.1 tM in PSS had no significant 
effect on APD50 or APD80 in either ventricle compared with the control group 5 (Figure 
94). There was not even a trend towards a drug-induced effect of glibenclamide at 0.1 tM 
in PSS. A trend was noted, however, towards a shorter APD in hearts perfused with 
glibenclamide at 0.1 tM in KS, compared with those perfused with glibenclamide at 0.1 
µM in PSS. This reached significance for LV APD50 (Figure 94). 
Mechanical function study 
Both glibenclamide and Ro caused a marked and concentration-dependent egative 
inotropic effect. Glibenclamide significantly reduced LVDP at concentrations between 
0.1 and 10 µM. Ro significantly reduced LVDP at concentrations of 0.5 and 5 µM (Figure 
95). 
Discussion 
Potency of glibenclamide to block KATP channels 
The highly pro-arrhythmic effect of Ro at 10 µM was abolished by glibenclamide at 1 µM 
during both normal perfusion and the first 9 minutes of ischaemia, and was greatly and 
significantly attenuated at most subsequent time points. This suggests that glibenclamide 
at 1 p. M might be sufficiently potent to inhibit the APD changes caused by Ro at 0.5 and 
5 µM that were reported in Chapter 5. However, in the present study, glibenclamide at 1 
µM failed to abolish Ro-induced electrical effects at minute 10 of ischaemia and at most 
time points during reperfusion. In the light of this and the suggestion on page 113 that, in 
the control groups, KATP channels open sufficiently to cause ischaemic APD-shortening 
at minute 10, glibenclamide at 1 µM may not have been potent enough to prevent the 
combined opening influence of Ro and ischaemia on KATP channels. In the present study, 
glibenclamide at 0.1 µM had no effect on APD during normal perfusion. This might be 
interpreted in two ways. 1) Ig , rp may have flowed during normal perfusion (as suggested 
on page 113), but glibenclamide at 0.1 µM blocked KATP channels insufficiently to 
lengthen APD. 2) Perhaps Iic p did not flow during normal perfusion, in which case 
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glibenclamide at 0.1 ý µM would not be able to block at this time, whether or not it could 
block open KATp channels. However, both of these interpretations contradict the 
conclusions made in Chapter 5. Glibenclamide is more likely to block open KATp 
channels at 1 µM than at 0.1 µM, yet glibenclamide at 1 µM shortened, rather than 
lengthened APD (see page 104). In addition, if no KATp channels were open prior to 
ischaemia, then an APD-lengthening by glibenclamide at 10 µM (see page 104) at that 
stage would not be expected. These puzzling contradictions, plus the lack of a reasonable 
explanation for APD-shortening by glibenclamide at 1 µM that was seen in Chapter 5, 
indicate that both interpretations 1 and 2 above are erroneous. It is possible, however, that 
glibenclamide at 0.1 µM did block KATp channels, but exerted additional effects, and that 
the influence on APD of these two processes cancelled each other out. 
Relationship between "electrical and mechanical effects of glibenclamide 
In the suction electrode validation study (see Appendix), positive and negative inotropic 
drugs caused APD-lengthening and -shortening, respectively [compare Figure Q (page 
A28) with Figure 40 (page 91)]. In the present study, Ro was markedly negatively 
inotropic. Ro at 3 µM reduced both contractility and APD in a study on guinea-pig RV 
papillary muscles (69). The relationship between electrical and mechanical drug effects in 
that study, is consistent with findings for all drugs in the present study except 
glibenclamide. In the present study, glibenclamide was significantly negatively inotropic 
at concentrations of 0.1 µM and higher, which agrees with the findings in this laboratory 
of Huang, Fagbemi & Northover (personal communication), except that Huang et al noted a 
more pronounced negative inotropic effect of glibenclamide at 0.1 µM using KS, 
compared with PSS. Blockade of KATP (or any other K+ channel) would be expected to be 
positively inotropic, through increased systolic Ca2+ influx, caused by APD-prolongation. 
Reports of effects of glibenclamide on myocardial contractility are variable. There are 
several reports of an attenuation of KATp opener-induced negative inotropism, by 
glibenclamide (205,206,207), and one clinical report of positive inotropism by glibenclamide 
(208). In a review by Levey et al (209), there are several references to positive inotropic 
effects of sulphonylureas in non-human heart muscle. These effects were species- 
dependent and did not include glibenclamide. Pogatsa & Dubecz (210) reported both 
positive inotropic and hypertensive effects of the sulphonylureas gliclazide and 
carbutamide in the dog in vivo. In that study, in contrast, glibenclamide reduced both 
myocardial contractility and arterial blood pressure. There are several reports of negative 
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inotropic effects of glibenclamide, which include effects prior to ischaemia. Billman et al 
(211) reported a glibenclamide-induced reduction in LVDP, in dogs with healed 
myocardial infarctions, both before and during exercise. Both Mitani et al (212) and Bril et 
al (32) reported effects of glibenclamide on mechanical function in rat isolated hearts. Bril 
et al noted a "non-significant reduction" in LVDP by glibenclamide at both 1 and 10 µM 
prior to ischaemia, in addition to an attenuation of the reduction in LVDP seen during 
ischaemia. Mitani et al reported negative inotropic effects of glibenclamide between 10 
and 50 tM during normal perfusion, which reached significance at 50 µM. It is 
noteworthy that Bril et al (32) reported a lack of effect of glibenclamide when it was 
administered during ischaemia, instead of prior to ischaemia, which is consistent with the 
time-dependent effect of glibenclamide reported by MacKenzie et al (193). 
The available evidence suggests that under most experimental conditions, glibenclamide 
is a negative inotrope. The reason for the disparity in the range of concentrations of 
glibenclamide which reduced myocardial contractility, between the present study and 
those of both Mitani et al (212) and Bril et al (32) is unclear, but may have involved 
differences between the perfusion solutions used. The similar degree of glibenclamide- 
induced reduction in coronary flow rate seen in the present study and in that of Bril et al 
(32) (in which the perfusion HOP was 0.8 m), suggests that the drug-induced reduction in 
LVDP was not secondary to vasoconstriction. 
The negative inotropic effect of glibenclamide is strongly suggestive of effects additional 
to KATp blockade. These may account for the curious effects of glibenclamide on APD 
seen in this model, and must influence the interpretation of data which might be obtained 
in an investigation of the electrical effects of combinations of glibenclamide and Ro. For 
these reasons, it was considered prudent to review current reports on effects of 
glibenclamide additional to KATp blockade. 
Is glibenclamide a specific KATP blocker? 
Several reports suggest that glibenclamide, particularly in the micromolar range, exerts 
effects additional to KATP blockade, including modulation of both ion channels and 
metabolism. Despite this, in numerous reports on KATp channels, an involvement of these 
channels in an observed response is concluded from an ability to be prevented by prior 
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treatment with glibenclamide. 
Effects of glibenclamide on ion channels 
Ca2+ channels 
Bian & Hermsmeyer (213) recorded L-type Ca2+ channel currents, using whole cell voltage 
clamping of rat aortic smooth muscle. In that study, glibenclamide at 10 tM inhibited 
these currents by 20%. Glibenclamide-induced increases in Ca2+ release from the 
sarcoplasmic reticulum (SR), have been suggested by both Xiong et al (214) and Chopra et 
al (215) In the first of these studies, an oscillatory outward current, which was present in 
single smooth muscle cells of rabbit portal veins, was inhibited by ryanodine, a known SR 
Ca2+ releaser (216). This current was inhibited by glibenclamide at 30 µM, but not at 1 
µM. In the second study, glibenclamide at 5 µM or higher enhanced SR Ca2+ release in 
rabbit airway smooth muscle cells. Chopra et al (215) speculated that this could have been 
due to reduction in a SR K+ conductance. 
Cl- channels 
Using whole cell voltage clamping in guinea-pig ventricular myocytes, Tominaga et al 
(217) demonstrated that the f 3-adrenoceptor agonists isoproterenol and forskolin, both at 1 
µM, activated a time-independent, outwardly rectifying Cl- current. Glibenclamide, when 
applied externally at concentrations greater than 1 µM, inhibited this current in a 
concentration-dependent manner. Maximum inhibition (80%) was attained at 100 µM. In 
that study, DMSO at less than 1%, which was used to dissolve glibenclamide in the 
present study, produced no change in membrane currents. Glibenclamide has been shown 
to block whole cell Cl- currents in cells expressing the cystic fibrosis transmembrane 
regulator [CFTR, a cyclic adenosine monophosphate (cAMP)-regulated Cl- channel], with 
an IC50 of 20 µM (218). Hongre et al (219), in a study on CFTR, observed glibenclamide- 
induced inhibition of a Cl- current, with an IC50 of 100 µM. They found no effect of 
glibenclamide at 30 µM. A cAMP-regulated Cl- channel has been identified in guinea-pig 
ventricular cells by Harvey & Hume (220). Devor et al (221) identified a cAMP-stimulated 
Cl- current in voltage clamped cultured cells, which was abolished by glibenclamide at 60 
µM. 
K+ channels other than KATP 
Beech et al (222) recorded single channel and whole cell currents, in rabbit portal vein 
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smooth muscle cells and found that the delayed rectifier was inhibited by glibenclamide 
with an IC50 of 100 µM. It is noteworthy that the KATP channel has recently been 
suggested (223,224) to represent a voltage-insensitive state of the delayed rectifier channel. 
Reeve et al (225) described a voltage-gated, Cat+- and (ATP); -independent K+ current, in a 
human neuroblastoma cell line, which was inhibited by glibenclamide at concentrations 
between 1 and 20 µM. Lin et al (226) proposed the existence of a novel, pharmacologically 
distinct class of sulphonylurea-sensitive K+ channels. These workers recorded a single 
channel K+ current in rat corpus striatum neurones, which was activated by dopamine 
receptor agonists, and blocked by glibenclamide between 1 and 10 µM. The 
sulphonylurea tolbutamide was more potent than glibenclamide in this respect, which is 
opposite to their potency ratio on KATP channels (227). 
Effect of glibenclamide on plasmalemma ion transport 
In a report by Deleers et al (228), glibenclamide at concentrations between 0.6 and 2 mM 
transported the paramagnetic ion of praseodymium (Pr3+) across the lipid membrane of 
synthetic monolamellar vesicles. These authors suggested that since there is usually a 
similarity between the transport of Pr3+ and other cations, glibenclamide might facilitate 
cation transport generally across the plasmalemma. 
Effects of glibenclamide on cardiac cellular metabolism, which are thought to be 
independent of KATP blockade 
Effects of glibenclamide on myocardial lactate production have been demonstrated in 
several species. In a study on rabbit isolated myocardial tissue, Venkatesh et at (201) 
reported an inhibitory effect of glibenclamide at 10 µM on lactate production during 
ischaemia, which was greater at 100 µM, than at 10 µM. In the Langendorff-perfused 
hearts of rat, guinea-pig and rabbit, Wilde et at (229) found that glibenclamide at 3 tM ; 
increased lactate production over that observed in the absence of the drug. Weiss & Lamp 
(230) found a similar effect. The effects of glibenclamide in both of these studies were 
observed during normoxia. A sulphonylurea-induced increase in lactate production might 
have been caused by stimulation of glycolysis. Such a link has been provided in a study 
by Kramer et at (231) on rat isolated perfused hearts using tolbutamide, in which an 
increase in lactate production was associated with both an increase in glycolytic flux and 
a decrease in the contribution of glucose to overall ATP production. In a study by 
Ogbaghebriel & Shrier (232), using rabbit isolated atrial myocytes, a 4-AP-sensitive 
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transient outward current (ITO) was measured. DNP abolished ITO but activated a steady- 
state outward current. Glibenclamide at 5 µM blocked this latter current and partially 
restored ITO. This effect on ITO may have occurred through reactivation of a transient 
outward K+ channel by glycolytically-derived ATP. It is noteworthy that ATP derived 
from glycolysis is thought to be more efficient at inhibiting KATP channels than that 
derived from oxidative phosphorylation (230). Glibenclamide also may affect metabolism 
of fatty acids. Cook (233) demonstrated, in a study on mitochondria isolated from rat heart 
muscle, that carnitine transferases were inhibited by glibenclamide with an IC5o of 40 
µ. M. These authors suggested that this might have important implications for metabolic 
regulation of fatty acid oxidation. 
Implications for the present study 
Effects of glibenclamide on Ca2+ channels would be expected to affect the inotropic as 
well as the electrical state of the heart. Indeed, both positive and negative inotropic effects 
of glibenclamide have been reported (see pages 173 & 174). The negative inotropic effect 
of glibenclamide seen in the present study, was consistent with the glibenclamide-induced 
effect on Ca2+ channels reported by Bian & Hermsmeyer (213). The potential influence of 
Ca2+ currents on arrhythmogenesis will be discussed in detail in Chapter 8. Cl- channel 
blockade by glibenclamide might conceivably affect the outcome of an arrhythmia 
investigation using this drug. Ruiz-Petrich et al (234) suggested that a Cl- current, probably 
activated by endogenous catecholamine release, played a leading role in the early 
decrease in APD observed in hypoxic rabbit hearts. Blockade of this current might be 
expected to prolong APD. Involvement of Cl- in arrhythmogenesis has been suggested in 
a study by Ridley & Curtis (235), in which rat isolated hearts were perfused with a PSS in 
which Cl- was substituted in varying degrees with the nitrate ion (NO3-). In a control 
group, with no Cl- substitution, 50% of hearts entered VF during 30 minutes of regional 
ischaemia. In groups of hearts perfused with Cl-: N03- ratios of 75: 25 and 0: 100, the 
incidence of ischaemic VF fell to 0%, in both groups. A similar reduction in VF was 
observed during reperfusion following 10 minutes of ischaemia. Blockade of the delayed 
rectifier, or any other K+ channel, might prolong repolarisation, a class III effect which 
could influence arrhythmogenesis (236). 
With the exception of the study on rat neurones by Lin et al (226), in all reports I have 
found so far on effects of glibenclamide independent of KATP blockade, these additional 
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effects occurred at concentrations greater and usually substantially greater than 1µM, 
sometimes even at millimolar concentration. In several of these reports, the effects of high 
concentrations of glibenclamide were compared directly with those seen at 1 µM. In these 
cases, glibenclamide at 1 tM appeared to affect only KATP channels. In a Langendorff- 
perfused rat heart model of ischaemia and reperfusion, Sargent et al (237) investigated the 
specificity of glibenclamide at 1 µM for KATP blockade. For comparison they used a 
mechanistically diverse range of agents with anti-ischaemic actions. These authors 
concluded that glibenclamide at 1 µM antagonised drug-induced KATP activation, but did 
not antagonise drug-induced blockade of Na+ and Ca2+ channels, Cat+-activated K+ 
channels, or delayed rectifier K+ channels. In addition, glibenclamide at 1 µM did not 
inhibit the sodium/hydrogen exchanger. A lack of effect of glibenclamide at 10 µM on 
inward rectifier current has been demonstrated by Quayle et al (238). There are no reported 
effects on the delayed rectifier with low concentrations of glibenclamide. Moreover, any 
such effect might have a negligible influence in the rat (146). No reports were found of 
effects of glibenclamide on Na+ channels. 
This literature review suggests that the use of glibenclamide at 1 µM, is appropriate to 
investigate cardiac electrophysiological effects of KATP blockade. Reports of specific 
KATP blockade using concentrations of glibenclamide higher than 1 µM, however, should 
be interpreted with caution. 
How specific are KATP openers for KAT? channels? 
It may be due to the high frequency of reports involving glibenclamide, that effects of this 
drug have been revealed additional to KATP blockade. Reports involving KATP openers 
are also numerous and a few indicate effects additional to KATP activation. Balwierczak et 
al (239) reported the presence of a voltage-sensitive and Cat+-dependent K+ channel, 
BKCa, in porcine coronary arteries. Cromakalim, which is structurally related to Ro, 
increased the open probability of this channel and relaxed arteries pre-contracted with 
various concentrations of KCI. This is consistent with similar studies on smooth muscles 
from both the rabbit (240) and the rat (241). It is noteworthy that in the porcine study (239), 
cromakalim inhibited muscle contraction with IC50 values of between 0.06 and 0.51 µM. 
Holevinsky et al (242) reported KATP activation by U83757, which is structurally related to 
pinacidil but not to Ro, in rat isolated ventricular myocytes. They used voltage clamping 
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in cultured smooth muscle cells and noted glibenclamide-sensitive hyperpolarisation by 
U83757, at concentrations between 0.01 and 1 µM. They concluded that this was due to 
both KATP activation and Cl- channel inhibition. Cardiac muscle is known to differ in its 
sensitivity to KATP openers compared with smooth muscle (see page 15). Perhaps BKog 
activation, or Cl- channel inhibition are involved in this phenomenon. 
Choice of concentration of glibenclamide to be used in the following drug 
combination experiments 
The work of several researchers (31,190.193,196,201), that is detailed on pages 109 & 110 
suggests that drug-induced KATP blockade, particularly during ischaemia, requires a 
concentration of glibenclamide in the micromolar range. In the present study, 
glibenclamide at 1 µM abolished the electrical effects of a high concentration of Ro (10 
µM). In the following experiments, Ro will be used at a maximum concentration of 5 tM 
in combination with glibenclamide. In view of this and the degree of specificity of 
glibenclamide for KATP blockade which might reasonably be expected at a concentration 
of 1 µM, it was decided to investigate ischaemia- and drug-induced KATP activation by 
using glibenclamide at 1 µM in these experiments. 
The effect on APD of various combinations of Ro and glibenclamide 
Introduction 
The aim of these experiments was three-fold. Firstly, to investigate any antagonism 
between the effects on APD of Ro, both at 0.5 and 5 µM, and glibenclamide at 1 µM. 
This was with a view to establishing the involvement of KATP channels in the Ro-induced 
electrical effects that were described in Chapter 5. Secondly, to study the effects on APD 
of a combination of Ro at 0.5 µM and glibenclamide at 10 µM. This was with a view to 
investigating the cause of the curious anti-arrhythmic effect of this drug combination, that 
was reported in Chapter 3. Thirdly, it was hoped that a correlation of the results from all 
of the APD recording experiments carried out in this thesis, might shed light on potential 
electrophysiological mechanisms of arrhythmogenesis in this model, whether or not these 
were caused by modulation of KATp channels. 
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Method 
Electrical recording 
This was as described on pages A2 & A3 of the Appendix. LV and RV APD50 and APD80 
were recorded every minute prior to, during and following 10 minutes of LV regional 
ischaemia, except during the first 2.5 minutes of reperfusion, when recordings were taken 
every 10 seconds. LV lag was not measured. Groups of hearts were treated 
contemporaneously with the following drug combinations: Ro at 0.5 µM with 
glibenclamide at 1 µM, Ro at 5 µM with glibenclamide at 1 µM, and Ro at 0.5 tM with 
glibenclamide at 10 µM. Results from each of these groups were compared with a 
contemporaneous control group, namely hearts 45-59 of the APD running controls, 
referred to here as control group 6. 
Data analysis 
At each time point, comparisons were made between LV and RV APD in the control 
group, between LV APD of control and drug combination-treated groups, and between 
LV and RV APD in drug combination-treated groups, using a Mann Whitney test. 
Temporal APD changes within each ventricle were analysed during ischaemia and 
reperfusion in all groups, according to the method detailed on page 66. The ischaemic 
APD peak and the reperfusion APD nadir (each defined on page 66) were both noted. The 
distribution of APD data in both the control group and the group treated with the 
combination of Ro at 0.5 µM plus glibenclamide at 10 µM, was analysed prior to 
ischaemia and during the first 90 seconds of reperfusion. 
Results 
, ,_ 
Control APD changes 
In control group 6, LV APDso and APD80 lengthened significantly during ischaemia, LV 
APD80 shortened significantly during reperfusion, and RV APD did not shorten during 
reperfusion [Table 9 (page 200)]. These temporal changes were consistent with control 
groups (1-4) above [see Tables 5&7 (page 114)]. In control group 6, as in groups 2,3 
and 4, LV APD-lengthening was accompanied by significant RV APD80-lengthening. In 
control group 6, as in groups 1,3 and 4, LV and RV APD values were not significantly 
shorter at minute 10 of ischaemia, than values at minute 10 of normal perfusion. In 
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control group 6, as in group 1, but in contrast to groups 2,3 and 4, there was no 
significant LV APD-shortening below values at minute 10 of normal perfusion, at any 
time point during ischaemia [Figures 96 & 98 (page 206)]. During reperfusion, LV 
APD80 was significantly shorter than the ischaemia minute 10 value, at most time points 
in the first 90 seconds (Figure 99). This was not the case in the right ventricle, although a 
trend towards RV APDso-shortening was seen (Figure 97). There was no trend towards 
reperfusion APD-lengthening prior to shortening, in either ventricle. A frequency 
distribution analysis of APD values obtained in this group of hearts (Figures 100 & 101), 
shows that the majority of LV APD80 values fell between 10 and 25 ms in the first 90 
seconds of reperfusion, with no long-footed APs occurring during this time. Temporal 
changes in normal interventricular differences in APD80 did not follow any trend, since 
LV APD80 shortened significantly below RV APD80 at two time points during the first 90 
seconds of reperfusion (Figures 98 & 99). 
Effect of drug combinations on APD during normal perfusion 
In groups of hearts treated with glibenclamide at 1 pM in combination with Ro at both 0.5 
and 5 µM, LV APD50, LV APD8O, RV APD50 and RV APD50 values were not 
significantly different from those of the contemporaneous controls. There was not even a 
trend towards drug combination-induced effects in either of these groups (Figure 102). 
Glibenclamide at 1 µM prevented the APD-shortening effect of Ro at 5 tM that was 
produced in the study reported in Chapter 5 [compare Figure 102 with Figure 45 (page 
122)]. Ro at 0.5 gM prevented the APD shortening effect of 1 tM glibenclamide that was 
produced in the same study [compare Figure 102 with Figure 72 (page 149)]. The 
combination of 0.5 tM Ro and 10 µM glibenclamide caused significant LV APD- 
lengthening over the contemporaneous control values, and a trend towards a similar effect 
in the right ventricle (Figure 102). This effect was similar to that produced in Chapter 5, 
by glibenclamide at 10 tM without Ro [compare Table 9 with Table 7 (page 116)]. It is 
noteworthy that in hearts treated with the combination of 0.5 µM Ro and 10 tM 
glibenclamide, the drug combination-induced effect on LV APD at minute 10 of normal 
perfusion was larger than at any earlier time point, for APD50 and APD80 (Figures 112 & 
114). This was not the case in hearts perfused with 10 tM glibenclamide without Ro, in 
the study reported in Chapter 5 [see Figures 77 & 79 (page 154)]. A frequency 
distribution analysis of APD values obtained during normal perfusion of hearts in this 
drug combination-treated group, revealed a possible cause of both the APD-lengthening 
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and the large SEM value for LV APD80 at minute 10: there were long-footed APs in this 
group of hearts at that time point (Figure 103). In the study reported in Chapter 5, these 
APs were not seen in hearts that were treated with 10 µM glibenclamide without Ro, at 
that time point [see Figure 89 (page 166)]. The LV APD80 values that were obtained 
between 0 and 10 minutes of normal perfusion may have been more consistent in the drug 
combination-treated group of hearts than in the group treated with 10 tM glibenclamide 
without Ro [compare Figure 103 with Figure 89 (page 166)]. Such a phenomenon could 
have been due to an antagonism between effects of glibenclamide at 10 µM and Ro at 0.5 
µM. 
Effect of drug combinations on subsequent APD changes, compared with the 
contemporaneous control group 
Combination of Ro at 0.5 1Mand glibenclamide at 1 µM 
In the group of hearts treated with this drug combination, there was no significant 
difference between LV APD50 and APD80 values and respective control values, at any 
time point during ischaemia and reperfusion, except for LV APD80 values at minute 8 of 
ischaemia (Figures 104-107). A similar drug combination-induced effect may have been 
seen at adjacent time points with the APD50 and APD80 values. Glibenclamide at 1 tM 
prevented the attenuation of ischaemic LV APD-lengthening that was produced by Ro at 
0.5 µM in the study reported in Chapter 5 [compare Table 9 with Table 5 (page 114)]. 
Glibenclamide at 1 µM also prevented the LV APD80-shortening effect of Ro at 0.5 µM, 
that was seen at each time point during ischaemia in that study [compare Figure 106 with 
Figure 48 (page 125)]. The trend towards shorter LV APD values after minute 4 of 
ischaemia, that was produced in hearts treated with 1 µM glibenclamide in that study [see 
Figures 73 & 75 (page 150)], was prevented by the present drug combination. 
Combination of Ro at 5 4Mand glibenclamide at 1 µM 
In the group of hearts treated with this particular drug combination, there was no 
significant difference between LV APD50 or APD80 values and respective control values, 
at any time point during ischaemia and reperfusion, except for LV APD50 values at 
ischaemia minute 9, and for LV APD80 values 20 seconds after reperfusion (Figures 108- 
111). These exceptions were unlikely to have been anomalous, since similar drug 
combination-induced trends were seen at adjacent time points. Glibenclamide at 1 µM 
prevented the abolition of ischaemic LV APD-lengthening that was produced by Ro at 5 
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µM in the study reported in Chapter 5 [compare Table 9 with Table 5 (page 114)]. 
Glibenclamide at 1 µM also prevented the ischaemic LV APD-shortening effect of Ro at 
5 µM, that was produced prior to the CEA-induced loss of APD data in that study 
[compare Figures 108 & 110 with Figures 50 & 51 (page 127)]. After 5 minutes of 
ischaemia there was a trend towards a glibenclamide-induced reversal of the effects of 5 
µM Ro that were described above (Figures 108 & 110). 
In the present group, 1 of 15 hearts (7%) exhibited electrical silence. This was recorded in 
the left ventricle, at minutes 8,9 and 10 of ischaemia. Three instances of ischaemic CEA 
were seen. These were recorded from different hearts, and at only one time point in each. 
In hearts of the contemporaneous control group, no electrical silence or CEA was 
recorded at any time point during ischaemia. In Chapter 5, in the group of hearts treated 
with 5 µM Ro without glibenclamide, 5 of 15 hearts (33%) exhibited LV electrical 
silence, and 8 of 15 hearts (53%) exhibited CEA, during ischaemia. Both electrical 
silence and CEA were seen in significantly more hearts in that group than in the 
contemporaneous controls, namely group 1 (p < 0.05, X2 with Yate's Correction). In the 
present group, there were not significantly more hearts exhibiting either electrical silence, 
or CEA, compared with the contemporaneous control, group 6 (p < 0.05, x2 with Yate's 
Correction). Glibenclamide at 1 µM prevented the disruption of normal APs that was 
produced by Ro at 5 µM during ischaemia, as described in Chapter 5. 
Combination of Ro at 0.5µM and glibenclamide at 10µM 
In the group of hearts treated with this drug combination, there was no significant 
difference between LV APD50 or APD80 values and their respective control values, at any 
time point during ischaemia, except at minute 7 (Figures 112 & 114). It is unclear 
whether this exception was anomalous, since a similar trend occurred at adjacent time 
points with APD50, but not with APD80. During reperfusion, LV APD50 and APD80 
values did not shorten significantly below respective control values (Figures 113 & 115) 
and LV APD80 values were significantly longer than these at several time points (Figures 
114 & 115). Glibenclamide at 10 tM prevented the ischaemic LV APD-shortening below 
respective control values, that was produced by Ro at 0.5 tM in the study reported in 
Chapter 5, in a similar manner to 1 µM glibenclamide. Ro at 0.5 µM prevented the effect 
of LV APD-lengthening over respective control values at ischaemia minute 10, that was 
produced by 10 µM glibenclamide in that study [compare Table 9 with Tables 5&7 
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(page 114)]. The trend towards APD80-lengthening at minutes 5-9 of ischaemia, that was 
produced by 10 tM glibenclamide in that study [see Figure 79 (page 156)], was also 
prevented by 0.5 µM Ro, in the present study (Figure 114). 
Effect of the drug combinations on simultaneous LV and RV APD changes 
In the three drug combination-treated groups, as in the contemporaneous control group, 
LV APD was significantly longer than RV APD at most time points prior to ischaemia 
(Figures 116,118,120,122,124 & 126). In each of these groups, the normal 
interventricular difference in APD80 was maintained at most time points in the first 5 
minutes of ischaemia, but was lost at most subsequent time points. There were no clear 
trends in any of the groups. Glibenclamide at 1 tM prevented both the ischaemic loss and 
the subsequent reversal of the normal interventricular difference in APD80 that was 
produced by Ro at both 0.5 and 5 µM, and reported in Chapter 5 [compare Figures 118 & 
122 with Figures 55 & 58 (page 132)]. 
Effect of ischaemia and reperfusion on APD in drug combination-treated hearts 
Ischaemia 
In each of the three drug combination-treated groups and in the contemporaneous control, 
LMA occlusion caused a significant lengthening of LV APD50, LV APD80, RV APD80, 
but not RV APD50 values (Table 9). This was also the case in both of the glibenclamide- 
treated groups and the controls contemporaneous with these, that were used in the study 
reported in Chapter 5 [see Table 7 (page 116)]. In hearts treated with glibenclamide at 1 
µM in combination with Ro at both 0.5 and 5 µM, LV APD50 and APD80 did not shorten 
below respective values at minute 10 of normal perfusion, at any time point during 
ischaemia (Figures 116,118,120 & 122). Glibenclamide at 1 pM prevented the 
ischaemic LV APD-shortening effects of Ro at both 0.5 and 5 µM, that were produced in 
the study reported in Chapter 5 [see Figures 46,48,50 & 51 (page 123)]. In the present. _ 
study, in the group treated with the combination of Ro at 0.5 µM and glibenclamide at 10 
µM, temporal changes in LV APD50 and APD80 values were similar during ischaemia to 
those produced in the contemporaneous control groups (Figures 112 & 114). However, in 
contrast to the present control, in the groups treated with the combination of 
glibenclamide at 1 µM plus Ro at both 0.5 and 5 µM, LV APD$o values were longer at 
several time points between minutes 5 and 10 of ischaemia, than at minute 10 of normal 
perfusion (Figures 106 & 110). A trend towards a similar effect was produced in the study 
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reported in Chapter 5, in hearts that were treated with glibenclamide at both 1 and 10 µM, 
without Ro [see Figures 75 & 79 (page 152)]. 
Reperfusion 
In the group of hearts treated with the combination of Ro at 0.5 tM and glibenclamide at 
10 µM, reperfusion did not cause significant shortening of LV APD80 (Table 9& Figure 
115). Such a drug-induced effect was also seen in the group that was treated with Ro at 
0.5 µM without glibenclamide, in the study reported in Chapter 5 [see Table 5 (page 114) 
& Figure 49 (page 126)]. The inability of reperfusion to shorten LV APD80 values 
significantly in these groups, is in contrast to all of the other groups studied so far (drug- 
treated or control) in which APD was recorded every 10 seconds during reperfusion [see 
Table 9, Table 4 (page 76) & Tables 5&7 (page 114)]. In the group of hearts treated with 
the combination of Ro at 0.5 µM and glibenclamide at 1 µM, LV APD50, in addition to 
LV APD80 shortened significantly during reperfusion (Figures 117 &119). This was not 
the case for the group of hearts that was treated with Ro at 0.5 µM without glibenclamide, 
in the study reported in Chapter 5 [see Figures 47 & 49 (page 124)]. Glibenclamide at 1 
µM abolished the prevention of reperfusion-induced APD-shortening, that was produced 
by Ro at 0.5 µM in that study. In the present study, in groups treated with glibenclamide 
at 1 µM in combination with Ro at both 0.5 and 5 µM, both LV and RV APD80 may have 
lengthened prior to significant LV APD80-shortening (Figures 119 & 123). In the group 
treated with the combination of 0.5 µM Ro and 1 µM glibenclamide, such a trend was 
also reflected for APD50 values (Figure 117). However, any LV or RV APD-lengthening 
did not reach significance compared with respective values at ischaemia minute 10, at any 
time point in the first 3 minutes of reperfusion, in either of these groups (Figures 117, 
119,121 and 123). 
However, in hearts treated with the combination of Ro at 0.5 . tM and glibenclamide at 10 
µM, APD80 lengthened significantly in the right ventricle at 10 seconds of reperfusion 
(Figure 127). This was reflected by a similar trend for LV APD80 and also for RV APD50 
(Figure 125). These reperfusion-induced APD changes were caused by long-footed APs, 
which were recorded sufficiently frequently at 10 seconds of reperfusion (see below), that 
the resulting small size of the standard error of mean APD80 values permitted the effect to 
reach significance. It is noteworthy that in the group of hearts that was treated with Ro at 
0.5 µM without glibenclamide in the study described in Chapter 5, a similar significant 
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lengthening of RV APD80 occurred [compare Figure 127 with Figure 56 (page 133)]. 
Reperfusion-induced long-footed APs 
These were not seen in control group 6, but were seen in each of the three drug 
combination-treated groups (Table 10). In the group treated with the combination of Ro at 
0.5 µM and glibenclamide at 10 µM, 6 of 15 hearts (40%) exhibited long-footed APs in 
the first 90 seconds of reperfusion. This was significantly more than in the 
contemporaneous controls, namely group 6 (p < 0.05, x2 with Yate's Correction). In no 
other drug-treated group that was used for APD recording so far, was such an effect of 
reperfusion on APs produced, using a contemporaneous control group in each case for 
comparison. In the group treated with a combination of Ro at 0.5 µM and glibenclamide 
at 10 µM, the frequency distribution of LV APD data obtained in the first 90 seconds of 
reperfusion is shown in Figure 128. Six long-footed APs were recorded during this time 
and there was a trend towards shorter APD50 values but not shorter APD80 values. The 
LV APD80 values were widely scattered in comparison with values from the group that 
was treated with 10 µM glibenclamide without Ro and reported in Chapter 5 [see Figure 
90 (page 167)]. 
Discussion 
These results have provided evidence to suggest that the effects of Ro on APD that were 
produced prior to, during and following 10 minutes of regional ischaemia, as reported in 
the study in Chapter 5, were caused by KATP activation. They provide further support for 
the claims made in that same study, namely that KATP activation occurs after 9 minutes of 
ischaemia in the control groups. They provide further insights into potential mechanisms 
of arrhythmogenesis in the present model. These three aspects of the work will be 
discussed separately. Conclusions are based on the antagonism produced between the 
electrical effects of the KATP opener and the KATP blocker in the present study, on evident 
consistencies in APD data which run throughout all of the control and drug-treated groups 
used so far, and on certain exceptions from otherwise consistent APD data, obtained from 
these groups. 
The effects of Ro on APD are caused by KATP activation 
The effects of Ro on APD that were seen in the study reported in Chapter 5 involved 
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drug-induced APD changes from control values at the. same time points, certain temporal 
APD changes within both the control and Ro-treated groups, and various temporal 
changes in the normal interventricular APD differences in those groups. In the present 
study, glibenclamide at 1 pM abolished all of these Ro-induced effects. This suggests that 
Ro-mediated effects on APD are caused by KATP activation. The degree of specificity of 
1 µM glibenclamide for KATP blockade, which was discussed in the last section, 
strengthens this evidence, since any glibenclamide-induced electrical effects additional to 
KATP blockade, are likely to have been minimal in the present study. 
In Chapter 5, it was suggested (page 100) that the Ro-induced effects on temporal 
changes in LV APD during ischaemia and reperfusion, were the most relevant indicators 
of the drug's ability to modulate arrhythmogenesis. The present results support this, but 
indicate that during reperfusion, temporal changes in the RV APD may also be relevant to 
the Ro-induced effects. Both ischaemia- and reperfusion-induced temporal APD changes 
that were seen in groups treated with Ro without glibenclamide, are compared below with 
changes seen in all of the groups that have been used so far for APD recording. These 
groups include control groups 1-4 and 6, groups treated with Ro at 0.5 and 5 µM, groups 
treated with glibenclamide at 1 and 10 µM, and groups treated with combinations of 
glibenclamide at 1 µM plus Ro at both 0.5 and 5 µM, and with the combination of Ro at 
0.5 µM and glibenclamide at 10 µM. They will be referred to hereafter as "APD groups". 
Time course of ischaemia-induced LV APD changes 
In all of the APD groups except those treated with Ro without glibenclamide, LMA 
occlusion within 3 minutes caused lengthening of LV APD50 and APD80 values over the 
pre-ischaemic value. In those groups, LV APD then returned to approximately pre- 
ischaemic values over the next 4 minutes. After 7 to 10 minutes of ischaemia, LV APD80 
(but not LV APD50) values shortened to below the pre-ischaemic value at one or more 
time point, in each of three control groups. In the other two control groups, no LV APD- 
shortening below the pre-ischaemic value was seen. The largest degree of ischaemic LV 
APD80-shortening below the pre-ischaemic value in any of the control groups, was 30%. 
In groups treated with Ro at 0.5 and 5 µM, without glibenclamide, corresponding values 
were 48% and 48%, respectively. In all of the other drug-treated APD groups (all of 
which were also exposed to glibenclamide), LV APD50 and APD80 values did not fall 
below the pre-ischaemic value at any time point. 
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Time course of reperf usion-induced LV and RV APD80 changes 
In most of the APD groups, there was a trend towards lengthening for both LV and RV 
APD8O values during the first 30 seconds of reperfusion. This was followed by a 
significant LV (but not RV) APD80-shortening during the next minute. This will be 
analysed in more detail. 
In all of the APD groups, except control group 6 and the group treated with glibenclamide 
at 10 µM, there was a trend towards reperfusion-induced LV APD80-lengthening in one, 
or both ventricles. In all of the APD groups, however, any LV or RV APDso-lengthening, 
did not reach significance. In all of the APD groups, APD-lengthening reached 
significance only for RV APD80 values. This occurred in three groups, namely control 
group 4, the group treated with a combination of Ro at 0.5 p. M plus glibenclamide at 10 
µM, and the group treated with Ro at 0.5 µM without glibenclamide. Reperfusion- 
induced APD80-lengthening has already been associated with long-footed APs (see pages 
181 & 182). Of all the APD groups, long-footed APs were produced in significant 
numbers only in hearts treated with a combination of Ro at 0.5 µM plus glibenclamide at 
10 µM. There is no clear KATp activation-dependent effect on either APD-lengthening or 
long-footed APs during reperfusion. This does not mean, however, that reperfusion- 
induced APD-lengthening might not be relevant to arrhythmogenesis. 
Clearly, reperfusion-induced LV APD80-shortening may be modulated by KATp 
activation. In all of the control groups used so far, reperfusion caused significant LV 
APD80-shortening to below the value at ischaemia minute 10. In the group treated with 
Ro at 0.5 µM, however, this did not occur and this Ro-induced effect was abolished by 
glibenclamide at 1 µM, implicating KATp activation in this prevention of reperfusion- 
induced APD-shortening. So when did this KATp activation-induced effect occur? In the 
group treated with Ro at 0.5 µM, KATp activation did not occur prior to ischaemia 
sufficiently to shorten APD, but KATP activation did occur during ischaemia, and may 
have occurred during reperfusion. In this group, LV APD80 had shortened by 48% by 
minute 10 of ischaemia, and reperfusion did not cause further shortening. This suggests a 
KATp activation-induced effect on LV APD during ischaemia, that was manifested as 
prevention of further reperfusion-induced LV APD80-shortening. In the group treated 
with the combination of Ro at 0.5 µM and glibenclamide at 10 µM (the only other APD 
group in which there was no significant reperfusion-induced LV APD-shortening), LV 
188 
APD did not shorten during ischaemia. This seems to contradict the above interpretation. 
In this group, however, it is likely that the prevention of reperfusion APD-shortening was 
caused by effects additional to those on KATp channels, which presumably might have 
"swamped" the effect of KATp blockade. Such an effect might have been a negative 
inotropic effect from glibenclamide. In this group, however, it cannot be assumed that 
glibenclamide mediated its electrical effects solely through actions additional to KATp 
blockade. That is because during reperfusion, 10 µM glibenclamide in the absence of 0.5 
µM Ro produced different effects to the drug combination. This suggests that Ro and 
glibenclamide may not act solely on the same receptor. 
In both of the groups treated with 0.5 µM Ro, whether or not in combination with 
glibenclamide at 10 µM, the drug-induced electrical effects that were produced during 
reperfusion may have been mediated through ischaemic cardioprotection, albeit via 
different mechanisms. This will be discussed in more detail in Chapter 8. 
KATp activation occurs after 9 minutes of ischaemia in control groups 
Based on findings using glibenclamide at two concentrations, the above suggestion was 
made first in the study reported in Chapter 5. Both temporal and interventricular APD 
changes during ischaemia were produced by 1 tM glibenclamide. Additional effects on 
control APD were produced by 10 tM glibenclamide. With hindsight, the effects of 1 µM 
glibenclamide have provided the strongest evidence so far that KATP channels opened 
after 9 minutes of ischaemia. These effects were small, however, compared with the 
degree of antagonism seen in the present study between the effects of Ro and 
glibenclamide during ischaemia. This might not be surprising, since KATP activation 
occurred so late in the ischaemic phase in the control group. The effects were significant, 
however. Evidence for ischaemic KATP activation in the control groups, is strengthened 
when viewed in conjunction with results from all of the APD groups. As stated above, in 
three of the controls, LV APD8'0 shortened significantly below the respective pre-' 
ischaemic value, for at least one time point during ischaemia. In no APD group treated 
with glibenclamide, whether in combination with Ro or not, did LV APD50 or LV APD80 
values shorten below the respective pre-ischaemic values, at any time point during 
ischaemia. These "APD-lengthening" effects of 1 µM glibenclamide were not likely to 
have been caused by an underlying pre-ischaemic effect on APD, since 1 µM 
glibenclamide shortened APD at that time. This could not be said for 10 µM 
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glibenclamide. Incidentally, possible involvement of KAB modulation in the APD- 
shortening produced by 1 µM glibenclamide was implied in the present study, since, 
curiously, Ro at 0.5 µM abolished it. This remains a puzzle. 
Insight into some potential mechanisms of reperfusion arrhythmogenesis in the present 
model 
In Chapter 3, Ro at 5 tM was shown to cause VT during ischaemia. In Chapter 5, this 
was correlated with severe ischaemic APD-shortening. The correlation exists, irrespective 
of whether KATp channels are actually involved in the effect of Ro. Similarly, in the 
present study, irrespective of possible KATp channel involvement during reperfusion 
arrhythmogenesis, the APD changes seen during reperfusion may be correlated with 
reperfusion arrhythmogenesis in the study reported in Chapter 3. In the control group 
used in that study, reperfusion was strongly arrhythmogenic. This was also the case in 
both groups that were treated with glibenclamide without Ro. Only in the groups treated 
with Ro at 0.5 p. M or the combination of Ro at 0.5 µM plus glibenclamide at 10 µM, was 
a significant reduction in the incidence and duration of reperfusion VT produced. In the 
present study, only in the groups exposed to those same drug treatments was there 
protection against reperfusion-induced APD-shortening. This suggests that reperfusion 
APD-shortening per se might cause arrhythmias, irrespective of the APD value at 
ischaemia minute 10 from which it started. 
A problem with this interpretation is that CEA occurred during reperfusion, particularly 
in those groups for which the measurement of APD-shortening is most relevant. When 
CEA was present, APD could not be measured. Thus when APD data is available, hearts 
may have been protected from arrhythmias. This produces self-selection of the 
reperfusion APD data. 
It is possible, therefore, that reperfusion-induced APD-lengthening, and not shortening, 
might have caused arrhythmias. In a study by Priori et al (243), in which MAPs were 
recorded from the hearts of anaesthetised cats, reperfusion after 10 minutes of left 
coronary artery occlusion caused EADs to develop in the reperfused zone in 54% of trials, 
with a mean onset time of 28 seconds. In 62% of these cases, this was accompanied, 
within seconds, by reperfusion arrhythmias. In a similar study conducted by Pogwizd & 
Corr (122), reperfusion following 10 minutes of ischaemia caused ventricular tachycardia 
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within 15 seconds after reperfusion in each of the 6 cats used. In 75% of these cases, an 
arrhythmia was initiated via a mechanism "not involving reentry". Results from these 
studies (122,243) are consistent with the hypothesis, therefore, that in the present model, it 
was reperfusion APD80-lengthening (possibly through afterdepolarisation-induction), that 
caused arrhythmias. 
It cannot be ruled out, however, that APD-shortening, particularly of a spatially 
heterogeneous nature (as implied in the review by Coronel (52)) initiates, as well as 
sustains, reperfusion arrhythmias. In a study by Coronel et al (244) on pig isolated hearts, 
reperfusion following 10 minutes of regional ischaemia caused shortening of APD in the 
reperfused zone, after 45 seconds. This was associated with a 38% incidence of 
reperfusion VF. These authors concluded that the APD-shortening played a role in the 
genesis of reperfusion VF, through reentry. In the study by Priori et al (243) arrhythmias 
were recorded in 62% of post-ischaemic reperfusion trials. In 38% of these, arrhythmias 
were not accompanied by EADs. In the study by Pogwizd & Corr (122), in 25% of hearts' 
which displayed reperfusion VF, this was reportedly caused by intramural reentry. 
The nature of the arrhythmogenic trigger during reperfusion is unknown (52). However, 
both APD-shortening and EADs may contribute, and triggered activity may play the 
primary role (122,243). The arrhythmia may then be sustained by both reentrant and non- 
reentrant mechanisms (122), although reentry has been suggested as being of primary 
relevance (16.52). Afterdepolarisations may be "necessary, but not sufficient" for 
reperfusion arrhythmias. My finding that significant long-footed AP-induction occurred 
only in a group that was expected to have been protected from arrhythmias, may simply 
be because in that group the "feet" were not long enough to cause arrhythmias, and hence 
in circumstances where they could be recorded. 
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The effect on arrhythmias of various combinations of Ro and 
glibenclamide 
Introduction 
In the last section, evidence was provided that the effects of Ro on APD that were 
presented in Chapter 5, were due to KATp activation. It is, therefore, likely that both the 
pro- and anti-arrhythmic effects of Ro that were presented in Chapter 3, were also due to 
KATP activation. The present experiments were designed with two aims. Firstly, to test 
this hypothesis by recording arrhythmias in groups of hearts treated with combinations of 
Ro and 1 tM glibenclamide. Such drug combinations might be expected to have no effect 
on arrhythmias compared with a contemporaneous control group. Therefore, it was 
decided to treat an additional group of hearts for comparison with a combination of Ro at 
0.5 µM and glibenclamide at 10 µM, which would be expected to cause an anti- 
arrhythmic effect. Secondly, it was hoped that in combination with data obtained from all 
of the electrical recording experiments carried out so far, results from the present 
experiments might permit a correlation of the time course of APD changes and 
arrhythmogenesis, caused by reperfusion. 
Method 
Drug perfusion and arrhythmia recording 
Groups of hearts were treated with the following drug combinations: Ro at 0.5 tM plus 
glibenclamide at 1 µM, Ro at 5 µM plus glibenclamide at 1 µM, and Ro at 0.5 µM plus 
glibenclamide at 10 µM. Arrhythmias were recorded prior to, during and following 10 
minutes of LV regional ischaemia. The protocol for perfusing hearts and recording 
arrhythmias is described in detail on pages 20 & 13, respectively. 
Data analysis 
Arrhythmias 
Both the incidence and the duration of VT were recorded at 1 minute intervals. Data were 
compared with a contemporaneous control group, namely hearts 127-137 of the 
arrhythmia running controls, referred to here as the "new control". Results from this 
group were compared with the first control group used in the study in Chapter 3, as 
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described on page 21, and which is referred to here as the "old control". Comparisons 
were also made between the present groups and several of the drug-treated groups used in 
the earlier study. 
Measurement of the time course of reperfusion-induced electrical changes 
For all of the APD groups used so far, the mean time to both the longest and shortest LV 
APD80 values during the first 90 seconds was calculated. The control and drug-treated 
groups used so far in this thesis for arrhythmia recording (including the present), in which 
the same drug treatments were used as for the APD groups are collectively referred to 
hereafter as the "arrhythmia groups". The mean time to onset of the first episode of VT 
was calculated in each of these groups. The temporal relationship between VT onset and 
LV APD80 changes was analysed using all of the APD and arrhythmia groups. 
Results 
Arrhythmias 
Control groups 
In the new control group, reperfusion was strongly arrhythmogenic, and both the 
incidence and the duration of VT were similar to the old control group at each time point 
[Figure 129 (page 239)]. The total duration of reperfusion VT also was similar in both 
control groups [compare Figure 132 with Figure 18 (page 50)]. 
Combination of glibenclamide at 11Mplus Ro at both OS and 5µM 
In groups of hearts treated with these drug combinations, both the incidence and the 
duration of VT was similar to the contemporaneous controls at each time point (Figures 
130 & 131). The total duration of reperfusion VT in these drug combination-treated 
groups was also similar to the controls (Figure 132). No significant differences were 
found between any of the control or drug combination-treated groups, in the incidence or 
the duration of VT recorded at any time point, or in the total duration of reperfusion VT. 
Glibenclamide at 1 µM prevented the significant reduction in both the incidence and - 
duration of VT that was produced by Ro at 0.5 µM during the first minute of reperfusion 
and at all subsequent time points, in the study reported in Chapter 3 [compare Figures 130 
& 131 with Figures 14 & 16 (page 46)]. Glibenclamide at 1 µM also prevented the 
significant reduction in the total duration of reperfusion VT, that was produced by 0.5 µM 
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Ro and reported in that study [compare Figure 132 with Figure 18 (page 50)]. 
Glibenclamide at 1 tM prevented the significant increase in both the incidence and 
duration of VT that was produced by Ro at 5 tM during ischaemia, in the study reported 
in Chapter 3 [compare Figures 130 & 131 with Figures 15 & 17 (page 47)]. 
Glibenclamide at 1 µM also prevented the significant increase in the total duration of 
reperfusion VT that was seen in the group treated with 5 µM Ro in that study [compare 
Figure 132 with Figure 18 (page 50)]. It is noteworthy that in that group, only those hearts 
which displayed VT immediately before the start of reperfusion, also displayed VT 
during reperfusion. 
Combination of Ro at 0.5 uMand glibenclamide at 10 pM 
At most time points during reperfusion, this drug combination significantly reduced both 
the incidence and the duration of VT compared with the contemporaneous control group 
(Figures 130 & 131). During the first minute of reperfusion, however, both the incidence 
and the duration of VT were not significantly lower than corresponding control values. 
The combination markedly and significantly reduced the total duration of reperfusion VT 
compared with the controls (Figure 132). These effects were similar to those produced by 
this same drug combination in the study reported in Chapter 3 [compare Figures 130-132 
with Figures 14,16 & 18 (page 46)], but were markedly different from those seen in the 
other groups in the present study. In contrast to the study reported in Chapter 3, these 
drug combination-induced effects occurred in the absence of a significant difference in 
LV surface temperature compared with the controls. 
Temporal changes in VT and LV APD80 during reperfusion 
Time to VT onset 
In the new and the old control groups, the mean time to the onset of any VT that was 
recorded during the first 10 minutes of reperfusion was similar, at 16.1 ± 8.5 (n=9 values) 
and 18.2 ± 7.6 s (n=9 values), respectively. In the only other arrhythmia control group, 
namely the one that was contemporaneous with the group treated with glibenclamide at 1 
µM, the corresponding value was not significantly different from that of either of the 
other arrhythmia control groups, at 8.3 ± 1.1 s (n=7 values). In each of the drug-treated 
arrhythmia groups, except for the one treated with Ro at 5 µM, the time to VT onset was 
not significantly different from the corresponding contemporaneous control values. In the 
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group treated with Ro at 5 µM, the only heart that did not display VT immediately prior 
to reperfusion, also did not develop VT during reperfusion. The other hearts remained in 
VT during reperfusion. In each of the APD groups in which significant LV APD80- 
shortening was recorded at any time point during the first 10 minutes of reperfusion, the 
LV APD80 nadir was recorded within the first 90 seconds. In order to compare the time 
course of these APD changes with the time to onset of VT in corresponding arrhythmia 
groups, the mean onset time was calculated for the first episode of VT recorded within the 
first 90 seconds of starting reperfusion. In most cases, this value was the same as the 
onset time for the first episode of VT recorded during the first 10 minutes of reperfusion. 
There were 3 exceptions, namely the group treated with glibenclamide at 10 µM, the 
group given a combination of Ro at 0.5 µM with glibenclamide at 10 p. M (both from 
Chapter 3), and the group treated with a combination of Ro at 5 µM plus glibenclamide at 
1 µM (from the present study). In each of these groups, the first episode of VT was 
recorded after 90 seconds in either 1 or 2 of the hearts. Analysis of the mean time to onset 
of those episodes of VT starting during the first 90 seconds of reperfusion, however, 
again revealed no significant drug-induced effect on the VT onset time, except for the 
group treated with Ro at 5 µM (Figure 133). 
Time to the shortest LV APD80 value 
In each APD group in which a significant reperfusion-induced LV APD80-shortening has 
been recorded, the mean time to the shortest LV APD80 value recorded during the first 90 
seconds of reperfusion, was less than 60 seconds (Figure 133). More reperfusion LV 
APD80 data was available for each group using this method of analysis (minimum n value 
= 7) than when the APD nadir value was recorded (minimum n value = 4). In 6 of the 9 
APD groups in which significant reperfusion-induced LV APD80-shortening was 
recorded, the mean time to the shortest LV APD80 value was less than the time at which 
the APD nadir was recorded. The reverse was true in the 3 exceptional groups, namely 
control groups 2 and 6, and the group treated with glibenclamide at 10 µM. There was, 
therefore, not even a consistent trend towards a difference appearing in the time to the 
shortest LV APD80 value and the time point at which the LV APD80 nadir was recorded 
in the APD groups. The time at which the LV APD80 nadir was recorded correlated with 
the onset time of the shortest LV APD80 values recorded in these groups. 
In each of the 4 drug-treated APD groups in which significant reperfusion-induced LV 
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APD80-shortening has been recorded, the time to the shortest LV APD80 value was not 
significantly different from the respective control value, and there were not even any 
drug-induced trends towards changes from the respective control values (Figure 133). 
Time to the longest LV APD80 value 
In each of the 11 APD groups in which the LV APD has been measured during 
reperfusion, the time to the longest LV APD80 value that was recorded during the first 90 
seconds of reperfusion, was not significantly different from the time to the shortest value. 
In 5 of these groups, the longest LV APD80 value tended to be recorded later than the 
shortest value. Therefore, the time to the longest LV APD80 value did not correlate with 
any LV APD80-lengthening that was seen prior to any shortening in the APD groups. This 
might not be surprising, since the reason that reperfusion-induced APD80-lengthening 
rarely reached significance in these groups, was that so little APD data was available prior 
to the LV APD8o-shortening (see page 103). Many of the longest LV APD80 values 
consequently were found after the shortest. For this reason, the time to the longest LV 
APD80 value was not correlated with the time to VT onset in Figure 133. 
Correlation of temporal changes in LV APD80 and VT, during reperfusion 
It should be stressed that although such correlation permits a statistical analysis to be 
made, it is recognised that comparison of the maximum of one parameter with the onset 
time of another, may be of limited value. In 3 of the 5 APD control groups used in this 
thesis, the time to the shortest LV APD80 value was significantly longer than the time to 
the onset of VT in the corresponding arrhythmia control groups. In the other 2 APD 
control groups, there was a trend towards a similar temporal relationship with the 
corresponding arrhythmia control groups (Figure 133). This temporal relationship 
appearing between the shortest LV APD80 value and the time to onset of VT, was also 
evident in each of the 4 drug-treated groups in which a comparison could be made, with 
significance being attained in two of these groups (Figure 133). 
Discussion 
Three things emerge from the results. Firstly, these results provide evidence to suggest 
that both the pro- and the anti-arrhythmic effects of Ro that were presented earlier in 
Chapter 3, were caused by KATp activation. Secondly, they shed light on the temporal 
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relationships existing between reperfusion-induced LV APD-shortening and the onset of 
reperfusion VT. Finally they strengthen the links between the various KATp activation- 
induced electrical effects that have been seen in this thesis. These will now be discussed 
in turn. 
The effects of Ro on arrhythmias are caused by KATP activation 
This claim is based firstly on the abolition by glibenclamide at 1 µM of the effects of Ro 
on arrhythmias as presented in Chapter 3. This was evident in a lack of effect on 
arrhythmogenesis of combinations of glibenclamide with Ro at either 0.5 or 5 µM. This 
was demonstrated, moreover, in relation to two separate but contemporaneous groups of 
hearts. The first was a control group in which arrhythmias followed a pattern similar to 
the control group that was used to demonstrate the effects of Ro on arrhythmias in 
Chapter 3. The second was a drug combination-treated group, for which an anti- 
arrhythmic effect had been predicted, and indeed was confirmed. 
Time course of reperfusion-induced VT onset and LV APD80-shortening 
In the group of hearts treated with Ro at 5 µM in Chapter 3, the reperfusion arrhythmias 
that were recorded may be looked upon as a continuation of those produced during 
ischaemia, since the arrhythmias spanned the onset of reperfusion and no heart developed 
VT first during reperfusion. In each of the other arrhythmia groups, hearts developed VT 
within approximately 30 seconds of reperfusion. None of the drug-treatments used for 
those groups significantly altered the time course of arrhythmogenesis compared with 
contemporaneous control groups. This might have been simply because in those hearts in 
which a drug treatment did not reduce arrhythmogenesis during reperfusion, that drug- 
treatment also was unable to significantly alter the time course of arrhythmogenesis. 
Alternatively, in'those groups of hearts in which a drug-treatment reduced the incidence 
of reperfusion arrhythmias, a potential drug-induced effect on VT onset time might have 
been concealed due to the small amount of VT onset data from these groups. Even if a 
significant effect on VT onset time had been produced in these "protected" groups of 
hearts, interpretation of such an effect would have been limited by self-selection of the 
VT onset data. Such self-selection, however, did not impede interpretation of data from 
other arrhythmia groups. In those treated with glibenclamide at 1 µM, with or without Ro, 
there was a trend towards a drug-induced delay in the time to VT onset, compared with 
control values. Since the KATP channels were presumably closed in these groups, this 
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implies that drug-induced KATP blockade (not necessarily during reperfusion), might 
delay the onset of reperfusion VT in this model. However, as stated above, such an effect 
did not reach significance in any group, and was likely to have been negligible. 
Arrhythmia data obtained from each group in the present study further support the 
possibility that reperfusion arrhythmias are associated with LV APD80-shortening in the 
present model, and that attenuation of these might be caused by prevention of such APD- 
shortening. However, the trend towards the shortest APD values occurring after the VT 
onset times in corresponding groups, indicates only that APD was markedly shortened at 
a time when this might facilitate arrhythmias through reentry. This does not imply a lack 
of a causal link between APD-shortening and genesis of arrhythmias, therefore, since 
APD may have shortened enough to cause VT, even before any APD nadir was detected. 
The link between KATP activation-induced electrical effects 
Since KATP activation seems to be responsible for the effects of Ro on both APD and 
arrhythmias, this would suggest that both the pro- and the anti-arrhythmic effect of Ro 
described in this thesis, was caused by a KATP activation-induced effect on APD. In 
Chapter 3, Ro produced a concentration-dependent effect on the duration of ischaemic 
arrhythmias. In Chapter 5, Ro produced a concentration-dependent effect on ischaemic 
LV APD (most clearly seen in the reduction by Ro of the peak ischaemic LV APD80). It 
seems likely that both of these electrical effects were caused by a concentration- 
dependent increase in the current flowing from ischaemic myocytes via KATP channels. In 
which case, KATp activation may be pro-arrhythmic (during ischaemia) when IKJTP is 
large, and anti-arrhythmic (during reperfusion) when IKATP is smaller. These disparate 
effects on arrhythmias probably are mediated through differing degrees of ischaemic 
APD-shortening. During ischaemia when IKATP is large, severe APD-shortening would be 
expected to cause arrhythmias by promoting reentry, as discussed in the context of the 
pro-arrhythmic effect of Ro at 5 µM, on pages 100 & 101. During ischaemia when ITp 
is smaller, as with Ro at 0.5 µM, APD-shortening might be mild enough not to cause 
arrhythmias, but would be expected to attenuate both systolic Ca2+ influx and the rise in 
cytosolic [Ca2+]. This might then reduce the arrhythmogenic stimulus of intracellular 
Ca2+ (Ca2+); overload during reperfusion, a possibility that is discussed in more detail in 
Chapter 8. 
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Summary of Chapter 6 
Glibenclamide at 1 µM was sufficiently potent to abolish the highly arrhythmogenic 
effect of 10 tM Ro that was reported in Chapter 3, and may have exerted minimal effects 
additional to KATP blockade. Further evidence has been provided that, in the absence of 
drugs, KATP channels open significantly, but only after approximately 9 minutes of 
ischaemia. Glibenclamide at 1 µM abolished the effects of Ro that were reported in 
Chapters 3 and 5, namely effects on arrhythmias and APD, respectively. This provides a 
link between these Ro-induced electrical effects and suggests that KATP activation may be 
either pro- or anti-arrhythmic, depending upon both the degree of ischaemic APD- 
shortening that it caused, and whether arrhythmias occurred during ischaemia or 
reperfusion. The KATP activation-induced pro-arrhythmic effect during ischaemia (of Ro 
at 5 µM), was associated with a marked KATP activation-induced APD-shortening, which 
would be expected to have facilitated reentrant arrhythmias at that time. The KATP 
activation-induced anti-arrhythmic effect during reperfusion (of Ro at 0.5 µM) was 
associated with KATP activation-induced, non-arrhythmogenic APD-shortening during 
ischaemia, which would be expected to have attenuated both systolic Ca2+ influx during 
ischaemia and the subsequent Ca2+ overload-induced arrhythmogenesis during 
reperfusion. In the group of hearts treated with the combination of Ro at 0.5 µM plus 
glibenclamide at 10 µM, an anti-arrhythmic effect during reperfusion may also have been 
associated with an ischaemic phase cardioprotective mechanism, albeit of a different 
nature, and possibly relating to the marked negative inotropic effect of 10 µM 
glibenclamide. The absence of significant reperfusion-induced APD-shortening in both 
that group of hearts and the group treated with Ro at 0.5 pM without glibenclamide, may 
have contributed to the anti-arrhythmic effect seen in these groups, possibly by inhibiting 
the formation of a reentrant substrate during reperfusion. 
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Table 9 
APD (ms) [mean ± SEM (n APs)] at various time points, from both control and 
drug-treated groups 
Ischaemia-induced APD peak: recorded in first 3 minutes of ischaemia 
Reperfusion-induced APD nadir: recorded in first 90 seconds of reperfusion 
group 6= control group, contemporaneous with all drug combination groups 
com 1= combination of Ro at 0.5 . tM and glibenclamide at 1 tM 
corn 2= combination of Ro at 5 tM and glibenclamide at 1 . tM 
corn 3= combination of Ro at 0.5 gM and glibenclamide at 10 µM 
0's denote significant differences from normal perfusion minute 10 
is denote significant differences from ischaemia minute 10 
*'s denote significant differences from contemporaneous control group 
NV = no value recorded 
Normal Ischaemia- Ischaemia Reperfusion- 
perfusion induced peak minute 10 induced nadir 
minute 10 . group 6 
LV APD50 14.9 ± 1.4 (14). 39.4 ± 3.9 (13) 16.6 ± 2.4 (8) 10.4 ± 1.3 (5) 
group 6 t 
LV APD80 34.7 ± 2.8 (14) 71.9 ± 4.7 (14) 41.1 ± 3.1 (8) 15.3 ± 1.5 (7) 
group 6 
RVAPD50 10.6 ± 0.8 (13) 17.8 ± 3.5 (13) 14.7 ± 2.7 (7) 9.1 ± 1.7 (10) 
group 6 
RV APD80 23.1 ± 1.4 (13) 40.0± 2.8 (13) 23.1 ± 3.4 (9) 18.4 ± 1.4 (9) 
Corn 1 t 
LV APD50 15.3 ± 0.6 (11) 46.1±4.3 (13) 18.8 ± 1.8 (11) 7.3 ± 1.1 (5) 
Coral t 
LVAPD8O 34.7±2.2(11) 82.5±6.2(14) 41.8±3.7(11) 15.9±3.5(4) 
Corn 1 
RVAPD50 10.7 ± 1.1 (9) 26.1 ± 8.1 (8) NV 9.2 ± 1.8 (4) 
Com1 
RV APD8o 25.5 ± 2.5 (12) 48.8 ± 9.7 (13) 28.0 ± 4.4 (5) 22.2 ± 2.9 (5) 
Com 2 
LV APD50 16.2 ± 1.7 (12) 36.0±5.0 (14) 22.0 ± 2.7 (10) NV 
Com 2 ID 0 t 
LV APD80 34.5 ± 3.7 (13) 66.6 ± 5.3 (15) 44.5 ± 3.8 (10) 14.9 ± 4.0 (4) 
Com 2 
RVAPD50 10.8 ± 0.6 (12) 20.1 ± 5.2 (9) NV 12.1 ± 2.2 (4) 
Com 2 
RV APD8O 23.2 ± 1.7 (13) 50.4±9.7 (11) NV 28.0 ± 7.0 (4) 
Com 3 
LV APD50 20.8 ± 2.3 (11) 39.1±4.3 (9) 18.7 ± 3.0 (9) 13.2 ± 4.0 (4) 
Cora 3 
LVAPD8O 49.3 ± 6.1 (13) 78.8 ± 4.4 (14) 42.6 ± 5.0 (9) 35.4 ± 5.6 (5) 
Cora3 fi 
RVAPD50 13.0 ± 1.5 (9) 21.5 ± 3.8 (7) 15.9 ± 3.6 (4) 7.8 ± 0.9 (7) 
Cora3 
RV APDga 34.3 ± 5.7 (13) 47.1 ± 4.8 (15) 26.7 ± 1.7 (9) 
126.2± 
5.7 (7) 
200 
Table 10 
Details of all long-footed APs and corresponding data, recorded during the first 90 
seconds of reperfusion 
Long-footed APs are defined as those in which APD80 80 ms 
Group 6= control group, contemporaneous with all drug-treated groups 
Heart number in control group= that of APD running control (see Chapter 7) 
gl = glibenclamide 
NV = no value recorded 
Heart 
no. 
Seconds 
following 
re perfusion 
LV 
APD50 
(ms) 
LV 
APD80 
(ms) 
RV 
APD50 
(ms) 
RV 
APD80 
(ms) 
Ro 0.5 µM 
+ gl 1 µM 
9 20 NV NV 66.9 87.5 
10 10 50.6 120.6 78.7 121.2 
10 20 7.7 78.0 NV 102.7 
Ro 5µM + 
g11pM 
5 20 60.6 90.0 74.4 88.8 
5 30 NV 95.6 NV NV 
5 40 95.0 115.0 107.0 121.0 
5 50 NV 93.7 84.0 94.0 
9 10 25.0 80.6 NV 121.9 
11 10 NV 94.4 18.1 55.0 
11 20 NV 87.5 11.9 20.0 
Ro 0.5 µM 
+ gl 10 pM 
1 10 NV NV 25.0 85.0 
7 10 NV 130.0 157.5 175.0 
9 10 44.4 80.6 12.5 33.1 
10 10 NV 96.2 NV 112.7 
10 60 23.7 80.0 NV 34.4 
13 40 18.1 135.6 13.1 75.6 
14 90 NV 87.5 8.7 23.1 
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Figure 92 
Incidence of VT 
Values are means 
Solid symbols denote significant differences between drug-treated and 
contemporaneous control groups, at same time points 
Asterisks denote significant differences between drug-treated groups 
at same time points 
There were no significant differences between control groups 
at same time points 
PSS control, contemporaneous with Ro at 10 tM + 
glibenclamide at 1 µM group (n=12 hearts) 
-0- Ro at 10 µM + glibenclamide at 1 µM (n=10 hearts) 
ý- PSS control, contemporaneous with Ro at 10 µM group 
(n=12 hearts) 
A- Ro at 10 µM (n=7 hearts) 
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Figure 93 
Duration of VT 
Values are means, with error bars omitted for clarity 
Solid symbols denote significant differences between drug-treated and 
contemporaneous control groups, at same time points 
Asterisks denote significant differences between drug-treated groups 
at same time points 
There were no significant differences between control groups 
at same time points 
PSS control, contemporaneous with Ro at 10 tM + 
glibenclamide at 1 tM group (n=12 hearts) 
---Z- Ro at 10 µM + glibenclamide at 1 µM (n=10 hearts) 
ý- PSS control, contemporaneous with Ro at 10 tM group 
(n=12 hearts) 
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Figure 94 
Effect of glibenclamide on LV and RV APD, 
during normal perfusion with different solutions 
Values (taken from minute 10) are means, error bars = SEM 
There were no significant differences between control group 5 
and the group treated with glibenclamide at 0.1 µM in PSS 
Crosses denote significant differences between drug-treated groups 
Q Control group 5, contemporaneous with glibenclamide 
at 0.1 µM in PSS group (n=15 hearts, 12 APs) 
El Glibenclamide at 0.1 µM in PSS 
(n=14 hearts, 11-13 APs) 
B Glibenclamide at 0.1 tM in KS 
(n=12 hearts, 9-12 APs) 
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Figure 95 
Effect of glibenclamide and Ro on LVDP 
during perfusion with PSS 
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Asterisks denote significant differences between drug-treated and 
contemporaneous control groups 
Crosses denote significant differences from higher concentrations 
of a drug 
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Figure 96 
LV and RV APD in control group 6 
Values are means, with error bars omitted for clarity, n=15 hearts 
Solid symbols denote significant differences in APD values 
between ventricles, at same time points 
Asterisks denote significant differences between the APD value 
at minute 10 and subsequent values during ischaemia, in either ventricle 
ED Left ventricle (n=4-15 APs) 
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Figure 97 
LV and RV APD in control group 6, during reperfusion 
Values are means, with error bars omitted for clarity, n=15 hearts 
There were no significant differences in APD values 
between ventricles, at same time points 
There were no significant differences between the APD value 
at minute 20 and subsequent values, in either ventricle 
-ý-- Left ventricle (n=5-9 APs) 
--a- Right ventricle (n=7-10 APs) 
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Figure 98 
LV and RV APD in control group 6 
Values are means, with error bars omitted for clarity, n=15 hearts 
Solid symbols denote significant differences in APD values 
between ventricles, at same time points 
Asterisks denote significant differences between the APD value 
at minute 10 and subsequent values during ischaemia, in either ventricle 
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Figure 99 
LV and RV APD in control group 6, 
during reperfusion 
Values are means, with error bars omitted for clarity, n=15 hearts 
Solid symbols denote significant differences in APD values 
between ventricles, at same time points 
Asterisks denote significant differences between the APD value 
at minute 20 and subsequent values, in either ventricle 
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Figure 100 
Frequency distribution of LV APD data from 
control group 6, 
during normal perfusion 
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Figure 101 
Frequency distribution of combined LV APD data from 
control group 6, 
in the first 90 seconds of reperfusion 
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Figure 102 
Effect of various combinations of Ro and glibenclamide 
on LV and RV APD, during normal perfusion 
Values (taken from minute 10) are means, error bars = SEM 
Asterisks denote significant differences between drug-treated groups 
and contemporaneous control group 
Q Control group 6, contemporaneous with all drug-treated groups 
(n=15 hearts, 13-14 APs) 
Ro at 0.5 tM + glibenclamide at 1 tM 
(n=15 hearts, 9-12 APs) 
Ro at 5 µM + glibenclamide at 1 µM 
(n=15 hearts, 12-13 APs) 
  Ro at 0.5 tM + glibenclamide at 10 µM 
(n=15 hearts, 9-13 APs) 
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Figure 103 
Frequency distribution of LV APD data from 
Ro at 0.5 µM + glibenclamide at 10 µM group, 
during normal perfusion 
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Figure 104 
Effect of the combination of Ro at 0.5 µM 
and glibenclamide at 1 µM on LV APD 
Values are means, with error bars omitted for clarity 
There were no significant differences in APD values 
between groups, at same time points 
Asterisks denote significant differences between the APD value 
at minute 10 and subsequent values during ischaemia, in either group 
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Figure 105 
Effect of the combination of Ro at 0.5 µM 
and glibenclamide at 1 µM on LV APD, during reperfusion 
Values are means, with error bars omitted for clarity 
There were no significant differences in APD values 
between groups, at same time points 
Asterisks denote significant differences between the APD value 
at minute 20 and subsequent values, in either group 
- a- Control group 6 (n=15 hearts, 5-9 APs) 
IB Ro at 0.5 µM + glibenclamide at 1 tM 
(n=15 hearts, 4-13 APs) 
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Figure 106 
Effect of the combination of Ro at 0.5 µM 
and glibenclamide at 1 µM on, LV APD 
Values are means, with error bars omitted for clarity 
Solid symbols denote significant differences in APD values 
between groups, at same time points 
Asterisks denote significant differences between the APD value 
at minute 10 and subsequent values during ischaemia, in either group 
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Figure 107 
Effect of the combination of Ro at 0.5 µM 
and glibenclamide at 1 µM on LV APD, during reperfusion 
Values are means, with error bars omitted for clarity 
There were no significant differences in APD values 
between groups, at same time points 
Asterisks denote significant differences between the APD value 
at minute 20 and subsequent values, in either group 
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(n= 15 hearts, 4-13 APs) 
50 
45 
40 
35 
APD80 
30 (ms) 
25 
20 
15 
10+ 
19 
217 
19.5 20 20.5 21 21.5 22 22.5 23 
1 
Reperfusion Time (minutes) 
Figure 108 
Effect of the combination of Ro at 5 µM 
and glibenclamide at 1 µM on LV APD 
Values are means, with error bars omitted for clarity 
Solid symbols denote significant differences in APD values 
between groups, at same time points 
Asterisks denote significant differences between the APD value 
at minute 10 and subsequent values during ischaemia, in either group 
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Figure 109 
Effect of the combination of Ro at 5 µM 
and glibenclamide at 1 µM on LV APD, during reperfusion 
Values are means, with error bars omitted for clarity 
Solid symbols denote significant differences in APD values 
between groups, at same time points 
Asterisks denote significant differences between the APD value 
at minute 20 and subsequent values, in either group 
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Figure 110 
Effect of the combination of Ro at 5 µM 
and glibenclamide at 1 µM on LV APD 
Values are means, with error bars omitted for clarity 
Solid symbols denote significant differences in APD values 
between groups, at same time points 
Asterisks denote significant differences between the APD value 
at minute 10 and subsequent values during ischaemia, in either group 
--a- Control group 6 
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(n=15 hearts, 4-15 APs) 
70 
60 
50 
APD80 
(ms) 
40 
30 
20 
10 
Time (minutes) 
220 
05 10 15 20 25 30 
F LMA occlusion 
Figure 111 
Effect of the combination of Ro at 5 tM 
and glibenclamide at 1 µM on LV APD, during reperfusion 
Values are means, with error bars omitted for clarity 
Solid symbols denote significant differences in APD values 
between groups, at same time points 
Asterisks denote significant differences between the APD value 
at minute 20 and subsequent values, in either group 
--Q- Control group 6 
(n=15 hearts, 5-10 APs) 
E Ro at 5 µM + glibenclamide at 1 µM 
(n=15 hearts, 4-10 APs) 
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Figure 112° 
Effect of the combination of Ro at 0.5 µM 
and glibenclamide at 10 µM on LV APD 
Values are means, with error bars omitted for clarity 
Solid symbols denote significant differences in APD values 
between groups, at same time points 
Asterisks denote significant differences between the APD value 
at minute 10 and subsequent values during ischaemia, in either group 
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(n=15 hearts, 4-15 APs) 
E Ro at 0.5 µM + glibenclamide at 10 µM 
(n=15 hearts, 4-13 APs) 
40 
35 
30 
APD50 
25 
20 
15 
10 
Time (minutes) 
222 
05 10 15 20 25 30 
LMA occlusion 
Figure 113 
Effect of the combination of Ro at 0.5 µM 
and glibenclamide at 10 µM on LV APD, during reperfusion 
Values are means, with error bars omitted for clarity 
There were no significant differences in APD values 
between groups, at same time points 
There were no significant differences between the APD value 
at minute 20 and subsequent values, in either group 
-Q-- Control group 6 
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Figure 114 
Effect of the combination of Ro at 0.5 µM 
and glibenclamide at 10 µM on LV APD 
Values are means, with error bars omitted for clarity 
Solid symbols denote significant differences in APD values 
between groups, at same time points 
Asterisks denote significant differences between the APD value 
at minute 10 and subsequent values during ischaemia, in either group 
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Figure 115 
Effect of the combination of Ro at 0.5 µM 
and glibenclamide at 10 µM on LV APD, during reperfusion 
Values are means, with error bars omitted for clarity 
Solid symbols denote significant differences in APD values 
between groups, at same time points 
Asterisks denote significant differences between the APD value 
at minute 20 and subsequent values, in either group 
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(n=15 hearts, 5-9 APs) 
70 
60 
50 
APD80 
(ms) 40 
30 
20 
10 
225 
Reperfusion Time (minutes) 
Figure 116 
Effect of the combination of Ro at 0.5 µM 
and glibenclamide at 1 µM on LV and RV APD 
Values are means, with error bars omitted for clarity, n=15 hearts 
Solid symbols denote significant differences in APD values 
between ventricles, at same time points 
Asterisks denote significant differences between the APD value 
at minute 10 and subsequent values during ischaemia, in either ventricle 
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Figure 117 
Effect of the combination of Ro at 0.5 µM and 
glibenclamide at 1 µM on LV and RV APD, 
during reperfusion 
Values are means, with error bars omitted for clarity, n=15 hearts 
Solid symbols denote significant differences in APD values 
between ventricles, at same time points 
Asterisks denote significant differences between the APD value 
at minute 20 and subsequent values, in either ventricle 
-®- Left ventricle (n=4-13 APs) 
--Q- Right ventricle (n=4-6 APs) 
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Figure 118 
Effect of the combination of Ro at 0.5 tM 
and glibenclamide at 1 tM on LV and RV APD 
Values are means, with error bars omitted for clarity, n=15 hearts 
Solid symbols denote significant differences in APD values 
between ventricles, at same time points 
Asterisks denote significant differences between the APD value 
at minute 10 and subsequent values during ischaemia, in either ventricle 
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Figure 119 
Effect of the combination of Ro at 0.5 µM 
and glibenclamide at 1 µM on LV and RV APD, 
during reperfusion 
Values are means, with error bars omitted for clarity, n=15 hearts 
Solid symbols denote significant differences in APD values 
between ventricles, at same time points 
Asterisks denote significant differences between the APD value 
at minute 20 and subsequent values, in either ventricle 
--®- Left ventricle (n=4-13 APs) 
--a- Right ventricle (n=4-8 APs) 
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Figure 120 
Effect of the combination of Ro at 5 µM 
and glibenclamide at 1 µM on LV and RV APD 
Values are means, with error bars omitted for clarity, n=15 hearts 
Solid symbols denote significant differences in APD values 
between ventricles, at same time points 
Asterisks denote significant differences between the APD value 
at minute 10 and subsequent values during ischaemia, in either ventricle 
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Figure 121 
Effect of the combination of Ro at 5 µM 
and glibenclamide at 1 µM on LV and RV APD, 
during reperfusion 
Values are means, with error bars omitted for clarity, n=15 hearts 
Asterisks denote significant differences between the APD value 
at minute 20 and subsequent values, in either ventricle 
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Figure 122 
Effect of the combination of Ro at 5 µM 
and glibenclamide at 1 µM on LV and RV APD 
Values are means, with error bars omitted for clarity, n=15 hearts 
Solid symbols denote significant differences in APD values 
between ventricles, at same time points 
Asterisks denote significant differences between the APD value 
at minute 10 and subsequent values during ischaemia, in either ventricle 
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Figure 123 
Effect of the combination of Ro at 5 µM 
and glibenclamide at 1 µM on LV and RV APD, 
during reperfusion 
Values are means, with error bars omitted for clarity, n=15 hearts 
There were no significant differences in APD values 
between ventricles, at same time points 
Asterisks denote significant differences between the APD value 
at minute 20 and subsequent values, in either ventricle 
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Figure 124 
Effect of the combination of Ro at 0.5 tM 
and glibenclamide at 10 µM on LV and RV APD 
Values are means, with error bars omitted for clarity, n=15 hearts 
Solid symbols denote significant differences in APD values 
between ventricles, at same time points 
Asterisks denote significant differences between the APD value 
at minute 10 and subsequent values during ischaemia, in either ventricle 
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Figure 125 
Effect of the combination of Ro at 0.5 µM 
and glibenclamide at 10 µM on LV and RV APD, 
during reperfusion 
Values are means, with error bars omitted for clarity, n=15 hearts 
Solid symbols denote significant differences in APD values 
between ventricles, at same time points 
Asterisks denote significant differences between the APD value 
at minute 20 and subsequent values, in either ventricle 
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Figure 126 
Effect of the combination of Ro at 0.5 µM 
and glibenclamide at 10 µM on LV and RV APD 
Values are means, with error bars omitted for clarity, n=15 hearts 
Solid symbols denote significant differences in APD values 
between ventricles, at same time points 
Asterisks denote significant differences between the APD value 
at minute 10 and subsequent values during ischaemia, in either ventricle 
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Figure 127 
Effect of the combination of Ro at 0.5 µM 
and glibenclamide at 10 µM on LV and RV APD, during 
reperfusion 
Values are means, with error bars omitted for clarity, n=15 hearts 
Solid symbols denote significant differences in APD values 
between ventricles, at same time points 
Asterisks denote significant differences between the APD value 
at minute 20 and subsequent values, in either ventricle 
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Figure 128 
Frequency distribution of combined LV APD data from 
Ro at 0.5 µM + glibenclamide at 10 µM group, 
in the first 90 seconds of reperfusion 
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Figure 129 
Comparison between old and new arrhythmia 
control groups 
Old control = control group contemporaneous with drug-treated groups 
used in chapter 3 (see page 21) 
New control = control group contemporaneous with the 
drug combination-treated groups 
Values are means, with error bars omitted for clarity 
There were no significant differences in the incidence or the duration 
of VT between groups, at same time points 
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Figure 130 
Incidence of VT 
New control = control group contemporaneous with 
the present drug combination-treated groups 
Values are means 
Solid symbols denote significant differences between the control 
and drug combination-treated groups, at same time points 
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Figure 131 
Duration of VT 
New control = control group contemporaneous with 
the present drug combination-treated groups 
Values are means, with error bars omitted for clarity Solid symbols denote significant differences between the control 
and drug combination-treated groups, at same time points 
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Figure 132 
Total duration of VT, during reperfusion 
Values are means, error bars = SEM 
Asterisks denote significant differences between the control 
and drug combination-treated groups 
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Figure 133 
Time to both the onset of VT and the shortest LV APD80 value recorded 
during reperfusion 
VT values (squares) are mean times to the onset of the first episode of VT recorded during 
the first 90 seconds of reperfusion. APD values (circles) are mean times to the shortest 
LV APD80 value recorded in the first 90 seconds of reperfusion. Error bars = SEM. Glib 
= glibenclamide, i= group used in chapter 3, ii = group used in present experiments. 
APD values are not shown for groups treated with Ro at 0.5 µM or the combination of Ro 
at 0.5 µM plus glibenclamide at 10 µM, since no significant reperfusion-induced LV 
APD-shortening was recorded at any time point in these groups. 
is and $'s denote significant differences between VT and APD values in control and 
drug-treated groups, respectively. *'s denote significant differences in VT values between 
control and corresponding drug-treated groups. There were no significant differences in 
APD values between control and corresponding drug-treated groups. 
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Chapter 7 
Long term temporal variation in control 
electrical activity 
Introduction 
Few reports have been published concerning the long term changes in the incidence of 
arrhythmias generated in experimental models using the rat, or any other species. Curtis et 
al (49) reported that in conscious rats, the severity of ischaemia-induced arrhythmias in 
control groups of hearts did not vary significantly in their laboratory over a period of 
several years. These authors noted that some other workers have also seen a consistency 
in arrhythmogenesis in control hearts, in both conscious and anaesthetised rats. However, 
Abrahamsson et al (245) reported that the incidence of ischaemia-induced VF in control 
groups of anaesthetised rats was highly variable in their laboratory. Abrahamsson & 
Almgren suggested (103) that the season may have contributed to this variability. Cheung 
et al (246) reported that in acutely anaesthetised rats studied over a3 year period, there was 
a lack of reproducibility of ischaemia-induced arrhythmias in control hearts. They found 
that this variability was not related to season, year, diet, rat strain, ischaemic zone size, or 
serum [K+]. In clinical studies (247,248) and in a canine study (104), a seasonal variation in 
ischaemia-induced sudden cardiac death has been reported, in which more deaths 
occurred during Winter than Summer months. Scherlag et al (104) attributed this to 
increased sympathetic nervous activity in the Winter. In another clinical study, Heyer et 
al (249) reported a seasonal variation in the frequency of acute myocardial infarction, with 
most cases occurring during the very hot Summer months. Physiological oscillations, or 
"endogenous clocks" have been described by Bunning (250). This author noted that these 
may occur in unicellular organisms and isolated tissues, as well as in intact multicellular 
organisms. These oscillations are connected with biochemical processes, may exhibit 
periods ranging between hours and several years, and may persist even under seemingly 
constant environmental conditions (250). It is conceivable that in the present model, such 
oscillations might be expressed as a temporal change in the severity of reperfusion- 
induced arrhythmias, such as that reported in Chapter 3 of this thesis. 
244 
The aim of the present study was threefold. Firstly, to identify any rhythmic change in 
reperfusion arrhythmias under controlled environmental conditions. Secondly, to correlate 
any temporal changes in arrhythmias and in APD. Thirdly, to permit contemporaneous 
comparisons to be made between control and drug-treated groups of hearts. 
Methods 
Animal husbandry 
Male Sprague Dawley rats were bred and housed on site and fed ad libitum on a pellet 
and tap water diet. Food pellets (Diet 41B) were initially supplied by Pilsbury's, but after 
April 1994, by B&K Universal. Rats were exposed only to artificial illumination 
(fluorescent tubes) in the animal house, with an approximate 12 hour light and 12 hour 
dark cycle. This varied slightly at weekends. Air temperature in the animal house was 
maintained between 18 and 23°C and the relative humidity was kept above 50%. At 
approximately daily intervals, groups of rats, aged between 4 and 9 months, were 
transferred to the laboratory, and were maintained under similar conditions to the animal 
house, prior to being killed. 
Experimental protocol 
A group of 137 control hearts was used to study temporal changes in arrhythmias between 
11th February 1994 and 20th June 1995 and is referred to as the "arrhythmia running 
control". Another group, of 59 control hearts was used to study temporal changes in APD 
between 1st November 1994 and 20th June 1995 and is referred to as the "APD running 
control". In each group, approximately one heart was studied every 4 days, with hearts 
from the APD running control being used on the same days as those of the arrhythmia 
running control. All control hearts were subjected to 10 minutes of LV regional 
ischaemia. Details of the perfusion method are given on pages 6&7. The CEG was 
recorded from hearts of the arrhythmia running control, and both LV and RV epicardial 
APs were recorded from hearts of the APD running control. Details of these two electrical 
recording methods are given on page 13 and on pages 65 & 66, respectively. 
Experimental measurements and data analysis 
In arrhythmia running control hearts, both the incidence and the total duration of VT were 
calculated during the first 10 minutes of reperfusion. In APD running control hearts, LV 
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and RV APD50 and APD80 values were obtained at minute 10-of normal perfusion, and 
peak LV APD50 and APD80 values were calculated during ischaemia. As described in 
detail in Chapter 3, the following features were noted from hearts in each group. Prior to 
perfusing hearts, the date, the rat body weight and the air temperature close to the rats 
were noted. During perfusion, the coronary flow rate was noted and following 
reperfusion, the LV surface temperature, the total ventricular weight and the weight of 
ventricular muscle which was not perfused during LMA occlusion were noted. In 
addition, the temperature and relative humidity of the air inside the heated jacket were 
measured using a temperature and humidity probe (Type HM1 31, Vaisala, Finland). This 
was placed approximately 1 cm from the LV surface. Relative humidity values 
approaching 100% were subject to inaccuracies of approximately 10%. The ranges in all 
data were noted and a running mean (± SEM) of each recorded parameter was calculated 
for each set of 12 hearts. Running averages were necessary due to the highly variable 
nature of many of the recordings, particularly the electrical ones. They provided an 
indication of long term rhythmical changes. Temporal changes in the mean incidence or 
mean duration of reperfusion-induced VT were then plotted and compared with all other 
recorded parameters. Any variables which seemed to follow similar time courses were 
displayed using simple scatter plots. 
Results 
Reperfusion-induced arrhythmias 
VT duration values recorded over the 16 month period ranged from zero to 599 seconds. 
The running mean revealed considerable, possibly cyclical variation in both the incidence 
and duration of VT. Changes in the incidence and duration of VT followed a similar time 
course, with a trend towards low values (referred to as "dips") occurring twice [Figure 
134 (page 253)]. The first dip began in the middle of May 1994, reaching a nadir at 
approximately the middle of July 1994. The second dip began at the beginning of 
February 1995, reaching a nadir at approximately the beginning of April 1995. 
Comparison of arrhythmias with other arrhythmia running control parameters 
Rat body weight and total ventricular weight 
The range of body weight values was 354-643 g. The range of total ventricular weight 
values was 1.01-1.83 g. The running mean of both parameters displayed a trend towards a 
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gradual increase over the 16 month period, with the time course of changes bearing no 
relation to the temporal variation in reperfusion-induced VT (Figure 135). 
Weight of ischaemic zone 
Expressed as a percentage of the total ventricular weight, these values ranged between 28 
and 65%. The running mean displayed a small degree of temporal variation, with mean 
values ranging between 40 and 53%. A dip in the running mean, which reached a nadir in 
January 1995, bore no temporal relation to either of the dips in reperfusion-induced VT 
(Figure 135). 
Air temperature and humidity 
The laboratory air temperature was highly variable, ranging between 16 and 28°C. The 
heated jacket surrounding the heart kept the air close to the heart at between 24.0 and 
35.0°C, with running means ranging between 26.3 and 33.6°C. Temporal changes in air 
temperatures bore no relation to those of arrhythmias (Figure 136). The relative humidity 
of air close to the heart was maintained above approximately 70% and bore no relation to 
arrhythmias. 
LV surface temperature 
This ranged between 35.75 and 38.75°C. Running means ranged between 36.67 and 
37.72°C. There was a trend towards a dip between June and October 1994 (Figure 136). 
The time course of this dip was similar to that of the first dip in the incidence of 
reperfusion-induced VT, although by the middle of September 1994, when mean LV 
surface temperature values were still low, the mean VT incidence had returned to "base- 
line" values (Figure 136). There may have been a second dip in the running mean LV 
surface temperature between March and June 1995. 
The closest correlation between changes in arrhythmias and any of the other parameters 
measured in the arrhythmia running control, was seen with the LV surface temperature 
and the duration of reperfusion-induced VT (Figure 137). Although the time course of the 
first dip in each of these parameters showed a reasonable correlation, the second dip in 
VT duration (which displayed a magnitude similar to the first) was not concurrent with 
any large dip in LV surface temperature. Analysis of the distribution of un-meaned LV 
surface temperature data (Figure 138) revealed that 83% of values fell within 10C of 
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37.0°C, indicating a reasonable control of this variable. Analysis of the scatter of meaned 
data showed that over the 16 month period, LV surface temperature displayed a poor 
correlation with VT incidence, although there may have been a better correlation between 
LV surface temperature and VT duration (Figure 139). Mean LV surface temperature 
values did not correlate with mean coronary flow rate values (ml/min/g total ventricular 
weight) calculated during the 10 minute reperfusion phase. Since LV surface temperature 
was measured immediately after reperfusion, this suggested that any drop in temperature 
was not caused by heat loss from the heart to surrounding air in the relatively more poorly 
perfused hearts. 
Comparison of APD with other running control parameters 
The ranges of pre-ischaemic LV APD50, LV APD80, RV APD50 and RV APD80 values 
were 3.1-27.5,15.0-58.7,3.1-16.9 and 8.7-46.2 ms, respectively. The ranges of peak 
ischaemic LV APD50 and APD80 values were 12.5-78.1 and 33.7-112.5 ms, respectively. 
The ranges of running mean pre-ischaemic LV APD50, LV APD80, RV APD50 and RV 
APD80 values were 13.0-17.9,32.0-41.3,9.1-11.7 and 19.4-25.1 ms, respectively. The 
ranges of running mean peak ischaemic LV APD50 and APD80 values were 34.5-49.4 and 
65.3-85.9 ms, respectively. Each of the running means varied little over the 8 month 
period, and displayed no rhythm (Figure 140). The second dip in the incidence and 
duration of VT was recorded (from the arrhythmia running control) contemporaneously 
with these APD changes, but its time course did not correlate with any change in running 
mean APD values (Figure 140). The range of LV surface temperature values recorded in 
the APD running control was narrower than that seen in the arrhythmia running control, 
at 36.5-38.0°C. The running mean LV surface temperature values in this group ranged 
between 37.04 and 37.43°C, and any temporal variation was small, with no clear pattern 
of change. Analysis of the scatter of meaned data showed that LV surface temperature 
was not correlated with APD (Figure 141). 
Discussion 
Over a'16 month period, both the incidence and the duration of reperfusion-induced VT 
underwent considerable temporal variation in a control group. This may have been 
cyclical but was not related to the season. This temporal variation did not correlate with 
temporal variations in the weight of the ischaemic zone, rat body weight, total ventricular 
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weight, laboratory air temperature, or with a change of diet. There may have been a 
correlation between variations in the duration of reperfusion"induced VT and LV surface 
temperature. 
Gambassi et al (92) perfused guinea-pig isolated hearts at 37.0°C and found that 
reoxygenation following 15 minutes of hypoxia caused ventricular arrhythmias in 75% of 
hearts. When the temperature was reduced to 33°C, the incidence of arrhythmias fell to 
30%. The temperature difference used in that study was far greater than that recorded in 
the present study, yet it caused a similar variation in arrhythmias to that seen in the 
present study. It seems unlikely that the small variations in LV surface temperature 
recorded in the present study, could have caused such large variations in arrhythmias. 
However, this possibility cannot be excluded. 
The temporal variation in reperfusion-induced VT, therefore, may have been caused by 
one or more endogenous physiological oscillations, a possibility which is discussed 
below. One evolutionary response to the challenge imposed on organisms by seasonal 
change, has been to develop various means to identify the season by measuring day 
length, or the photoperiod. This is a reliable and noise-free marker of the phase of the 
seasonal cycle (251). All organisms studied so far, other than bacteria and blue-green 
algae, have been shown to manifest innate oscillations in their physiology. Such 
oscillations are inherited and may attain an appropriate phase relation with a 
synchronising agent, usually light, and thus become entrained by it (250). These 
oscillations are often circadian, having a period of approximately 24 hours, and they may 
drive other physiological cycles with periods of months, or even years. There are reports 
of circadian and seasonal variations in several physiological measurements among rats 
which have been exposed to either natural or artificial illumination. This is shown, for 
example, in measurements of basal metabolic rate (2), serum content of protein, glucose, 
fatty acids, cholesterol, magnesium ions, Ca2+ and lipid peroxidase (253,254,255,256), total 
counts of various blood cells (257), and cellular morphology and histochemistry (258). 
Under constant lighting conditions, circadian rhythms may revert to periods of between 
23 and 27 hours, and annual cycles may also become less consistent (250). Whether or not 
an endogenous cycle becomes entrained, various physiological processes may become 
coupled to it, including responses to external factors (250). There is ample evidence to 
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support this in the rat. For example, Otsuka et al (259) used anaesthetised male Wistar rats 
and found a circadian rhythm of bradycardic arrhythmias during ambulatory 
electrocardiogram monitoring, which was closely correlated with a circadian rhythm in 
paradoxical sleep. In the absence of light, these rhythms persisted, but reverted to a 25 
hour cycle. Lee et al (260) used anaesthetised male Sprague Dawley rats and found that 
renal injury caused by ischaemia and reperfusion was sensitive to the season. Porszasz & 
Worum (261) reported a seasonal variation in the susceptibility of the rat to 
experimentally-induced seizures. 
In intact animals, temporal variations in blood composition, such as described above, 
might give rise to temporal variations in arrhythmias. In a study by Abrahamsson & 
Almgren (103), treatment of anaesthetised rats with frusemide decreased serum [K+] and 
increased the incidence of ischaemia-induced VF compared to untreated rats. Since a 
seasonal variation in arrhythmias was seen in frusemide-treated rats in the absence of any 
variation in serum [K+], this suggests that a temporal variation in arrhythmias is not 
caused by a variation in serum [K+], although variations of other blood components might 
be involved. 
Endogenous clocks are not peculiar to intact animals. They cannot, therefore, simply be 
thought of as hormonal responses, for example, resulting from cooperation between the 
various endocrine glands, since isolated tissues also display such clocks. In a study using 
rat isolated perfused hearts, Hommel & Fischer (262) found a seasonal variation in glucose 
utilisation, which they concluded was the expression of an endogenous rhythm of the 
whole organism. Charnock et al (3) used isolated perfused atrial muscles of the ground 
squirrel, and demonstrated a seasonal variation in the contractile response to extracellular 
Cat+. Aiken & McArdle (264) used a rat isolated extensor digitaris muscle preparation, and 
found that an absence of (K+)a depolarised in the Autumn, but caused hyperpolarisation 
during the Winter, with a transition occurring during the Spring. Wirz-Justice (265) used 
brain slices from male Wistar rats and found a circadian rhythm in monoamine 
metabolism, which was linked to a similar rhythm in levels of gamma-aminobutyric acid. 
Kafka et al (266) found both circadian and seasonal rhythms in the numbers of a-and ß- 
adrenoceptors in rat fore-brain and hypothalamus. 
The mechanism underlying endogenous clocks is unknown. Pittendrigh & Minis have 
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suggested ( 1) that multicellular organisms may be considered to be a collection of many 
physiological oscillators, at least one of which involves a biochemical reaction that is 
modulated by a photosensitive enzyme. These authors speculated that photo-induction 
might occur when a metabolite reached a threshold level. Woodland Hastings (267) 
suggested that endogenous clocks may be associated with changes in the levels of enzyme 
synthesis. 
In the present study, as in the studies on isolated tissues described above, a temporal 
variation in a response was seen even though the preparation was perfused with an 
artificial liquid of constant composition. It is possible that the temporal variation in 
arrhythmias seen in the present study was caused by oscillations in cell membrane density 
of various ion channels or receptors, or perhaps in cellular metabolism. The findings of 
several researchers (262,263,264,265,266) are consistent with this hypothesis. In the present 
study, for an endogenous clock mechanism to have caused the temporal variation in 
reperfusion arrhythmogenesis, it would need to have been approximately synchronised in 
all rats. This is not inconceivable, since all rats shared the same accommodation and were 
exposed to the same environment. Even in the absence of time cues, such synchronisation 
might have occurred spontaneously, due to the close proximity of the rats to each other. 
Olfactory communication is a possibility. Seasonal variation may persist even under strict 
lighting regimes, possibly due to time cues other than light, such as external noise (258). A 
time cue also does not need to be of a constant nature: even a short pulse of light at the 
beginning and end of an 8 hour period (a skeleton photoperiod) may have the same effect 
on a biological rhythm as continuous light (251). In the present study, an endogenous clock 
may have been entrained by a time cue. It is noteworthy, however, that Thorp (255) 
observed an 8 month cycle in serum cholesterol levels and adrenal weight in rats which 
were exposed to natural lighting. 
In the present study, an 8 month cycle may also have occurred. This was evident from the 
running control experiments. In addition, in Chapter 3, a low incidence of VT was 
reported in a control group used in the middle of December 1993. This point in time was 
approximately 8 months earlier than the first recorded dip in the arrhythmia running 
control. In the other arrhythmia control groups used before and after this time, the 
incidence of VT was high. Hearts from the APD running control group and the 
arrhythmia running control group were perfused on the same days and under similar 
251 
conditions. In the APD running control group, there was negligible temporal variation in 
either pre-ischaemic APD or peak ischaemic LV APD values, indicating that temporal 
variation in arrhythmias was not caused by a variation in APD. 
Although the evidence cited in this discussion may support the possibility that temporal 
variation in VT seen in the present study could have been caused by an endogenous clock, 
it is equally possible that it was caused by external factors. Moreover, the apparent 
correlation between VT duration and LV surface temperature may have been coincidental 
and the observed temporal variation in arrhythmias may have been caused by another, as 
yet unknown variable. Fascinating as the study of temporal variation in arrhythmogenesis 
may be, such variations are a nuisance to pharmacologists. Abrahamsson et a! (245) 
stabilised a variable arrhythmogenic response to ischaemia in their model, by treating all 
hearts with frusemide. Von Mayersbach (258) has stressed the importance of using 
contemporaneous controls, and this policy was used in the present study. 
Summary of Chapter 7 
A temporal variation in the incidence and the duration of reperfusion-induced VT has 
been recorded from a control group of rats, over a 16 month period. This variation may 
have displayed a cycle with an 8 month period. The variation was not related to the 
season, or variations in APD, ischaemic zone weight, rat body weight, total ventricular 
weight, laboratory air temperature, or diet. Although temporal variation in arrhythmias 
may have been associated with a variation in LV surface temperature, or with some 
unknown external factors, it may have been caused by an endogenous physiological 
oscillation, or an endogenous clock. Evidence to support this hypothesis has been 
provided. 
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Figure 136 
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Figure 137 
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Figure 138 
Frequency distribution of un-meaned LV surface 
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Figure 140 
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`Chapter 8 
General Discussion 
Controversy surrounding the physiological and pathophysiological roles of cardiac KATp 
channels has been fuelled by apparently conflicting reports of the effect on arrhythmias of 
pharmacological modulation of these channels. The main area of contention is whether 
KATP openers are pro-arrhythmic or anti-arrhythmic. The main finding of the present 
study was that KATP activation can cause or prevent ventricular arrhythmias, depending 
on the concentration of the KATP opener used and on whether the effect was studied 
during ischaemia or during reperfusion. At first sight, this might seem to exacerbate the 
controversy. However, the electrophysiological mechanisms underlying ischaemia- and 
reperfusion-induced arrhythmias are likely to be different (268,269). Activation mapping 
studies in feline hearts have demonstrated that the majority of ischaemic arrhythmias are 
initiated through intramural reentry (270), but that the majority of reperfusion-induced 
arrhythmias are initiated by non-reentrant mechanisms (12), possibly afterdepolarisations 
(see pages 190 & 191). Moreover, evidence from studies of the effects of KATP openers 
on arrhythmias has been obtained from widely differing experimental models. Hence, the 
electrophysiological mechanisms of arrhythmogenesis are also likely to have differed. 
Since the model used may be an important source of the apparent conflict of evidence, it 
was considered prudent to review the reported effects on arrhythmias of both the KATp 
openers and the KATP blockers and then to discuss them in the context of my own 
findings in this thesis. 
Evidence for pro-arrhythmic effects of KATP openers 
Lu et al (88) reported that pinacidil was profibrillatory during 5 minute occlusions of the 
LMA in the rat heart in vivo. Wolleben et al (87) found that both pinacidil and cromakalim 
decreased the time to onset of VF during 30 minutes of low flow ischaemia in rat isolated 
hearts, and this was confirmed by Seigl et al (100) in a similar model. Ferdinandy et al (271) 
recently demonstrated a pro-fibrillatory effect of cromakalim during 10 minutes of LMA 
occlusion in rat isolated working hearts. Both Grover et al (30) and Tosaki et al (101) found 
that cromakalim was profibrillatory during reperfusion following 25 minutes of global 
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ischaemia in rat isolated hearts. Padrini et al (105) reported that under conditions of 
constant flow in guinea-pig isolated hearts, pinacidil promoted electrically inducable VF 
in a concentration-dependent manner. Both Fagbemi et al (272) and Friedrichs et al (273) 
reported profibrillatory effects of pinacidil following 12 minutes of global hypoxia and 40 
minutes of reoxygenation in the rabbit, which was confirmed by Chi et al (274) using a 
similar model. Wilde (275) found that cromakalim shortened the time to onset of VF 
during ischaemia in this species. Bellemin-Baurreau et al (191) reported that lemakalim 
increased the incidence of program stimulation inducable VF during 24 minutes of 
regional ischaemia in rabbit isolated hearts. Le Grand et al (118) reported pro-arrhythmic 
effects of nicorandil in rabbit isolated atria. De La Coussaye et al (120) used anaesthetised 
dogs and found that lemakalim caused a dose-dependent increase in mortality due to VF, 
in the absence of ischaemia. Kojima et al (276) induced VPBs by coronary infusion of 
nicorandil, in a similar model. Spinelli et al (277) found that pinacidil and cromakalim 
eased the induction of electrically inducable atrial arrhythmias in the dog. Chi et al (28) 
reported that in dogs with healed myocardial infarctions, pinacidil was profibrillatory 
when hearts were subjected to ischaemia for 1 hour. Di Diego & Antzelevitch (106) and 
Steinberg et al (278) both found that pinacidil caused spontaneous APs in canine isolated 
ventricular tissues. 
Evidence for anti-arrhythmic effects of KATP openers 
Fish et al (85) and Carlsson et al (279) both reported anti-arrhythmic effects of pinacidil in 
anaesthetised rabbits given either CsCI or clofilium to induce ventricular arrhythmias. 
Carlsson et al (279) recorded EADs using an endocardial MAP electrode and pinacidil 
dose-dependently reduced the incidence of both EADs and ventricular tachycardia. 
Takahashi et al (280) used a similar model and found that nicorandil reduced both the 
amplitude of EADs and the incidence of ventricular tachycardia. Kempsford & Hawgood 
(86) reported that nicorandil decreased the incidence of both VPBs and ventricular 
tachycardia during 15 minutes of regional ischaemia and reduced the incidence of VF 
during reperfusion in rat isolated hearts. D'Alonzo et al (281) found that both pinacidil and 
cromakalim were anti-fibrillatory during ischaemia in a similar model. Ferdinandy et al 
(271) found that cromakalim reduced the incidence of reperfusion-induced VF in rat 
isolated working hearts. D'Alonzo et al (62) reported that cromakalim and pinacidil 
reduced ectopic activity caused by coronary infusion of CsCI in anaesthetised dogs. 
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Grover et at (30), also using dogs, reported that cromakalim reduced both the frequency of 
ectopic beats and the proportion of hearts in VF during 5 hours of reperfusion following 
90 minutes of coronary artery occlusion. In a study by Kaszala et at (282) on anaesthetised 
dogs, nicorandil reduced the incidence of VF during both regional ischaemia and 
reperfusion. Fish et at (85) used canine Purkinje fibres and found that both cromakalim 
and pinacidil abolished quinidine-, CsCl- or sematilide-induced EADs and associated 
triggered activity. Lathrop et at (18) used a similar model and found that nicorandil 
abolished CsCl-induced EADs and reduced the amplitude of acetylstrophanthidin-induced 
delayed afterdepolarisations (DADs). Steinberg et at (278) found that pinacidil markedly 
reduced barium ion (Ba2+)-induced automaticity in a similar model. Spinelli et at (283) 
reported that pinacidil increased the current required to induce EADs, abolished ouabain- 
induced DADs and arrested Bat+-induced automaticity in canine isolated ventricular 
myocytes. 
Evidence for pro-arrhythmic effects of KATP blockers 
D'Alonzo et al (33) reported that glibenclamide exacerbated CsC1-induced ventricular 
arrhythmias in anaesthetised dogs. Pasnani & Ferrier (90) reported that glibenclamide 
increased the incidence of triggered arrhythmias in guinea-pig isolated RV free wall 
segments exposed to conditions of simulated ischaemia and reperfusion. Ballagi-Pordany 
et al (284) found that tolbutamide and gliclazide increased both the number of VPBs and 
the duration of VF during 30 minutes of LMA occlusion in rat isolated hearts. 
Evidence for anti-arrhythmic effects of KATP blockers 
In rat isolated hearts, Kantor et al (89) found that glibenclamide abolished irreversible VF 
during 30 minutes of either regional or global ischaemia, Rees & Curtis (93) found that 
glibenclamide was defibrillatory during 30 minutes of regional ischaemia, Wolleben et al 
(87) and Homburg et al (285) both found that glibenclamide reduced the incidence of VF 
during low flow ischaemia, and Ballagi-Pordany et al (284) found that glipizide decreased 
both the number of VPBs and the duration of VF during ischaemia. Tosaki et al (101) 
reported that glibenclamide reduced the incidence of reperfusion-induced ventricular 
tachycardia and VF following 25 minutes of global ischaemia, and Bril et al (32) reported 
a similar effect (see page 24 for details), again in rat isolated hearts. Both Pogatsa et al 
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(286) and Zhang et al (99) reported an anti-arrhythmic effect of glibenclamide during 
ischaemia, in rat hearts in vivo. Gwilt et al (287), Reiß et al (288) and Tosaki & Faha (289) 
reported finding anti-arrhythmic effects with glibenclamide during ischaemia in guinea- 
pig isolated hearts. Both Wilde (275) and Adams et al (290) reported anti-arrhythmic effects 
with glibenclamide during ischaemia in rabbit hearts either in vitro or in vivo. Lightbown 
et al (205) have demonstrated that glibenclamide reduced the incidence of ischaemic 
ventricular tachycärdia and VF in the cat in vivo. Billman et al (211) used a model in which 
dogs with healed myocardial infarctions were subjected to 2 minute periods of coronary 
artery occlusion during exercise. This caused VF in all the control animals. 
Glibenclamide prevented VF in 13 of 15 dogs. 
Primary and secondary electrophysiological effects of KATP modulators 
KATP openers are potent vasodilators at concentrations showing no direct electrical effect 
on cardiac myocytes, as in the present study, although anti-arrhythmic effects of KATP 
openers have been reported in association with minimal haemodynamic effects (85a82) In 
some species, such as the dog, vasodilation may enhance coronary collateral supply, 
causing secondary electrophysiological effects. Indeed, in some reports, both pro- and 
anti-arrhythmic effects of KATP openers have been seen only in the presence of significant 
increases in coronary flow (62.277). However, in a study by Bellemin-Baurreau et al (191), 
both high and low concentrations of lemakalim caused maximal vasodilation, but only at 
the high concentration (5 µM), was a pro-arrhythmic effect seen. Although KATP 
modulators may have minimal effect on heart rate (211,282), the pro-arrhythmic effect of 
pinacidil reported by Chi et al (28) was associated with, and may have been secondary to, 
an increased heart rate. In addition, in this study the infarct size may have been larger in 
the drug-treated group than the controls, which might have contributed to the pro- 
arrhythmic effect. Indeed, anti-arrhythmic effects of cromakalim have been associated 
with reductions in infarct size (30). In the present study, both pro- and anti-arrhythmic 
effects of Ro were observed under controlled coronary flow rates and neither Ro nor 
glibenclamide significantly affected heart rate. In addition, myocardium would not be 
expected to have infarcted in the present study, any variations in the size of non-perfused 
zones were negligible and extracardiac factors, such as neural influences, were absent. 
Therefore, effects of KATP modulation in this study can be considered direct cardiac 
effects. Although secondary effects of KATP modulators can affect arrhythmogenesis, it is 
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clear that primary electrophysiological effects occur. 
Consistencies in the evidence 
Although the conflict of evidence is often dwelt upon, it is clear from the majority of 
reports that KATP blockade with glibenclamide generally is anti-arrhythmic during 
ischaemia (87,89,93,99,205,211,275,284,285,286,287,288,289,290). This is true for varying species and 
ischaemic protocols. No arrhythmias were seen during ischaemia in the present study, so 
no anti-arrhythmic effect could have been detected. Glibenclamide had no significant 
effect on reperfusion arrhythmias. Most of the conflicting evidence arises from reports of 
the effects of KATP openers. However, the majority of pro-arrhythmic effects were seen 
during ischaemia or hypoxia in intact hearts, either in vitro or in vivo 
(28,87,88,100,191,271,272,273,274,275,276). This is supported by the present study, in which Ro 
exhibited a concentration-dependent pro-arrhythmic effect during ischaemia. However, 
Ro also caused pre-ischaemic arrhythmogenesis, in agreement with other studies 
(106,120,276,278). Many workers have used arrhythmogenic stimuli, either with or without 
ischaemia, to demonstrate pro-arrhythmic effects. This was true, for example, at low 
[K+]0 (118,274), after myocardial infarction (28) or with electrical stimuli (105,118). Anti- 
arrhythmic effects of KATP openers have been reported during ischaemia (86.281,282), 
although the high concentration of nicorandil used (86,282) may have reduced arrhythmias 
by donating nitric oxide (282). The majority of anti-arrhythmic effects of KAB openers 
result from prevention of drug-induced triggered activity in intact hearts or isolated 
tissues (18,62,85,278,279,280,283). Studies designed to assess the effect of KATp openers on 
reperfusion arrhythmias in the absence of ischaemic arrhythmias are rare. Three reports 
have been found of the effects of KATP openers on reperfusion arrhythmias in rat isolated 
hearts (30,101,271). How many hearts were in ventricular tachycardia during ischaemia was 
not stated in two of these reports (30,101). Ferdinandy et al (271) have reported a mild anti- 
arrhythmic effect during reperfusion, with cromakalim at a concentration that did not 
cause ischaemic arrhythmias. Similarly, in the present study Ro reduced the incidence and 
the duration of VT during reperfusion. This occurred at a concentration at which hearts 
were still in NSR immediately prior to reperfusion. The possible underlying cause of this 
effect is discussed later. 
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Drug concentration-dependency of effects of KATP modulators on arrhythmias 
This is perhaps most clearly illustrated by the differential effect of Ro on arrhythmias in 
the present study. Only high concentrations of Ro (5 and 10 µM) induced arrhythmias. 
Only a low concentration of Ro (0.5 µM) inhibited arrhythmias and this was seen only 
during reperfusion. A differential effect of a KATP opener on arrhythmias has recently 
been reported (271), with cromakalim at 60 pM causing VF in 30% of hearts during 
ischaemia, but cromakalim at both 10 and 60 µM reducing the incidence of VF during 
reperfusion. Steinberg et al (278) reported that pinacidil below 30 pM inhibited Bat+- 
induced automaticity, but caused spontaneous APs above 30 µM. Wilde (275) reported that 
cromakalim was pro-arrhythmic during ischaemia at 3 µM, but not at 1 µM. Similarly, 
Bellemin-Baurreau et al (191) reported that lemakalim was pro-arrhythmic during 
ischaemia at 5 µM, but not at 1 pM. Concentration-dependent reductions in the incidence 
of triggered arrhythmias (18,279), and a dose-dependent increase in mortality due to VF 
(120) have also been reported. It is often difficult to compare drug concentrations between 
studies due to unknown drug plasma concentrations and the differing potencies of various 
KATp openers. Moreover, superimposing an arrhythmogenic stimulus, in particular 
ischaemia, may be more important to the experimental outcome than the drug 
concentration used. For example, in the present study Ro at 5 µM had a negligible effect 
on arrhythmias prior to ischaemia, but was pro-arrhythmic during ischaemia, when the 
KATP channels may have become "sensitised" to open. 
The link between KATP opener-induced and ischaemia-induced KATP activation 
In the present study, KATp channels seemed to open after 9 minutes of ischaemia. [ATP]; 
would be expected still to be in the millimolar range at this time, perhaps as high as 10 
mM (291). - Half maximal inhibition of KATp channels in excised membrane patches occurs 
at 17-25 tM ATP (292,293), so KATp channels would be expected still to be closed after 9 
minutes of ischaemia. Several explanations for such a discrepancy have been suggested, 
such as a lower sensitivity of KATp channels to [ATP]; in intact cells compared to excised 
membrane patches, heterogeneity among the sensitivity of KATp channels to [ATP];, and 
perhaps cellular compartmentation of ATP (23,91). It has been suggested that opening of 
only a small proportion of KATp channels might induce sufficient current flow to shorten 
APD, since cardiac KATp channels have both a high density and a high conductance. A 
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compelling reason to think that KATp channels open even in the presence of micromolar 
[ATP]i is that several ligands other than (ATP)1 are able to modulate the sensitivity of 
KATp channels to blockade by (ATP);, such as intracellular nucleoside diphosphates (34). 
Within only a few minutes of ischaemia, intracellular levels of adenosine diphosphate 
(ADP) and phosphates rise as phosphocreatine is progressively metabolised (200). 
Intracellular ADP (ADP)i may compete with (ATP); for the inhibitory ATP binding site, 
and may also bind to a separate receptor, the nucleoside diphosphate receptor, or NDP, 
and promote channel opening (294). During ischaemia, both intracellular and extracellular 
acidosis occurs (295). A fall in intracellular pH has been shown to open KATp channels 
even in the presence of (ATP); (296,297). Ischaemia-induced intracellular lactate 
accumulation may also promote KATp activation (298). Adenosine, which is also released 
from myocardium during ischaemia (see Parratt (299)), may stimulate KATp opening 
(300.301). It may be speculated that during the first 9 minutes of ischaemia in the present 
model, increased concentrations of intracellular ligands (other than ATP) fail to overcome 
the inhibitory effect of (ATP)i on the KATp channel. This would explain the lack of effect 
of glibenclamide on APD during that time indicating that KATp channels had not opened. 
It is noteworthy that Ro at 0.5 µM, by opening KATp channels, shortened APD during, but 
not prior to ischaemia. It is conceivable that an ischaemia-induced increase in the 
concentration of any one of the KATp channel activating ligands described above, might 
have "tipped the balance" in favour of KATp activation in this case. Terzic et al suggested 
(34) that KATp opening drugs fall into two functional groups: those that open KATp 
channels by antagonising the inhibitory effect of (ATP);, and those that additionally bind 
to some other site, such as the NDP. The concentration of a KATp opener at particular 
binding sites, plus the superimposed effects of ischaemia might then determine whether 
or not KATp channels open. For example, Jahangir et al (302) reported that the KATp 
activating effect of nicorandil was enhanced by both (ADP)i and acidosis in guinea-pig 
ventricular myocytes. 
Model-dependency of electrophysiological mechanisms of arrhythmogenesis 
The models of arrhythmia that have been described can be classified according to whether 
reentrant or non-reentrant arrhythmogenic mechanisms might be expected to 
predominate. For example, in intact hearts, ischaemia would favour reentry (270), whilst 
reperfusion might favour afterdepolarisations (243). In most of the isolated tissue 
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preparations described, non-reentrant mechanisms were specifically promoted. By 
shortening APD, KATp activation, particularly using high concentrations of KATp openers 
in the presence of ischaemia, would be expected to promote reentrant arrhythmias. This is 
supported by the finding that Ro at 5 µM caused glibenclamide-sensitive APD-shortening 
and VT during ischaemia. This is perhaps the most important contribution of the present 
study. Wilde has recently reported that during global ischaemia in rabbit isolated hearts, 
cromakalim caused a concentration-dependent potentiation of both QT interval- 
shortening and arrhythmogenesis (see Wilde (5) Figure 2). KATp opener-induced 
arrhythmogenic shortening of the refractory period and the QT interval have been 
reported in other intact heart studies (105,191). KATp opener-induced APD-shortening and 
arrhythmogenesis that is characteristic of reentry has been reported in isolated tissue 
studies (106,118,278). It is noteworthy that Miyazaki et al (303) recently demonstrated in 
anaesthetised dogs, that nicorandil enhanced ischaemic APD-shortening when 
administered at a dose that is used clinically to treat hypertension. These authors 
acknowledged that although nicorandil did not cause arrhythmias, it might have done so 
had they chosen an ischaemic episode of longer than 5 minutes. Ischaemia-induced 
reentry may also be facilitated by slowing of conduction, caused by (K+)o accumulation. 
As discussed in Chapter 3, [K+]o increases within seconds of ischaemia. However, 
conduction velocity remains virtually unchanged until [K+]o exceeds approximately 10 
mM, which would not be expected until approximately 10 minutes of ischaemia had 
occurred (52). This may partly account for the lack of ischaemic arrhythmias in the present 
model. In the rabbit isolated heart, Wilde has shown that cromakalim did not enhance 
(K+)a accumulation and even attenuated it after 19 minutes of ischaemia (see Wilde (275) 
Figure 1), suggesting that the KATp opener-induced arrhythmias were not caused by 
slowing of conduction, but by APD-shortening. This is supported by the present study, 
since the Ro-induced APD-shortening and the VT were prevented by glibenclamide. 
The weight of evidence supports an anti-arrhythmic effect of KATP blockade during 
ischaemia [see "Consistencies in the evidence" (page 265)]. Since the majority of 
ischaemic arrhythmias are likely to be reentrant, this suggests that the anti-arrhythmic 
effect of KATP blockade during ischaemia was probably through prevention of reentry. 
Glibenclamide would thus be expected to, and indeed has been shown to prevent both 
APD-shortening (290,304) and (K+)o accumulation (89). However, such effects may serve 
only to delay arrhythmogenesis, and APD-shortening-induced cardioprotection, as seen in 
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the present study with Ro at 0.5 µM, would be lost. 
Reported anti-arrhythmic effects of KATP openers have most frequently involved 
inhibition of afterdepolarisations in isolated tissue preparations. In many of these reports, 
EADs were induced by K+ channel blockade and may have been antagonised by an 
outward K+ current such as IKATp. In Chapter 6, it was suggested that the anti-arrhythmic 
effect of Ro at 0.5 µM also involved the inhibition of afterdepolarisations. Outward IKATp 
may have contributed to this effect during reperfusion, although this was not specifically 
investigated by perfusing hearts with Ro during reperfusion only. 
Reperfusion arrhythmogenesis and its attenuation by KATP activation 
The biochemical changes underlying electrophysiological disturbances during both 
ischaemia and reperfusion have been reviewed recently (2)" Those changes which appear 
to be most relevant to reperfusion arrhythmogenesis are (Ca2+)i overload, washout of 
(K+)o and protons, and the formation of free radicals. Reperfusion-induced (Ca2+); 
overload is considered to be particularly arrhythmogenic, by causing oscillatory release of 
sarcoplasmic reticular Cat+, and subsequent afterdepolarisations (305,306). Avkiran has 
recently suggested (307) that (Ca2+)i overload may provide a common pathway for 
reperfusion arrhythmogenesis, involving both proton washout and free radical formation. 
It is frequently proposed that a physiological role for KATP activation would be to reduce 
[Ca2+]i during ischaemia, thereby conserving contractile ATP. Such an effect might also 
attenuate the rise in [Ca2+]i during reperfusion. Brooks et al (97) simultaneously recorded 
[Ca2+]; and arrhythmias in rat isolated hearts during 10 minutes of global ischaemia and 
reperfusion, using aequorin, a Ca2+ indicator. At a perfusate [Ca2+] of 3 mM, ischaemia 
caused a transient rise in systolic [Ca2+]i, which peaked after 2 minutes. Reperfusion 
caused a marked increase in [Ca2+];, which was immediately followed by ventricular 
tachyarrhythmias in 10 of 11 hearts. At a perfusate [Ca2+] of 0.5 mM, the ischaemic rise 
in systolic [Ca2+]; was attenuated. No hearts displayed reperfusion arrhythmias, and 
systolic [Ca2+]; remained close to pre-ischaemic values over the first minute of 
reperfusion. The long-footed APs recorded in the present study may have been caused by 
an increase in [Ca2+]i during the first few seconds of reperfusion. Behling & Malone (308) 
recently reported that the KATP opener BMS- 180448 reduced cytosolic [Ca2+] prior to, 
during and follöwing 25 minutes of global ischaemia in rat isolated hearts. Jiang et al (119) 
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reported that lemakalim simultaneously reduced systolic [Ca2+]i and APD in human and 
guinea-pig ventricular myocytes, in a concentration-dependent manner. In the present 
study, therefore, Ro at 0.5 tM may have exerted its anti-arrhythmic effect by attenuating 
the systolic Ca2+ transient during ischaemia. This may have occurred via KATp activation- 
induced APD-shortening, thereby inhibiting both a rise in [Ca2+]i and afterdepolarisations 
during reperfusion. As discussed in Chapter 6, the APD-shortening seen after 
approximately 1 minute of reperfusion in several models, including the present one, may 
have been caused by (K+)o washout. A heterogeneous undershoot of [K+]o would favour 
unidirectional conduction block. Concurrent (Ca2+); overload-induced 
afterdepolarisations might then provide suitably timed impulses to permit degeneration of 
a triggered arrhythmia into a reentrant arrhythmia. In the present study, the prevention of 
APD-shortening during reperfusion (below that seen during ischaemia), may have 
contributed to the anti-arrhythmic effect of Ro at 0.5 µM. APD-shortening then would 
contribute less to the formation of a reentrant substrate. Such an electrical effect would be 
consistent with the anti-arrhythmic effect of the combination of Ro at 0.5 µ. M and 
glibenclamide at 10 µM, although this cannot be considered to involve KATP channels 
solely. Perchenet & Kreher t127l found that ischaemic preconditioning of rat isolated 
hearts prevented reperfusion-induced APD-shortening in the absence of a substantial 
effect on APD during the first 10 minutes of ischaemia. Coronel et al (U4) reported that 
ischaemic preconditioning caused an anti-arrhythmic effect during reperfusion in pig 
isolated hearts. This was associated with a slowing of both APD-shortening and [K+]o 
undershoot during reperfusion, possibly corresponding to a decreased re-uptake of K+, 
caused by depressed Na+-K+ ATP ase activity (52). Although KATp activation may have 
been involved in this anti-arrhythmic effect, Ro at 0.5 µM may not have mimicked such 
an effect in the present study, since KATp channels do not appear to be involved in 
ischaemic preconditioning in the rat (for recent review, see Parratt & Kane (24) and see 
also Yabe et al (309)). 
Critique of the present model and ideas for future experiments 
Perhaps the most important criticism, which limits extrapolation of the present results to 
the in vivo situation, is that Langendorff hearts perform little external volume work 
compared to ejecting hearts. In the latter it may not be possible to exploit KATP openers to 
shorten APD just enough to be cardioprotective, without risking arrhythmias through 
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excessive APD-shortening. ATP would be expected to be used up faster than in 
Langendorff hearts, thereby promoting further KATp opening and APD shortening. The 
recent study by Ferdinandy et al (271) illustrates the harm ischaemia may cause in a 
working heart model with a KATp opener at a concentration that is significantly anti- 
arrhythmic during reperfusion. Evidence of APD changes using KATp openers in a similar 
model, particularly during ischaemia, would be valuable. Such evidence may be difficult 
to obtain, however, using the present APD recording technique since part of its success 
lay in the static nature of the suction electrodes, which might be compromised in a 
working heart. Grover et al (310) recently reported a cardioprotective effect (in this case, 
an increase in the time to onset of ischaemic myocardial contracture in guinea-pig isolated 
hearts) with a KATp opener (BMS-180448) which did not shorten APD during ischaemia. 
An investigation into the effects of this drug on APD and arrhythmias, in a working heart 
model, would be useful. In the present study, the anti-arrhythmic effect of Ro was mild, it 
was observed at only one concentration, and the perfusate ionic composition was initially 
adjusted to highlight the effect. These factors may partly account for the scarcity of 
similar findings by other researchers, and may also preclude exploitation of such an anti- 
arrhythmic effect in vivo. A limitation relating to APD recordings in the present study 
was that APs could not be recorded during arrhythmias. It would be interesting to 
investigate temporal changes in APD during reperfusion in the absence of arrhythmias, by 
using, for example, a high [K+] or a low [Ca2+] perfusate. This would limit self-selection 
of APD data and although APD changes could still not strictly be associated with 
arrhythmogenesis, this may be better than not recording APD at all. Since it has been 
suggested that Ro at 0.5 pM inhibited reperfusion-induced afterdepolarisations by 
attenuating an ischaemic rise in [Ca2+]i, it is important to discover whether Ro also 
prevents afterdepolarisations when perfused only during reperfusion. Such an 
investigation should present few technical problems. 
It is necessary to investigate further the anti-arrhythmic effect of a combination of Ro at 
0.5 tM with glibenclamide at 10 µM, especially since it did not involve ischaemic APD- 
shortening or the attendant risk of pro-arrhythmia. Rees & Curtis (93) observed an 
ischaemic anti-arrhythmic effect of a similar drug combination and hypothesised that the 
two drugs may have exerted differential effects in ischaemic and perfused muscle. They 
acknowledged that the QT interval changes they recorded did not support this, however, 
and concluded that the effect involved a mechanism distinct from modulation of Icp. 
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These authors suggested that such a mechanism might have been related to effects of 
glibenclamide additional to KATp blockade. In both the present study and that of Rees & 
Curtis (93), the anti-arrhythmic effect of the drug combination is unlikely to have been 
caused solely by effects of glibenclamide additional to KATp blockade, since 
glibenclamide did not prevent arrhythmogenesis when administered without a KATP 
opener. It is possible that in both of these studies, glibenclamide and the KATP opener 
were exerting effects additional to modulation of IK, Tp (see pages 174-179), and that 
prevention of arrhythmias by a combination of such effects might only be revealed at high 
concentrations of glibenclamide. This hypothesis allows the prevention of KATP 
activation-induced effects of Ro at 0.5 µM by glibenclamide at 1 pM, and would also 
explain why glibenclamide at 10 µM lacked an effect on arrhythmias in the absence of 
Ro. Such a hypothesis might be tested by combining suitable concentrations of a variety 
of KATP openers and blockers, specifically to look for anti-arrhythmic effects. Candidate 
drug combinations could then be tested for their effects on contractility, APD changes 
during ischaemia and reperfusion, and also on single channels and whole cell currents. 
Clinical studies of KATP modulating drugs 
Clinical trials using KATP openers as antihypertensives have not revealed any pro- 
arrhythmic effects (311,312). This may relate to the substantially lower drug concentration 
required to cause vasodilation, compared to any direct cardiac electrophysiological 
effects. However, Goldberg (313) reported that 30% of patients taking pinacidil displayed 
T wave flattening and inversion, which was unrelated to fluctuations in blood pressure, 
heart rate or serum [K+] but may have been related to changes in APD. Nony et al (314) 
reported that pinacidil decreased T wave amplitude and increased heart rate in 10 healthy 
volunteers. It is worth emphasising that in the presence of ischaemia, these effects might 
have been more pronounced. Clinical trials involving KATP blockers do not suggest any 
adverse cardiac effects. Cacciapuoti et al (315) studied 19 non-insulin-dependent diabetes 
mellitus patients, who each displayed transient myocardial ischaemia associated with 
VPBs, transient ventricular tachycardia, or both. Treatment with glibenclamide for 14 
days significantly reduced the incidence of both VPBs and episodes of non-sustained 
ventricular tachycardia during transient ischaemia, but it did not change the number or the 
duration of acute myocardial ischaemic attacks and did not reduce the incidence of 
spontaneous (non-ischaemic) ventricular arrhythmias. 
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Concluding remarks 
The most contentious issue regarding the role that KATp channels might play in cardiac 
arrhythmogenesis, is whether pharmacological activation of KATp channels is pro- or anti- 
arrhythmic. The present study has illustrated that in rat isolated hearts, KATP activation 
can be both pro- and anti-arrhythmic, depending on the concentration of the KATp opener 
used, and on whether arrhythmias were studied during ischaemia or reperfusion. Evidence 
has been provided which links the pro-arrhythmic effect of a KATp opener with severe 
shortening of APD during ischaemia. Theoretical reasons and circumstantial evidence 
exist that KATp activation might cause arrhythmias by promoting reentry, through such 
APD shortening. Mild KATp activation induced an anti-arrhythmic effect during 
reperfusion in the present experiments, which may have been caused by an ischaemic 
cardioprotective mechanism. That would be consistent with inhibition of (Ca2+); 
overload-induced afterdepolarisations during reperfusion. It may not be possible to 
exploit this type of cardioprotective mechanism through KATp activation in the clinical 
setting, since the risk of promoting reentrant arrhythmias through APD-shortening might 
outweigh any benefit from preventing triggered arrhythmias. 
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Appendix 
Suction electrode construction and validation 
Construction 
A novel type of suction electrode, the "brush suction electrode" was constructed [Figure 
A (page A12)]. A length of braided silk suture (Mersilk W582 4/0, Ethicon) was wound 
around one end of a polythene tube [internal diameter (ID) 1 mm, external diameter (ED) 
1.3 mm], forming the outer pole. A brush of 10 stainless-steel wires [46 SWG (standard 
wire gauge), soldered together 2 mm from their ends] was inserted into the tube, forming 
the inner pole. ' These wires were rigid enough to maintain the integrity of the brush 
throughout its use. The distances between the end of the tube and the ends of inner and 
outer poles were 0.5 and 0.75 mm, respectively (Figure B). Twin-core screened pick-up 
wire was connected to these poles. One copper wire core was interwoven with the outer 
pole, 3 mm from its tip. The other was soldered directly to the inner pole, 4 cm from its 
tip and placed outside the suction tube. Typical examples of APs recorded using this 
electrode are shown in Figure C, i& ii. 
Several suction electrodes were tested before settling on the above design. For example, a 
suction electrode with a sponge outer pole (Figure D), designed, used and kindly donated 
by Roche Research Institute, recorded APs typically having a lower signal to noise ratio 
(Figure C, iii) than those recorded with the brush electrode. A scaled down version of the 
brush suction electrode, with a 0.7 mm ID suction tube and a single stainless-steel wire 
(22 SWG) inner pole, occasionally provided high amplitude (30 mV) APs (Figure C, iv), 
but these signals were short-lived, prohibiting their use over a half hour experiment. The 
most stable type of recording occurred with the brush suction electrode held rigidly, but 
with only light pressure, against the wall of the heart (Figure E) using a brass strip similar 
to that of the occlusion bracket. This configuration removed artifacts, presumably 
mechanical, which occurred when the electrode was allowed to move freely with each 
beat. "Fine-tuning" of the electrode was achieved by adjusting the depths of the inner (see 
Figure A, legend 12) and outer poles, relative to the end of the suction tube. With the 
inner pole in the position shown in Figure B, on application of suction, a small tab of 
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epicardium was seen to enter the tube and contact the inner pole to a depth set by the end 
of the wire brush. A larger depth prevented this contact, and a smaller depth hindered 
adhesion of the muscle wall. Outer pole depth appeared to influence the level of 
background noise. Relative pole depths were maintained constant throughout subsequent 
experiments. Electrical interference was minimised by screening all wires as close to their 
exposed ends as possible. Screening wires, electrode brass supports, and all metal parts of 
the Langendorff apparatus were connected, via heavy single core copper wire, to a mains 
earth terminal. 
AP recording 
Hearts were perfused under similar conditions to the control group detailed on page 21. 
During the stabilisation phase, a suction electrode was applied to the surface of the left 
ventricle, approximately 4 mm distal to the coronary ligature (Figure E). The heated 
jacket was raised around the electrode and its supporting bracket. The outer pole was 
saturated with PSS and the polythene tube was evacuated to approximately 200 mm Hg 
below atmospheric pressure, using a water-driven vacuum pump (Type Edwards High). A 
voltage then appeared between the inner and outer poles. Voltage signals were low-pass 
filtered at 5 kHz with AC coupling, digitised, stored on magnetic disc and displayed using 
a scroll-type oscilloscope (Gould Windograph, kindly donated by Roche). The 
oscilloscope input resistance was 11.6 M. Linearity of response was ± 0.5% up to a full 
scale deflection of 2.5 V. The Windograph "glitch" recording setting was used, allowing a 
sampling rate of 4.5 k samples/s. The time-base accuracy was better than ± 1%, according 
to the manufacturers. Following the stabilisation period, APs were recorded at 10 cm/s for 
a few seconds, at selected intervals during an experiment, by using the Windograph 
"monitor mode". In conjunction with the glitch setting, this permitted AP recording 
during an entire experiment, on two 4 inch high density magnetic discs. 
Data analysis 
At the end of an experiment, measurements were made from the first AP recorded in each 
interval. APs were "stretched" using on-screen cursors and the "fit to screen" option. This 
allowed accurate measurement of the relatively short APD: the cursors being positioned 
at the base and peak of the AP, respectively. Differences in voltage and time between 
these two points (termed APA and APD, respectively) were displayed. By moving the 
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reference cursor to points at 50% and 80% of the baseline voltage, the new potential 
differences displayed represented APD50 and APD80, respectively. 
Statistics 
The incidences of AP types were compared using a X2 test (with Yate's Correction). AP 
parameters were compared using a Mann Whitney test, since values were not normally 
distributed. P<0.05 was considered to be significant. 
Exclusion criteria 
1) Following staining of the non-perfused zone (described on page 8), hearts were 
excluded from AP measurement if the suction electrode site was not located entirely 
within the non-perfused zone. 
2) Frequently, APs exhibited a "notched" configuration. This was assumed to be 
artifactual under certain circumstances. To avoid measuring a false APD in these APs, the 
following rule was applied: APD80 was measured to the outside of the AP dome (Figure 
F, i: point 2). Therefore, when measuring APD80, if the reference cursor impinged on 
points 1 or 2, but not 3 or 4 of Figure F, i, APD80 was not recorded. An example of an AP 
for which APD8o was excluded is shown in Figure F, iii. Any APs which exhibited a 
discontinuous signal (usually during the upstroke) were excluded. These were 
encountered rarely with the brush suction electrode. APD and APA were not measured 
from signals indicative of arrhythmias, ie in which deflections were at a substantially 
accelerated, or an irregular rate. 
AP recording prior to, during and following 10 minutes of regional ischaemia 
Introduction 
The aim was to record APD in a group of hearts, perfused under conditions similar to 
those of the arrhythmia control groups above. 
Method 
An attempt was made to minimise injury to the left ventricle through suction, by applying 
suction only during AP recording. In one heart, APA and APD50 were measured at 1 
second intervals following suction application. After 15 seconds, both APA and APD50 
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had peaked (Figure G), so suction was switched on 15 seconds prior to AP recording from 
subsequent hearts, using a three way valve which allowed pressure to return to 
atmospheric between recordings. A control group of hearts was perfused with PSS for 30 
minutes, and LV APD80 was measured at each minute as described above. A second 
group of hearts was perfused under the same conditions, except that the LMA was 
occluded for 10 minutes. APD80 values were compared at each time point. 
Results 
In the control group (non-occluded hearts) at minute 10 of normal perfusion, LV APD80 
was 34.8 ± 4.6 ms (n=10 APs). This was not significantly different in LMA-occluded 
hearts, at 40.8 ± 3.3 ms (n=15 APs). LMA occlusion caused a rapid and transient 
lengthening of APD80 to a peak value 84% longer than in the control at the same time 
point. There was no significant APD-shortening during ischaemia compared to the control 
(Figure H). During reperfusion, APD80 rapidly and transiently shortened to a nadir 46% 
below that in the control group at the same time point (Figure H). 
LV AP configuration changes during ischaemia, and the influence of a RV suction 
electrode on these changes 
Introduction 
The long-term objective was to record LV and RV APD simultaneously. But there were 
two aims to the present experiment. Firstly, to record AP changes during ischaemia and 
reperfusion in more detail than in the last experiment. Secondly, to assess the influence of 
a suction electrode placed on the right ventricle, on recorded changes in LV AP 
configuration. 
Method 
APs were recorded from the left ventricle as described on page A2, with the following 
exceptions. 
1) A second brush suction electrode was constructed as described on page Al. In one 
group of hearts, this electrode was placed on the RV epicardial wall, opposite the LV 
electrode, and equidistant from the apex. The RV electrode was supported rigidly, in the 
same manner as the LV electrode. Suction was applied continuously to both electrodes, 
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using the same vacuum line. Electrodes were swapped for each experiment, to control for 
any inter-electrode differences. 
2) In a second group of hearts, APs were recorded in the absence of a RV electrode. 
3) LV APA was recorded in addition to APD80. 
4) During the first 3.5 minutes of reperfusion, APs were recorded every 10 seconds. 
5) LV AP configuration was recorded at minutes 5 and 10 of normal perfusion, and at 
each minute of ischaemia, by measuring parameters B&C (see Figure L). 
Results 
LV APD80 
Regional ischaemia and reperfusion caused similar changes (Figure I) to those seen in the 
last experiment. The RV suction electrode had a negligible influence on APD80 (Figures I 
& J). The nadir of reperfusion APD-shortening occurred after approximately 1 minute 
(Figure J). 
LV APA 
At minute 10 of normal perfusion, in the presence and absence of the RV suction 
electrode, this was 11.4 ± 1.8 and 10.2 ± 1.2 ms (n=14 &5 APs), respectively. LMA 
occlusion caused a rapid and significant increase within 1 minute (Figure K). There are 
uncertainties attached to APA measurement from MAPs (see page 64), and APA changes 
must be interpreted with caution. Simply increasing the amplifier gain naturally increased 
APA, but without altering APD80. This, and the differing time-course of changes in APA 
and APD during ischaemia (compare Figures I& K), suggest that ischaemic APD- 
lengthening is independent of changes in APA. The presence of the RV electrode had a 
negligible effect on APA at any time-point (Figure K). 
LV AP configuration 
In those APs exhibiting a notch, ie in which C-B was positive (Figure L), changes in 
parameters B and C appeared to follow similar time-courses to that of APD80. Any 
changes in notch amplitude (C-B) were relatively small during ischaemia (Figure L). 
Incidence of notched APs 
Pre-ischaemic AP data was grouped, as was ischaemic AP data. In the absence of the RV 
electrode, the incidence of notched APs recorded during normal perfusion was 38% 
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(n=13 APs). This was not significantly different in the presence of the RV electrode, at 
68% (n=28 APs). Corresponding values during ischaemia were not significantly different 
from these, or from each other, at 58 and 66% (n=62 & 148 APs), respectively. 
These results suggest that LV and RV APD80 could be measured simultaneously without 
mechanical interference resulting from the use of two, as opposed to one suction 
electrode. 
Measurement of LV APDso and APDgo, and investigation into a new method of 
measuring APD 
Introduction 
About half of the APs recorded in the above experiments were notched. Notched APs also 
have been recorded intracellularly from hearts of several species (107,108,09), so it is 
possible that the notched APs seen in these experiments were real. Occasionally, 
however, APs were recorded in which the notch dipped below the baseline, ie parameter 
B (see Figure L) was negative. In the above experiments, the APD of such APs was 
measured only when the AP dome was sufficiently high not to distort APD, as in Figure 
F, i& ii. The APD was, therefore, not measured for APs such as that of Figure F, iii. The 
aim of the present study was to establish the validity of using this method of measuring 
APD, by comparing it with a method which assumed that notched APs in which 
parameter B was positive, were real, and therefore APD should be measured even if, as in 
the example in Figure F, iii, D was below R. 
Method 
LV APD50 and APD80 were measured prior to, during and following 10 minutes of LV 
regional ischaemia. APD of "standard" APs was measured as normal. The APD of each 
notched AP was measured according to one of the following methods. 
Method 1 
When parameter B was positive, APD was measured, irrespective of the height of the AP 
dome, and to the outside of the AP dome when necessary. 
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Method 2 
When parameter B was negative, APD was measured only when the AP dome was high 
enough not to distort APD: ie as in earlier experiments. 
Changes in mean APD using each method, were compared. 
Results and conclusion 
Both methods yielded similar APD values during normal perfusion and ischaemia 
(Figures M& 0). At normal perfusion minute 10, APD80 was approximately 2.5 times 
longer than APD50. During reperfusion, the two methods yielded different results (Figures 
N& P). 
It was decided to use method 2 in all future experiments (as in the earlier experiments), 
since an artifactually short APD might be recorded during reperfusion using method 1. 
This cautious approach still revealed significant APD-shortening during reperfusion. 
Effect of inotropic drugs on AP configuration, recorded simultaneously from left 
and right ventricles 
Introduction' " 
The aim was to investigate the effect of varying myocardial contractility on AP 
configuration, to establish whether the AP notch was a mechanical artifact. 
Method 
APD50, APD80 and parameters A, B and C were recorded prior to, during and following 
10 minutes of LV regional ischaemia, in groups of hearts perfused with either verapamil 
at 0.5 µM, ouabain at 1.25 or 25 µM, or 4-aminopyridine (4-AP) at 1 mM. Drug 
concentrations were selected for their known effects on myocardial contractility 
(110,111,112). In separate groups of hearts, drug effects on LV developed pressure (LVDP) 
were recorded. A latex balloon was inserted into the left ventricle via an incision in the 
left atrial appendage. The balloon was connected to a pressure transducer (Bell and 
Howell) via a water-filled polythene tube. The balloon was inflated to a volume of 
approximately 0.5 ml using a syringe. LVDP was recorded on a previously calibrated 
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heated stylus chart recorder (MX 216, Lectromed). In all hearts, LVDP increased 
progressively following balloon inflation, reaching a plateau after approximately 15 
minutes. LVDP was measured at minute 20 of normal perfusion. 
Results - 
Effect of inotropic drugs on LVDP 
In the control group, hearts beat visibly, with or without the latex balloon in the left 
ventricle. LVDP was 76.6 ± 3.5 mm Hg (n=6 hearts). Verapamil at 0.5 tM stopped all 
visible ventricular contractions and decreased measured LVDP by 97%. Ouabain at 25 
tM increased LVDP by 60%. Ouabain at 1.25 µM and 4-AP at 1 mM had no significant 
effect on LVDP (Figure Q). 
Control AP characteristics 
At minute 5 of normal perfusion, the incidence of notched APs in the left ventricle was 
69% (n=16 APs) and the notch amplitude was 5.8 ± 1.2 mV (n=11 APs). Similar values 
were found in the right ventricle, at 57% (n=14 APs) and 3.2 ± 0.6 mV (n=8 APs), 
respectively. The incidence and amplitude of notched APs at minute 5 of ischaemia and at 
minute 5 of reperfusion were not significantly different from pre-ischaemic values in their 
respective ventricles. However, at minute 5 of ischaemia, 73% of APs (n=15 APs) in the 
left ventricle were notched, significantly more than in the right ventricle at this time 
(31%, n=13 APs). Following reperfusion, suction was stopped, and with the suction 
electrodes still in place, the zone of muscle rendered non-perfused by LMA occlusion was 
delineated as described on page 8. The position of each suction electrode relative to this 
zone was noted. In each heart, the LV suction electrode was situated centrally within this 
zone, and the RV suction electrode outside it. In the control group, the non-perfused zone 
weighed 47 ± 2% (n=16) of the total ventricular weight. This value did not differ 
significantly in any of the groups in which hearts were perfused with drugs. 
Effect of inotropic drugs and regional ischaemia on LV AP configuration 
Pre- and post-ischaemic data were combined. Of the drugs tested, only verapamil at 0.5 
µM significantly altered the configuration from control, with a reduction in the amplitude 
of the AP dome (Figure R). During normal perfusion, only ouabain at 25 pM significantly 
affected the AP notch, reducing its incidence to 19% (Figure S). During ischaemia, both 
verapamil at 0.5 µM and ouabain at either 1.25 or 25 µM reduced the notch incidence and 
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the notch amplitude, while 4-AP at 1 mM only affected the notch incidence, reducing it to 
70% of the pre-ischaemic value. 
Effect of inotropic drugs on APD80 during normal perfusion 
In the control group prior to ischaemia, APD80 was significantly longer in the left 
ventricle than in the right, by 47%. In the left ventricle, verapamil at 0.5 µM significantly 
shortened APD80, by 34%. Ouabain at 1.25 and 25 µM, and 4-AP at 1 mM, significantly 
lengthened LV APD80, by 36,57 and 41%, respectively. Similar drug effects (not always 
reaching significance) were observed in the right ventricle [see Figure 40 (page 91)]. 
Regional changes in APs during ischaemia and post-ischaemic reperfusion 
LMA occlusion in the control group elicited a transient and significant increase in APD80 
in both ventricles. This was accompanied by a significant increase in LV APA and a 
significant decrease in RV APA (Figure T). After 4 minutes of ischaemia, the normal 
interventricular difference in APD80 had disappeared. Reperfusion transiently and 
significantly reduced LV APD80. This effect was maximal after 50 seconds, at a value 
44% lower than at ischaemia minute 10. APD80 changes in the right and left ventricles 
followed similar patterns during the first 2 minutes of reperfusion, after which the normal 
interventricular difference in APD80 was re-established (Figures T& U). 
Effect of inotropic drugs on ischaemic APD-lengthening 
In the left ventricle, inotropic drug effects on APD observed prior to ischaemia, were seen 
during ischaemia. Following LMA occlusion, APD lengthened significantly in all groups, 
except ouabain at 25 µM (in which any lengthening did not reach significance). The time 
course of APD changes in these groups was similar to the control. Effects of these drugs 
on APD are examined in more detail in Chapter 6. 
Conclusion 
These results suggest that the AP notch is not a mechanical artifact, since verapamil 
markedly reduced ventricular contractility, but did not alter the incidence or the amplitude 
of the AP notch. In addition, ouabain, which was positively inotropic at 25 µM, reduced 
the incidence of the AP notch, an effect opposite to that which would be expected if the 
AP notch was mechanically generated. LV ischaemia increased LV APA, but decreased 
RV APA. A concurrent lengthening of both LV APD and RV APD suggests that APD 
A9 
and APA changes are not linked. Since verapamil, ouabain and 4-AP all altered APD in a 
predictable manner, and AP recordings were not subject to mechanical interference, this 
suggests that the APD changes caused by ischaemia and reperfusion were real. 
Effect of global ischaemia on LV and RV AP configuration 
Introduction 
It is conceivable that occlusion of the LMA with the occlusion bracket might exert a 
different mechanical influence on epicardium beneath the LV and RV electrodes. This 
would offer an explanation for the changes in LV and RV APA observed during 
ischaemia. In an experiment performed on two hearts during testing of various types of 
suction electrodes, 10 minutes of global ischaemia lengthened LV APD and APA. The 
aim of the present experiment was two-fold. Firstly, to investigate LV and RV APD and 
APA changes during global ischaemia, ie in the absence of potential mechanical influence 
from the occlusion bracket, in a statistically valid group size. Secondly, to compare the 
incidence of notched LV APs during global and regional ischaemia. 
Method 
As in the control group of the last experiment, with the following exceptions. 
1) The perfusion line was closed instead of tightening the coronary snare. 
2) Notch incidence was measured at normal perfusion minute 10 and ischaemia minute 5. 
Results 
APD and APA 
Global ischaemia caused a similar lengthening of LV and RV APD80, by 58 and 64%, 
respectively, and an increase in APA in both ventricles (Figure V). A comparison of AP 
changes between global and regional ischaemia was made (compare Figures T& V). RV 
APD80 peaked at similar values during global and regional ischaemia. During global 
ischaemia, APD80 peaked in both ventricles two minutes later than during regional 
ischaemia and APA increased in both ventricles to the same extent, in contrast to regional 
ischaemia. 
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Incidence of notched APs 
During normal perfusion, this was similar in left and right ventricles, at 67 and 60% (n=9 
& 10 APs), respectively. During ischaemia, the incidences of LV and RV notched APs 
were similar, at 91 and 100% (n=1 1 APs each), respectively. At minute 5 of regional 
ischaemia in the last experiment, the incidences of notched LV APs during normal 
perfusion and ischaemia were 69 and 73% (n=16 & 15 APs), respectively. In the present 
group of hearts, LV AP notch incidences were not significantly different from these at the 
same times. 
Conclusion 
These results suggest that ischaemic changes in both APD and APA were caused by 
interruption of coronary flow per se, and were not secondary to any mechanical influence 
of the occlusion bracket. In addition, global ischaemia, like regional ischaemia, had no 
effect on the incidence of the AP notch. 
Effect of LV surface temperature on APD 
Introduction 
The aim was to test whether LV regional ischaemia might cause a drop in LV surface 
temperature which could account for the ischaemia-induced APD prolongation. 
Method 
In a group of 6 control hearts from the last experiment, following the reperfusion phase 
the LV suction electrode was removed and replaced with a thermistor probe thermometer 
(Wayne Kerr). The experiment was then repeated in the absence of APD recording. 
Results and conclusion 
There was a trend towards a small drop in LV epicardial surface temperature during 
ischaemia, which did not reach statistical significance (Figure W). This suggests that any 
fall in LV temperature which may have occurred in this and the above experiments, 
would not have contributed substantially to the APD-lengthening seen during ischaemia. 
All 
Figure A 
Brush suction electrode 
16 
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1) Inner pole: brush of 10 stainless steel wires (46 SWG) 
2) Outer pole: braided silk winding 
3) Soldered copper winding, to maintain brush integrity 
4) Twin core screened pick-up wire 
5) Connection from inner and outer poles to oscilloscope input 
6) Connection to mains earth terminal 
7) Polythene tube: ID 1 mm, ED 1.3 mm 
8) Polythene o-ring insulator 
9) Brass strip support (attached to retort stand) 
10) Silicone rubber tube: internal diameter 6 mm, 
external diameter 9 mm ID 6 mm; OD 9 mm 
11) Polyurethane adaptor 
12) Depth of inner pole set here 
13) Tightened string loop 
14) Vacuum (200 mm Hg below atmospheric pressure) 
15) Single core insulated wire 
16) Polythene insulator 
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Figure B 
Tip of brush suction electrode 
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F 
1.0 
1) Fluid film 
2) Braided silk. winding of outer pole 
3) Copper wire: to amplifier 
4) Polythene tube 
5) Stainless steel wire of brush inner pole 
6) Solder support 
7) Tip of inner pole 
8) Tab of epicardial muscle, sucked into tube 
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Figure C 
Typical AN recorded from left ventricles using suction electrodes 
Time scale = 10 cm/s 
i& ii: APs recorded using brush suction electrode during normal 
perfusion, from separate hearts under similar conditions 
(APA = 16 and 22 mV respectively) 
iii: AN recorded using Roche suction electrode, during normal 
perfusion (APA =5 mV) 
iv: High amplitude (28 mV), but short-lived APs, recorded 
using a suction electrode (1 mm ID), during stabilisation 
period 
iii iv 
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Figure C 
Typical APs recorded from left ventricles using suction electrodes 
Time scale = 10 cm/s 
i& ii: APs recorded using brush suction electrode during normal 
perfusion, from separate hearts under similar conditions 
(APA = 16 and 22 mV respectively) 
iii: AN recorded using Roche suction electrode, during normal 
perfusion (APA =5 mV) 
iv: High amplitude (28 mV), but short-lived APs, recorded 
using a suction electrode (1 mm ID), during stabilisation 
period 
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Figure D 
Roche suction electrode 
ýýi 
-7 
-I--' 
S 
6 
1) Sponge outer pole: ED 8 mm 
2) Stainless steel outer pole connector 
3) Stainless steel inner pole 
4) "Shrink sleeving" 
5) PTFE tube 
6) Single core wire connection to oscilloscope 
7) Represents break in diagram 
Lengths (mm) a=2; b=3; c =1.2; d =0.4 
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Figure E 
Positioning of brush suction electrode on left ventricle 
1) Aortic cannula 
2) Brush suction electrode 
3) Occlusion bracket 
4) Rigid brass strip 
5) Coronary artery snare 
6) Braided silk suture 
7) Connection from suction electrode to oscilloscope input 
LV = Left ventricle 
S. 
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Figure F 
Examples of APs included (i & ii) and excluded (iii) 
from recording of APD8o 
R= point of 80% repolarisation 
Distance between cursors represents APDso 
i: Typical notched AP 
AP was 'stretched' using cursors. APD8O = 46 ms 
See page A3 for explanation of numbers 1-4 
ii: AP exhibiting small notch, 
AP was 'stretched' using cursors. APD80 = 32 ms 
iii: Severely notched AP 
AP was recorded at 10 cm/s and excluded from APD 
recording, since R is higher than the AP dome, D 
ll. 
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Figure G 
APD and APA following application of suction 
Values are means of 5 APs, recorded from 1 heart 
Error bars (where visible) = SEM 
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Figure H 
LV APD 
Values are means, error bars omitted for clarity 
Solid symols denote significant differences between groups 
at same time points 
--®- PSS control: no LMA occlusion (n=16 hearts, 10-16 APs) 
PSS: LMA occluded group 
(n=18 hearts, 9-18 APs) 
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Figure I 
LV APD 
Values are means, error bars omitted for clarity 
Solid symols denote significant differences between groups 
at same time points 
PSS control: no suction electrode on right ventricle 
(n=8 hearts, 4-7 APs) 
ý- PSS: suction electrode on right ventricle 
(n=17 hearts, 7-17 APs) 
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Figure J 
LV APD, during reperfusion 
Values are means, error bars omitted for clarity 
Solid symols denote significant differences between groups 
at same time points 
ý- PSS control: no suction electrode on right ventricle 
(n=8 hearts, 4-6 APs) 
- a- PSS: suction electrode on right ventricle 
(n=17 hearts, 7-15 APs) 
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Figure K 
LV APA 
Values are means, error bars omitted for clarity 
Solid symols denote significant difference between groups 
at same time points 
ý PSS control: no suction electrode on right ventricle 
(n=8 hearts, 4-7 APs) 
--0-- PSS: suction electrode on right ventricle 
(n=17 hearts, 7-17 APs) 
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Figure L 
Effect of ischaemia on parameters A, B&C in LV APs, 
in the absence of RV suction electrode 
Values are means, error bars omitted for clarity, n=17 hearts, 7-15 APs 
Parameter A was recorded only in notched APs 
Notched APs are defined as APs in which C-B is positive 
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Figure M 
LV APD 
measured using methods 1 and 2 (see page A6) 
Values are means, error bars omitted for clarity, n=12 hearts 
Solid symols denote significant differences between groups 
at same time points 
-ý- Method 1 (n=4-12 AN 
-0- Method 2 (n=4-11 APs) 
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Figure N 
LV APD during reperfusion, 
measured using methods 1 and 2 (see page A6) 
Values are means, error bars omitted for clarity, n=12 hearts 
Solid symols denote significant differences between groups 
at same time points 
-®-- Method 1 (n=4-8 APs) 
-0-- Method 2 (n=4-8 APs) 
20 
18 
16 
14 
APD50 
12 
(ms) 
10 
8 
6 
4 
2 
19 19.5 20 20.5 21 21.5 22 22.5 23 
reperfusion Time (minutes) 
A25 
Figure 0 
LV APD, 
measured using methods 1 and 2 (see page A6) 
Values are means, error bars omitted for clarity, n=12 hearts 
Solid symols denote significant differences between groups 
at same time points 
EDMethod 1 (n=4-12 APs) 
--a- Method 2 (n=4-12 APs) 
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Figure P 
LV APD during reperfusion, 
measured using methods 1 and 2 (see page A6) 
Values are means, error bars omitted for clarity, n=12 hearts 
Solid symols denote significant differences between groups 
at same time points 
--a- Method 2 (n=4-11 APs) 
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Figure Q 
Effect of inotropic drugs on LVDP, 
during normal perfusion 
Values are means, error bars = SEM 
Asterisks denote significant differences between 
contemporaneous control and drug-treated groups 
Q PSS control (contemporaneous with 
verapamil and ouabain-treated groups, n=7 hearts) 
0 Verapamil at 0.5 µM (n=3 hearts) 
El Ouabain at 1.25 µM (n=6 hearts) 
N Ouabain at 25 tM (n=5 hearts) 
® PSS control (contemporaneous with 
4-AP-treated group, n=7 hearts) 
4-AP at I mM (n=6 hearts) 
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Figure R 
Effect of inotropic drugs on the amplitude of A, B&C 
of LV APs, during normal perfusion 
Values are means, error bars = SEM, n=12-17 hearts, 14-19 AN 
The only significant difference in A, B or C between groups, 
is denoted by the asterisk 
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Figure S 
Effect of inotropic drugs on the incidence and amplitude of 
the AP notch in the left ventricle 
Values are means, error bars = SEM, n=12-17 hearts, 14-28 APs 
during normal perfusion, and 32-148 APs during ischaemia 
NV = no value 
Asterisks denote significant differences between control and 
drug-treated groups in either the normal perfusion or the ischaemic 
phase 
Crosses denote significant differences between like groups in different 
phases 
Q PSS control 
® Verapamil at 0.5 µM 
Q Ouabain at 1.25 µM --- 
Ouabain at 25 pM ßC 
4-AP at 1 mM 
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Figure T 
APD and APA 
Values are means, error bars omitted for clarity, n=17 hearts 
Solid symbols denote significant differences between groups at same 
time points 
--0- Left ventricle (n=7-17 APs) 
® Right ventricle (n=5-14 APs) 
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Figure U 
APD and APA during reperfusion 
Values are means, error bars omitted for clarity, n=17 hearts 
Solid symbols denote significant differences between groups at same 
time points 
--0- Left ventricle (n=7-17 APs) 
ED - Right ventricle (n=5-14 APs) 
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Figure V 
Effect of global ischaemia on APD and APA 
Values are means, error bars omitted for clarity, n=12 hearts 
Line breaks indicate insuffient data 
Solid symbols denote significant differences between groups 
at same time points 
--ý- Left ventricle (n=4-12 APs) 
-0-- Right ventricle (n=4-12 APs) 
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Figure W 
Effect of LMA occlusion on LV epicardial 
surface temperature 
38.00 
37.75 
37.50 
37.25 
Temperature 
(°C) 37.00 
36.75 
36.50 
36.25 
36.00 
Values are means, error bars = SEM, n=6 hearts 
There was no significant difference from the pre-occlusion value 
at any time point 
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